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INTRODUCTION 
 Siddha system is one of the unique systems of Indian medicine. Siddhars are believed 
to be the founders of siddha medicine. They handles the herbs, minerals, to prepare the 
medicine. 
 Significantly one the definitions off the siddha medicine is invasion of death “that 
which ensures preventive against mortality” –Thirumoolr. 
 The aim of the every system of medicine is to give healthiness to an individual. But 
siddha system is distinguished from other system because it gives both mental and physical 
health. 
 On the basis of our siddha text Osteoarthritis is inter correlated with keelvayu and 
more often keel vayu comes under 80 types of vadha diseases. In Yugi vaithiya 
chinathamani-800 one among them is “AZHAL KEEL VAYU”.  
 Osteoarthritis is a chronic degenerative disorder of multi factorial etiology 
characterized by loss of articular cartilage, hypertrophy of bone at the margins, subchondral 
sclerosis and range of biochemical and morphological alterations of the synovial membrane 
and joint capsule. Typical clinical symptoms are pain, particularly after prolonged activity 
and weight bearing; whereas stiffness is experienced after inactivity. 
 Primary Osteoarthritis is mostly related to aging. It can present as localized, 
generalized or as erosive osteo arthritis. Secondary osteoarthritis is usually followed by 
another disease. It is the second most common rheumatological problem and it is the most 
frequent joint disease with prevalence of 22% to 39% in India. Osteoarthritis the most 
common form of arthritis is a major contributor to functional impairment and reduced 
independence in older adults. 
 Among the 100 different types of arthritic conditions osteoarthritis is the most 
common, affecting 25 million people. Osteoarthritis more frequently as the age increased. 
Before age 45, Osteoarthritis more frequently in males, and after 55years of age, it occurs 
more frequently in females. 
 A variety of cause’s hereditary, developmental, metabolic and mechanical deficits 
may initiate processes leading to loss of cartilage. When bone surfaces become less protected 
by cartilage, bone may be exposed and damaged. As a result of decreased movement 
secondary to pain, regional muscles and ligaments may atrophy. When the severity increases, 
invasive treatment may be needed. 
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The author have selected the KANDATHIRI LEGHIYAM   (Internal) to evaluate 
their therapeutic efficacy in the treatment of Azhal Keel Vayu (OSTEOARTHRITIS) as 
above said drug formulation has not undergone any clinical so far. 
Internal Medicine  
       KANDATHIRI LEGHIYAM   -Agathiyar vaithiya Soorthiram 650 (Page No. 
161).The dosage   of the trail medicine is 6gms (BD) for 48 days. 
 External Medicine NAKKA PUSA MUKKUTTENNAI-Yughimuni Vaithiya 
kaviyam(Page no.37) with the dosage -60ml (for external application)   
The above medicine contains ingredients which have anti vadha property. 
Considering this they are chosen as trial medicines in this study. Varmam, and asanas are one 
of the best external therapies in Siddha system of medicine and the effectiveness of varmam 
and asanam in alleviating pain in Azhal Keel Vayu is also evaluated along with trial 
medicines. 
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                                            AIM AND OBJECTIVE 
AIM: 
   To Evaluate the clinical efficacy of “KANDATHIRI LEGHIYAM  ” (internal) and 
“NAKKA PUSA MUKKUTTENNAI”(external)  for the treatment of  Azhal Keel Vayu 
(OSTEOARTHRITIS). 
 
Primary objective : 
 To evaluate the clinical efficacy of “KANDATHIRI LEGHIYAM  ” (internal) and 
“NAKKA PUSA MUKKUTTENNAI (external) for the treatment of Azhal Keel Vayu  
(OSTEOARTHRITIS). 
 
Secondary objective:   
 To study the Siddha basic principles like envagai thervukkal including 
neerkkuri and neikkuri. 
 To evaluate the safety profile of the trial medicine. 
 To Evaluate the pharmacological study of trial medicine  
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    REVIEW OF LITERATURE 
SIDDHA ASPECT 
 According to our siddha literature the disease occur due to the variation of three 
humours namely vatham, pitham, kabam. 
Thiruvalluvar says 
 “lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~OziI!
! utqLkzi!w{<{qb!&e<X”/!
Three humours theory 
 The three ‘humors’ as described in siddha medicine is a golden line continuous in 
physiology, pathology and treatment.  The three humours vatham, pitham and kapham, whose 
balance is essential for maintenance of good health. 
 “uiklib<!hjmk<K!hqk<k!ue<eqbib<!gik<K!Osk<l!
! sQklib<!Kjmk<K”!
. Okjvbi<!lVk<Ku!hivkl< 
  Similarly a day is divided into three phases or parts and each part is said to be 
prominent phase of vatha, pitha and kaba.  In the human body vatha exists below the naval, 
pitha between the heart and naval and kapha above the heart, When the three humours are in 
equilibrium they are called as “UYIR THATHU”.  While they are getting deranged they are 
called kutras or Doshas.  There may be small fluctuation in physiological condition even in 
the healthy body. 
 The normal order of vatha, pitha, kaba is in proportion of 1: ½: ¼ respectively. 
 upr<gqb!uikl<!lik<kqjv!obie<xigqz<!
! kpr<gqb!hqk<kl<!ke<eqjzvuigq!
! npr<Gr<!ghf<kiemr<gqOb!giOzicz<!
! hvr<gqb!sQui<g<G!hqsogie<X!lqz<jzOb!
  Any changes in these proportions will be responsible for disease but the maintenance 
of their normal proportion gives vitality to the organism and assures the preservation of 
health and longevity of life. 
Thannilai valarchi 
(Accumulation and excitation) 
 The stage where the humour accumulates in a particular part as stagnant is called 
Thannilai valarchi. 
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 When the stagnant humour accumulated and permeated a structure there is an 
excitement from eversion towards similar and attraction towards contraries.  This is 
known as “Prakobam”. 
Piranilai Valarchi (Spreading) 
 This is the stage where the excited humour extends by viyana to another part. The 
derangement of kutram becomes located in parts of the body.  And being to cause disease of 
joints, blood, stomach, bladder and soon. 
 
I. Vatham 
 The term vatha denotes 
 Vayu 
 Dryness 
 Pain 
 Flatulence and 
 Lightness 
Location of vatham 
 Vatham is located in the hip, below the abdomen, moolatharam and sexual organs.  It 
is also said that vatha is settled in various places including bone, joints, nerves, vessels, hair 
follicles, muscles, sperm, urine and stools. 
Funtion of vatham 
 The function of vatha is stimulates the body and soul, voiding of excreta refreshesness 
and proper harmony of the seven thathu. 
Effects of vitiated vatha 
 Vayu -pain, exquisite pain, extreme dryness, palpitation, dislocation of the joints, 
dysfunction of the sexual organs, constipation, dysuria, thirst, pain in the long bone.  Unable 
to flexion and extension of the limbs, dark complexion and emaciation are the main ill effects 
of the vitiated vatha. 
II. Pitham 
 The term pitham denotes gastric juice, bile, energy, heat and anger etc. 
Location of pitha 
 Head, heart, bladder, abdomen, umbilicus, stomach, saliva, sweat, blood, eyes and 
skin are the sites of pitham. 
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Effects of vitiated pitham 
 Excessive heat in the body, improper digestion, excessive sweat, giddiness, syncope 
and immortal behaviours are some of the ill effects of vitiated. 
III.Kabam 
Location of kabam 
 The kabam is located in the tongue, chest, blood, bone marrow, bones, nerves, brain, 
large intestine, eyes and joints. 
Functions of kabam 
 The important functions of kabam are maintaining the unctuous and viscosity and 
proper functioning of the joints. 
Effects of vitiated kabam 
 Pain in the long bones, dysfunction of the joints, improper digestion, excessive sleep 
and inhibition of understanding capacity. 
Suvai 
 The food we eat has six tastes namely 
 Inippu 
 Pulippu 
 Uvarppu 
 Kaippu 
 Kaarppu 
 Thuvarppu 
Each of it is a mixture of two basic elements 
Inippu  - Mann + Neer 
Pulippu - Mann + Thee 
Uvarppu - Neer + Thee 
Kaippu - Kaatru + Aagayam 
Thuvarppu - Mann + Aagayam 
Karppu            -          Kaatru+ Thee 
Panchapootha theory 
 The five elements Aagayam, kaatru, thee, neer, mann are the basis for the world and 
the human being.  These five elements are subtle states (Sookuma nilai).  They manifest into 
a gross state (Sithula nilai) and become visible.  the manifestations of the five elements from 
the subtle state to gross are called as panchapootha panchi karanam. 
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 Panchapoothas are the foundations for thiridhosas which are the pillars that support 
our body structure. 
 Vayu constitute vatham 
 Theyu constitute pitham 
 Appu constitute kabam 
Relation between suvai, Panchapootham and Thiridhosam 
S.No. Suvai Panchapootham Thiridhosam 
1. Inippu Mann + Neer Kabam ↑ 
Vatham ↓ (-) 
Pitham  ↓ (+) 
2. Pulippu Mann + Thee Kabam ↑ 
Pitham  ↑ 
Vatham ↑ (-) 
3. Uppu Neer + Thee Kabam ↑ 
Pitham  ↑ 
Vatham ↑ (-) 
4. Kaippu Vayu + Aagayam Vatham ↑  
Kabam  ↓ (-) 
Pitham ↑ (-) 
5. Kaarppu Vayu + Thee Vatham ↑  
Pitham ↑ (-) 
Vatham ↓ (-) 
6. Thuvarppu Mann + Vayu Vatham ↑  
Kabam ↓ 
Pitham ↑ (-) 
↑  - Vetrunilai valarchi 
↓ - Thannilai valarchi 
(-) - Thannilai Adaithal 
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KEEL VAYU 
Other names 
 According to siddha maruthuvam textbook Keel vayu mentioned as 
 Santhu vali,Muttu vali,Megha soolai,Mudakku vayu,Ama vatham 
 Vitiated vatham produces disease in Keel (joints) called as -“Keel vayu”. 
 Pain in muttu (Joint) called as -“Muttuvali” 
 Disease which followed by megha noi called as -“Megha soolai” 
 Inability to use joints properly called as -“Mudakku vayu”. 
 Pain present in all joints called as -“Santhuvali”. 
 Improper digestion of food followed by increased kapham produces vadha disease 
called as -“Amavatham”. 
  In yakobu vidya sinthamani it is mentioned a “Mudakku vatha soolai”.  In 
Thanvanthri vaidya kaviyam it is said as “Mudakku vayu”. 
Iyal (Definition)  
 Keel vayu is a vatha disease characterized by pain and swelling of the joints, stiffness 
of the muscles and joints with tenderness frequently associated with fever, anorexia and 
insomnia.  It may be accompanied by emaciation, anaemia and restriction of joint movements 
and in some cases even immobility may occur. 
 According to agasthiar guna vagadam “Keel vayu” comes under the 80 types of vatha 
disease 
 “uzqB!jlBf<!ke<eqjz!ogm<M!
! uzqBme<!uQg<gs<!SvLl<!gib<f<K!
! Lm<Mg!OmiXl<!LMg<gqOb!ofif<K!
! Lm<Mg!me<eqe<!fQVl<!Svf<K!
! kir<ogi{i!uzqBme<!ofif<kqM!ll<Ol”!
. !shihkq!jgObM!
 “kieig!gQz<uik!Ovigl<!Ohjv!
! Ofib<!keg<G!higqbib<!uikOvig!ole<hiI!
! Fm<hLt<t!uikOvig!ole<hKf<!kie<!
! Nb<f<okMk<K!-kx<Gt<Ot!nmg<gl<!hiV”!
. ngk<kqbi<!G{uigml<!
 “Keel vayu” is further divided into 10 types in the text siddha maruthuvam according 
to sabapathi manuscript. 
 Azhal Keel vayu comes under these 10 subdivisions of Keel vayu. 
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When vatha vitiated, diet and habits which stimulates pitha it will produce                            
“Azhal Keel vayu”. 
• Azhal means pitham 
• Keel means joint 
• Vayu means vatham 
Noi Enn (Classification) 
 Keel vayu is classified into 10 types according to siddha maruthuvam textbook. 
 Vali Keel vayu 
 Azhal Keel vayu 
 Iya Keel vayu 
 Vali azhal Keel vayu 
 Vali iya Keel vayu 
 Azhal vali Keel vayu 
 Azhal iya Keel vayu 
 Iya vali Keel vayu 
 Iya azhal Keel vayu 
 Mukkutra Keel vayu 
In theraiyar vagadam among the 81 vatha diseases following are joint diseases. 
 Sooriya vatham 
 Seetha vatham 
 Mozhi vatham 
 Kuthi vatham 
 Santhu vatham 
 Vasi vatham 
 Kendai vatham 
 Sathi vatham 
 Thombai vatham 
 Kotai vatham 
In the text Athma rakshamirtham, the following are described as joint diseases 
 Muzhanthai vatham 
 Mudakku vatham 
 Kendaikal vatham 
 Santhu vatham 
 Thoal vatham 
 Muzhi vatham 
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Noi varum vazhi (Aetiology) 
 According to siddha medicine, causes of disease are due to the disturbance of thathus 
and they are attributed in the internal and external causes.  The internal causes are 
constitutional or karma rohams.  The external causes bring up direct from the disturbance of 
food and environment 
External cause 
Environmental factors 
 “uikui<k<!ke!gizOlOki!oue<eqz<!
! ! lVUgqe<x!Neq!gx<gm!likl<!
! Nkjeh<!hsqObiM!giIk<kqjg!ke<eqz<!
! ! nmVOl!lx<x!likr<gt<!ke<eqz<!
! OhigOu!slqg<gqe<x!gizliGl<!
. B,gq!sqf<kil{q!
  The vatha disease will be precipitated in the months from Aani to karthigai (June to 
December) 
 “hKlk<jkh<!H,g<g!jug<Gl<!hiElqgg<!giBl<!
! LKOueq!zqx<H!uqf<fQI!Lx<Xl<!.!gKole!
! ux<Xl<!ghl0Gl<!uiBlqGl<!uip<lif<ki<g<!
! Gx<x!fzqg<!Ogkqoke<!OxiK”/!
. sqk<k!lVk<Kuir<g!SVg<gl<!
In Muthuvenil kaalam, the increased solar radiation increases the evaporation of water 
content in the world, on the same time this similar action on the body produces increases 
absorption of mucous for digestion and develops the vitality of vatha disease.  So this disease 
occurs predominantly in Muthuvenil kaalam. 
Diet 
 “utqkV!gib<!gqpr<G!
! ujvuqzi!kbqzz<!Ogijp!
! Ltqkbqi<!Ohie<lqGg<G!
! Ljxbqzi!U{<c!Ogimz<!
! Gtqi<kV!utqbqx<!Oxgr<!
! Gtqh<Hx!Uzuz<!oh{<cI!
! gtqk<kV!Lbg<gl<!ohx<OxiI!
! gcosbz<!gVuqbilz<”!
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Diet and health which gives rise to vatha dhosa (ie) excessive intake of potato like 
roots and banana, excessive intake of cold substances like curd, exposure to cold, staying in 
hill station which increase kabam causes this disease.  Further this disease is followed by 
megha noi and may be hereditary. 
Physical factors 
 “hgvOu!uiklK!Ohigqk<kh<Ohi!
! ! h{<hig!oh{<Ohigl<!nKkie<!osb<bqz<!
! kgiOu!ouGK~v!upqfmg<gqz<!
! ! ftqvie!gix<XOl!heqOlz<!hm<miz<!
! fqgvOu!gib<gt<!geqgqpr<G!ke<je!
! ! lqg!uVf<kq!lQxqOb!kbqi<kie<!ogi{<miz<!
!
! LgvOu!LKogZl<jh!LXg<gq!ofif<K!
! ! Lpr<giZl<!g[g<giZl<!gMh<H{<miGl</!
. B,gq!sqf<kil{q!
Indulging in the sexual act during vitiation of vatha, walking for a long distance, 
exposing to dampness and cold, harmful combination like taking excessive curd after eating 
fruits, vegetables and tubers causes toxic factors which affects bone and muscle. 
 “kioee<x!gsh<OhiM!Kui<h<H!jgh<H!
! ! sikglib<!lqR<SgqEl<!sjlk<k!ue<el<!
! Noee<x!NxqeK!Hsqk<k!ziEl<!
! ! Ngibk<!OkxzK?!Gck<kziZl<!
! hioee<x!hgZxg<g!lqviuqpqh<H!
! ! hm<ceqob!lqgUXkz<!hivolb<kz<!
! Okoee<x!olipqbiI!Olx<sqf<jk!bikz<!
! ! sQg<gqvlib<!uiklK!oseqg<Gf<kie!
. B,gq!sqf<kil{q!
Intake of food item which are excess bitter, astringent and pungent tastes, intake of 
old cookded food items, drinking rain water, sleeping during day time and wakening at night, 
undue starving, strain due to excessive weight lifting and sexual perversion. 
According to Pararasa sekaram 
 okipqz<!ohXjgh<Hg<!giIk<kz<!Kui<k<kz<!uqR<SER<OsiXl<!
! ! hjpbkil<!uvG!lx<jxh<!jhf<kqjebVf<kqeiZl<!
! wpqz<!ohxh<!hgZxr<gq!-vuqeqZxr<gikziZl<!
! ! ljp!fqgi<!GpzqeiOz!uikr<Ogi!hqg<Gr<giO{!
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! Excessive intake of bitter, astringent, pungent taste diet, day sleeping, wakening 
during night intake of old cooked food items. 
  
gizr<gtqe<!lixqH{<[l<!giiqbk<!kiZf<k{<{QI!
! ! sizOu!bVf<kqeiZR<!sf<kqbq!Zm<giIf<kiZl<!
! Ogizlil<!Htqh<H!ofb<jbg<!Gjxux!ufVf<kqeiZl<!
! ! uiziI!Ljzfz<ziOt!uikLkx<!huqg<Gr<giO{!
Sitting in cold breeze, excess intake of sour and ghee in food items. 
In theraiyar vagadam 
 oub<bqzqz<!fmg<jgbiZl<!lqgk<k{<{QI!Gcg<jgbiZl<!
! ! osb<bqjp!lgtqjvs<!Osi<f<ke!huqg<jgbiZl<!
! jhbOe!d{<jlbiZl<!higx<gib<!kqe<jgbiZl<!
! ! jkbOz!uikOvigl<!seqg<G!ole<xxqf<K!ogit<Ot/!
. Okjvbi<!uigml<!
Excessive walking in hot sun, excessive intake of water, over sexual indulgence, 
intake of bitter gourd etc.  May play a disturbing role in the normal functions of vatham. 
Internal causes 
Kanma as a cause 
 In siddha system, many diseases are said to be precipitated by kanma, which means 
the deeds, good or bad committed by an individual in his previous and present births.  Vatha 
diseases, according to agasthiyar kanma kandam – 300 may also precipitated by kanma. 
Vadha kanma varalaru 
 F~ze<x!uikl<!uf<k!uegkiOeK!
! ! K{<jlbib<g<!ge<lk<kqe<!ujgjbg<!OgT!
! gizqOz!Okie<xqbK!gMh<hOkK!
! ! jggizqz<!Lmg<gqbK!uQg<gOlK!
! OgizqOz!hMgqe<x!uqVm<slie!
! ! Gpf<jk!lvf<kje!oum<mz<!Olz<!Okiz<!sQuz<!
! F~zqOz!sQu!Jf<K!giz<!Lxqk<kz<!
! ! fz<z!ogil<H!kjpLxqk<kz<!fuqk<kz<!kiOe!
. ngk<kqbi<!ge<l!gi{<ml<!
If attribute the following psychological factors such as removing the bark of living 
trees, breathing the legs of the animals, cutting the trees in the living branches and removing 
leaves. 
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Due to karmic law 
 nf<k{I!gx<H!liki<!nVtqb!sibk<kiZl<!
! ! Lf<kqb!uqjebiZl<!LgqIgi<h<h!Olgk<kiZl<!
! sqf<jkbqx<!ogiMjlbiZl<!squGV!fqf<jkbiZf<!
! ! okif<klil<!uqbikqbiZl<!Okie<xqMl<!GjzkiOe/!
.!ngk<kqbi<!
Clinical features 
 “hqk<kg<gQz<!uib<U!ke<eix<!
! hqxr<GgQt<!&m<M!uQr<gqs<!
! sqk<ki<osb<!lVf<K!uk<KR<!
! sQIhmik<!ke<jlk<!kigqk<!
! kk<kX!gib<s<sz<!g{<M!
!
! sizOu!kjekie<!kf<Ok!
! olk<kX!sqgqs<js!ke<eiz<!
! ole<Olz<!fQr<G!lh<hi”!
. shihkq!jgObM!
 Swelling of the joint 
 Fever 
 Restricted movement 
 Swelling of the joints will increased day by day.  Increased pitham act as synovid 
theid between the joint space which dries it.  It makes sound like “Kaluk, kaluk”.  
when the movement of the joint. 
 Sometimes it may cause inability to move the joints. 
MUKKUTRA VERUBADUGAL 
 In azhal Keel  vayu the following vayus are affected 
Vatham 
S.No. Vatham Physiological function Features in Azhal Keel 
Vayu 
1 Pranan Maintain the cardiac function, 
respiration 
Normal 
2 Abanan Act with downward movement Affected (Constipation) 
3 Viyanan Helps in various movements of body, 
responsible for sensation 
Restricted movement of the 
joint 
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4 Udhanan Control speech Normal 
5 Samanan Regulates all other vayus Affected 
6 Nagan Responsible for intelligence helps in 
opening and closing of eyes 
Normal 
7 Koorman Responsible for lacrimation.  Helps 
in visualization of all things of 
world. 
In aged patients acuity of 
vision is diminished. 
8 Kirukaran Produce cough and sneeze, helps in 
digestion 
Normal 
9 Thevathathan Responsible for lazziness. Rotation 
of eyeballs. 
Affected (Sleeplessness)  
10 Thanajeyan It leaves from the body by blowing 
up the cranium only on the 3rd day 
after death. 
 
- 
Pitham 
S.No. Pitham Physiological function Features in Azhal Keel 
Vayu 
1. Anar pitham Digests all the ingested 
particles. 
Affected (Indigestion) 
2. Ranjaga pitham Increases the blood and gives 
colour to the blood 
Affected 
3. Saathaga pitham Makes the work to complete 
what mind thinks to do 
Affected (Restricted 
movements) 
4. Prasaga pitham Gives colours to skin Normal 
5. Aalosaga pitham Responsible for vision of eyes Affected in old age peoples. 
 
Kabam 
 It is classified into 5 types 
S.No. Kabam Physiological function Features in Azhal Keel 
Vayu 
1. Avalambagam Controls other 4 types of kabam Affected 
2. Kilethagam Moistens the food Affected 
3. Pothagam Helps to know the taste Normal 
4. Tharpagam Gives cooling effect to the eyes Normal 
5. Santhigam Gives lubrication to joints Affected  
(Restricted movements) 
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In “azhal Keel vayu” the vatha kuttram is mainly affected followed by pitham and kabam. 
 When the vatha dosham is in vitiated condition, activity and dietary habits provoke 
the pitha dosham and derange the kabam. 
 The normal structural quality of the pitham is 
 Heat 
 Sharpness 
 Lubrication 
 Relaxation 
 Motion 
  In azhal Keel vayu the deranged pitham may produce stiffness, restriction of 
movements in the affected joints. 
  The normal structural quality of kabam is 
 Lubrication 
 Softness 
In azhal Keel vayu the deranged kabam may produce decreased secretion of synovial 
fluid may lead to loss of lubrication resulting in crepitation of joints. 
Udal Thathukkal 
There are seven udal thathukkal in human body 
S.No.  Physiological function Features in 
1. Saaram Strengthens the body and mind Affected 
2. Senneer Preserves brightness, boldness, 
power and knowledge 
Affected 
3. Oon Gives structure and shape to the 
body.  Responsible for 
movement 
Early stage  - Not affected 
Later stage  - Affected 
4.  Kozhuppu Lubricate the joints Affected 
5. Enbu Responsible to joint 
movements 
Affected 
6. Moolai It is present in the bones and 
gives strength 
Affected 
7. Sukkilam (or) 
suronitham 
Mean for reproduction Normal 
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PINIARI MURAI 
Diagnostic Procedure 
 Piniyarimuraimai is the method finding out the diseases, which is disturbing the body.  
This is based upon three main principles and Envagai thervugal. 
 
Envagai Thervu 
 “fic!^<hiqsl<!fifqxl<!olipq!uqpq!lzl<< < < << < < << < < <!
! &k<kqvl<!-ju!lVk<KuviBkl<< < < << < < << < < <”!
. Ofib<!fimz<!Ofib<!< < << < << < < Lkz<!fimz<< << << <!
2/ Naadi 
3/ Naa 
4/ Niram 
5/ Mozhi 
6/ Vizhi 
7/ Sparisam 
8/ Malam 
9/ Moothiram 
1. Naadi 
 Naadi is the vitiating element of the body which are vatham, pitham and kabam Naadi 
is otherwise called uyir thathukkal. 
 It is felt one inch below the wrist on the radial side by palpating with top of the index, 
finger, middle finger and ring finger which denotes vatham, pitham and kabam. 
Suitable places for pulse reading 
 “kiK!LjxOgt<!keqGkqs<!sf<okiM!
! YKX!gilqb!Lf<kq!ofM!liIH!
! giK!ofM&g<Gg<!g{<ml<!gvl<!HVul<!
! OhiKV!ds<sq!Hgp<!hk<Kl<!hiIk<kqOm” 
 
 Edaikalai  +  Abanan - Vatham 
Pinkalai + Pranan  - Pitham 
Suzhumunai + Samanan - Kabam 
“uikk<kqz<!Osk<Kl!ligqz<!uzqObiM!uQg<g!L{<mil<!
. ngk<kqbi<!fic!
“gi{h<hi!uik!lQxqz<!giz<jggt<!ohiVk<kq!OfiGl<”!
. giuqbfic!
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3/ Naa (Tongue) 
 Colour of the tongue and the dhosam responsible for its individually and collectively, 
clearness of the tongue, black, red, yellow, pallor condition of the tongue, coated tongue, 
excessive salivation, dryness of the tongue, ulceration, fissures, cancer like growth. 
 Vadha disease  - Dark in colour 
 Pitha disease  - Yellow in colour 
 Kaba disease  - White in colour 
In azhal Keel vayu dark dried tongue may be present. 
3. Niram (Colour) 
 Colour of the skin based on three dhosas derangement flushing of pallor of the face, 
black discolouration of eye and teeth. 
 In Azhal Keel vayu the affected area is red in colour. 
4. Mozhi (Speech) 
 Disorder of speech, increased tone in speech, low in voice, hoarseness of voice, rales 
and ronchi with dyspnoea. 
 In azhal Keel vayu decreased tone of speech because of the severity of disease. 
5. Vizhi (Eyes) 
 Normally vizhi affected in old age.  It colour based on derangement of dhosas 
collectively and individually redness, ulceration, pallor, sunken state of the eye, bulging of 
the eye balls, bluish discolouration, swelling excessive, lacrimination, condition of sight of 
vision, heaviness of eyelids. 
6. Sparisam (Sense of touch) 
 The abnormal increased sparisam is clinically called as inflammatory changes. 
 Increased sparisam – mithaveppam (warmth) felt on affected joint in azhal Keel vayu. 
7. Malam (Stod) 
 Constipation is common in vadha disease.  In azhal Keel vayu malam may be 
affected. 
8. Moothiram (urine) 
 The waste materials are excreted through urine from the body. 
Neerkuri 
 Urine is examined for its colour, froth, specific gravity, quantity frequency, odour. 
 “uf<k!fQIg<giq!wjm!l{l<!Fjv!wR<soze<!
! jxf<kqbZtuju!bjxGK!LjxOb” 
!
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In vatha disease 
 “Yr<gqb!uikk<OkiIg<G!fQIuqPr<!G{Ljxg<gqx<!
! H,r<ogic!gMk<Kofif<K!sqXk<Kme<!ohiVlq!uqPl<”!
Neikuri 
 Siddhars have explained a wonderful method to diagnose a disease by examine the 
urine with gingely oil. 
 
 “nVf<kq!lixqkLl<!nuqOviklib<!
! ! n0gz<!nzi<kz<!ngizU,{<!kuqi<f<kpzx!
! Gx<xtuVf<kq!dxr<gq!jugjx!
! ! Ncg<gzsk<!kiuqOb!giK!ohb<!
! okiV!L%Ik<kg<!gjzg<Gm<hM!fQiqe<!
! ! fQIg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe!
! The patient is subjected to normal for a day and the next day morning his/her urine is 
examined. 
 The very first urine of the patient is collected in a glass container.  The colour of the 
urine is noted and drop of gingely oil is added into the container without any oscillation and 
the spreading nature is examined. 
 “nVh<hLx<xiIg<!gu<uqkq!uqzg<Og”!
 Though the urine should be examined only in the morning, during emergency it may 
be done in any time. 
 “nvoue!fQ{<ce0Ok!uikl<!
! n[G!ofb<!hil<hqx<gi{qz<!neqzOfib<!
! NpqOhix<!hvuqx<!n0Ok!hqk<kl<!
! um<mlibqe<!k{quqzih<!hqk<k!Ofibil<!
! Lk<okik<K!fqx<gqe<!olipquoke<!ghOl!
! Lk<okeqe<!Jb!Ofib<kiOe”!
 If the oil spreads like a snake it indicates the vatham. 
 If it spreads like a ring it indicates the pitham. 
 It the oil does not spread and gives an appearance of a pearl it is the indication of 
kabam. 
 By the careful examination of the urine with gingely oil the physician may know 
whether the disease is unable or non curable.  For this purposes siddhars have 
explained various spreading nature of the urine to classify the disease. 
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Ivagai Nilam 
 The living places are divided on the basis of the natural geographical features into five 
distinct types known as “Thinai”. 
They are 
1. Kurinji  - Mountain and its surroundings 
2. Mullai  - Forest and its surroundings 
3. Marutham - Field and its surroundings 
4. Neithal - Sea and its surroundings 
5. Paalai  - Desert and its surroundings 
Kurinchi nilam 
 Inhabitants of this thinai frequently suffer from shivering, fever leading to dysfunction 
of blood, enlargement of liver and spleen, increase of kabam. 
Mullai nilam 
 Inhabitants of this thinai suffer from pitha disorders and also from disorders due to 
vatham, increased and liver enlargement. 
Neithal Nilam 
 Inhabitants of this thinai suffer from vatha disorders and also suffer excessive 
flatulence, enlargement liver and obesity. 
Marutha nilam 
 Inhabitants of this thinai are free from all disorders because all the three dhosas are 
always kept in proper proportion.  This is ideal for leading a healthy life. 
Palai Nilam 
 Inhabitants of this thinai suffer from disorders due to vatha, pitha, kaba diseases. 
Udal Vanmai 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Cheyarkai vanmai 
1. Iyarkai vanmai 
 Natural immunity of the body caused by mukkutram by birth. 
2. Kala vanmai 
 Growing of the body and strength according to the age. 
3. Cheyarkai vanmai 
 Improving the health by giving valuable food and medicines. 
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Relation between paruvakalam (season) Mukkutram and suvai 
S.No. Paruvakalangal Kuttram Suvai 
1. Kaarkalam            
(Avani and Purattasi)!
Vatham ↑ ↑ 
Pitham  ↑ 
Inippu 
Pulippu 
Uppu 
2. Koothirkalam      
(Iyppasi and Karthigai) 
Vatham (-) 
Pitham  ↑ ↑ 
Inippu 
Karippu 
Thuvarppu 
3. Munpanikalam      
(Maarkazhi and Thai)!
!
Pitham  (-) Inippu 
Pulippu 
Uppu 
4. Pinpanikalam         
(Maasi and Panguni) 
Kabam  ↑ Inippu 
Pulippu 
Thuvarppu 
5. Elavenir kalam       
(Chithirai and Vaikasi)!
!
Kabam ↑↑ Karippu 
Kaippu 
Thuvarppu 
6. Muduvenilkalam   
(Aani and Aadi) 
Vatham  ↑ 
Kabam (-) 
Inippu 
 
Ofib<!g{qh<H!uquikl<!)< < << < << < < Differential Diagnosis) 
1. Vali Keel vayu 
 “uzqg<Gk<kz<!uQg<gr<!gi[l<!uib<oki{<jm?!uxm<sq?!gib<s<sz<!
! kjzuzq!liIK!ch<Hk<!kir<ogi{i!uzquQg<!gf<kie<!
! fqzUgix<!gEg<G!xr<G!fQMOkit<!Lpr<jgg<!gix<gil<!
! lzg<Gmx<!gm<M!Oui<ju!uikk<kqz<!uib<uq!kiOl!
. shihkq!jgObM!
It is characterized by execruciating pain and swelling knee joints, hip joints, ankle 
joints, shoulder joints, elbow joints and associated with dryness of mouth, pyreixa, headache, 
palpitation, constipation and sweating. 
2. Iya Keel vayu 
 “gVkVr<!ghg<gQz<uiB!g{<ce<!dmzqjtg<Gl<!
! dVolzq!uig<Gr<!ogit<Tl<!d{<cjbs<!SVg<Gl<!-e<hf<!!
!
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! kVKbqz<!fQr<G!Lm<cx<!xir<!ogi{i!uZju!big<Gl<!
! -VlOz!uqg<gz<!uif<kq!Osijhhi{<!omPh<Hl<!hiOv”!
. shihkq!jgObM!
It is characterized by loss of weight, anorexia, severe pain in the knee joints, 
insomnia, cough, hiccough, vomiting, anaemia and dropsy.  The common site are vertebrae, 
hip joint, knee joint. 
3. Vali Iya Keel vayu 
 “ubr<ui!kg<g!hg<gqz<!uiBuie<!uzqlq!Vf<kOk!
! dbr<GfQI!Ogik<Kg<!gQz<gt<!yiqbqe<!kjzOhix<!gi[l<!
! fbr<ogit<t!Lmg<gz<!fQm<mz<!k{<{qmi!olb<Br<!giBl<!
! lbr<GX!Lxg<g!lqe<eib<!le<eqb!ofiqg<gm<!miOl”/!
! It is characterized by pain in the joints and effusion of joint fluid, swelling, restricted 
joint movement, pyrexia, fainting, insomnia, lymph adenopathy.  The affected joints look like 
“fox’s head”. 
Aim of treatment of Azhal Keel vayu 
 In siddha system, treatment is not only for removal of diseases but for the prevention 
and improving the body condition after removal of disease. 
 Prevention 
 Relieve pain 
 Restore function 
 Reduce disability if any 
Prevention 
 To prevent azhal Keel vayu is 
 Control the body weight by diet and exercise 
 Avoid the intake of excess sour, astringent, and bitter tasted foods. 
 Modify the nature of work gives stress to a particular joint (e.g) avoid prolonged 
standing and long distance walking. 
 To follow the “Noi Anuga Vithi” 
 The recurrence is prevented by yoga and Pranayama. 
Treatment 
 Normalizing the vitiated thiridosha there by retaining body’s natural health. 
 In azhal Keel vayu, the deranged vatham is brought to its normal state by purgation  
(uqOvsel<*!
! “uqOvsek<kiz<!uikf<kiPl<!
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1. 15 ml of vellai ennai is given with warm water early morning (single dose) in empty 
stomach before starting the treatment with trial drug. 
2. Internal Medicine- KANDATHIRI LEGHIYAM   6gms (bd)  
3. External medicine- NAKKA PUSA MUKKUTTENNAI(60ml) 
Apart from other departments sirappu maruthuvam department gives equal important 
to external therapy in siddha system of medicine along with its internal and external 
medicine. 
External therapies : Varmam, Yoga asanam. 
Varmam 
 Life energy flows in the body in a particular pathway.  There are certain key points in 
the body where the life energy “Vaasi” is concentrated.  Normally these are the points where 
two bones joint or a muscle inserts into a bone or the blood vessels, nerves are prominent.  
These points called “Varmam points”. 
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VARMAM THERAPY 
 The therapy of physical manipulation either by applying pressure on the varmam 
points or using massage therapy with specific medicated oil or blowing certain medicines in 
the nose or ear is called as varmam treatment. 
 Varmam are rhythmically tuned by varmam therapies for managing various disease 
like nervous disorders, arthrits, back pain, spinal problems etc. 
 Varma points to be manipulated for osteoarthritis are as follow. 
 Kaal Mootu varmam 
o Centre part of posterior aspect of both knee joints.  Mild pressure is 
applied using tips of middle three fingers. 
 Mootu suzharchi Varmam 
o This method stimulates varmam points around knee joint by a circulatory 
gripping massage around patella using thumb and index finger. 
 Santhu varmam 
o Location : On either side of the mootu varmam. 
 Sirattai varmam 
o Location : On the patella bone. 
 Mozhi poruthu varmam 
o Location : Posterior surface of the knee joint 
Yoga asanam 
 Yoga therapy is one of the form of relaxing body and mind.  Certain simple asana 
techniques are discussed to knee pain and strengthening thigh muscle. 
Asanam 
 Vajrasanam 
 Padmasanam 
 Utkatasanam 
 Gomukhasanam 
Vajrasanam 
 It is also known as the diamond pose or “thunderbolt” 
 It is a kneeling position sitting on the heels. 
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 The practitioner sits on the heels with the calves beneath the thighs.  There is a four 
finger gap between the knee caps, and the first toe of both the feet touch each other and sit 
erect. 
Benefits 
 This asana may help in digestive issues like constipation. 
 It strengthens the muscles of the legs and back. 
Padmasanam 
 It is also known as the LOTUS pose. 
 It is a cross legged sitting asana 
Benefits 
 Eases  menstrual discomfort. 
 Helps joints and ligaments flexible. 
Utkatasana 
 Chair pose, fiexe pose, lighting bolt pose. 
Benefits 
 This asana increases strength, balance and stability. 
 The hamstrings, quadriceps, gluteal muscles and the erector spinae muscles of the 
back are exercised and strengthened. 
Gomukhasana 
 It is otherwise known as low face pose 
The asana stretches several parts of the body simultaneously , including ankles, 
thighs, hips, chest, neck, arms and hands. 
Benefits 
It helps induce relaxation 
Helpful in relieving ailments like diabetes, high blood pressure and sexual malfuntion. 
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ASANAMS  
UKKATASANA GOMUKASANAM 
PADMASANAM VAJRASANAM 
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MODERN ASPECT 
ANATOMY OF KNEE: 
 Knee anatomy is about the structure of the knee – that is, the parts that makeup the 
knee. This article also tells you how a normal knee works and provides resources for 
problems of the knee joint or its parts including knee injuries. 
 Our knee is the most complicated and largest joint in our body. It’s also the most 
vulnerable because it bears enormous weight and pressure loads while providing flexible 
movement. When we walk, our knees support 1.5 times our body weight; climbing stairs is 
about 3-4 times our body weight and squatting about 8 times. 
 The knee joint is a synovial joint which connects the femur, our thigh bone and 
longest bone in the body, to the tibia, our shinbone and second longest bone. There are two 
joints in the knee the tibiofemoral joint, which joins the tibia to the femur and the 
patellofemoral  joint which joins the kneecap to the femur. These two joints work together to 
form a modified hinge joint that allows the knee to bend and straighten, but also to rotate 
slightly and from side to side. 
 The knee is part of a chain that includes the pelvis, hip, and upper leg above, and the 
lower leg, ankle and foot below. All of these work together and depend on each other for 
function and movement. 
 The knee joint bears most of the weight of the body. When we’re sitting, the tibia and 
femur barely touch; standing they lock together to form a stable unit. Let’s look at a normal 
knee joint to understand how the parts (anatomy) work together (function) and how knee 
problems can occur. 
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STRUCTURES OF THE KNEE: 
 
 The main parts of the knee joint are bones, ligaments, tendons, cartilages and a joint 
capsule, all of which are made of collagen. Collagen is a fibrous tissue present throughout our 
body. As we age, collagen breaks down. 
 The adult skeleton is mainly made of bone and a little cartilage in places. Bone and 
cartilage are both connective tissues, with specialized cells called chondrocytes embedded in 
a gel-like matrix of collagen and elastin fibers. Cartilage can be hyaline, fibrocartilage and 
elastic and differ based on the proportions of collagen and elastin. Cartilage is a stiff but 
flexible tissue that is good with weight bearing which is why it is found in our joints. 
Cartilage has almost no blood vessels and is very bad at repairing itself. Bone is full of blood 
vessels and is very good at self repair. It is the high water content that makes cartilage 
flexible. 
28 
 
Bones of the Knee 
 The bones give strength, stability and flexibility in the knee. Four bones make up the 
knee : 
 Tibia —commonly called the shin bone, runs from the knee to the ankle. The top of 
the tibia is made of two plateaus and a knuckle-like protuberance called the tibial 
tubercle. Attached to the top of the tibia on each side of the tibial plateau are two 
crescent-shaped shock-absorbing cartilages called menisci which help stabilize the 
knee. 
 Patella—the kneecap is a flat, triangular bone; the patella moves when the leg moves. 
It’s function is to relieve friction between the bones and muscles when the knee is 
bent or straightened and to protect the knee joint. The kneecap glides along the 
bottom front surface of the femur between two protuberances called femoral condyles. 
These condyles form a groove called the patellofemoral groove. 
 Femur—commonly called the thigh bone; it’s the largest, longest and strongest bone 
in the body. The round knobs at the end of the bone are called condyles. 
 Fibula—long, thin bone in the lower leg on the lateral side, and runs along side the 
tibia from the knee to the ankle. 
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 The knee works similarly to a rounded surface sitting atop a flat surface. The function 
of ligaments is to attach bones to bones and give strength and stability to the knee as the knee 
has very little stability. Ligaments are strong, tough bands that are not particularly flexible. 
Once stretched, they tend to stay stretched and if stretched too far, they snap. 
 Medial Collateral Ligament (tibial collateral ligament) – attaches the medial side of 
the femur to the medial side of the tibia and limits sideways motion of your knee. 
 Lateral Collateral Ligament (fibular collateral ligament) – attaches the lateral side of 
the femur to the lateral side of the fibula and limits sideways motion of your knee. 
 Anterior cruciate ligament – attaches the tibia and the femur in the center of your 
knee; it’s located deep inside the knee and in front of the posterior cruciate ligament. 
It limits rotation and forward motion of the tibia. 
 Posterior cruciate ligament – is the strongest ligament and attaches the tibia and the 
femur; it’s also deep inside the knee behind the anterior cruciate ligament. It limits the 
backwards motion of the knee. 
 Patellar ligament – attaches the kneecap to the tibia 
 The pair of collateral ligaments keep the knee from moving too far side-to-side. The 
cruciate ligaments crisscross each other in the center of the knee. They allow the tibia to 
“swing” back and forth under the femur without the tibia sliding too far forward or backward 
under the femur. Working together, the 4 ligaments are the most important in structures in 
controlling stability of the knee. There is also a patellar ligament that attaches the kneecap to 
the tibia and aids in stability. A belt of fascia called the iliotibial band runs along the outside 
of the leg from the hip down to the knee and helps limit the lateral movement of the knee. 
Tendons in the Knee 
 Tendons are elastic tissues that technically part of the muscle and connect muscles to 
bones. Many of the tendons serve to stabilize the knee. There are two major tendons in the 
knee—the quadriceps and patellar. The quadriceps tendon connects the quadriceps muscles of 
the thigh to the kneecap and provides the power for straightening the knee. It also helps hold 
the patella in the patellofemoral groove in the femur. The patellar tendon connects the 
kneecap to the shinbone (tibia)—which means it’s really a ligament. 
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 The ends of bones that touch other bones—a joint—are covered with articular 
cartilage. It’s gets its name “articular” because when bones move against each other they are 
said to “articulate.” Articular cartilage is a white, smooth, fibrous connective tissue that 
covers the ends of bones and protects the bones as the joint moves. It also allows the bones to 
move more freely against each other. The articular cartilages of the knee cover the ends of the 
femur, the top of the tibia and the back of the patella. In the middle of the knee are menisci—
disc shaped cushions that act as shock absorbers. 
 Medial meniscus 
o The medial meniscus is made of fibrous, crescent shaped cartilage and 
attached to the tibia, on the inside of the knee 
 Lateral meniscus 
o This is made of fibrous, crescent shaped cartilage and attached to the tibia, on 
the outside of the knee 
 Articular cartilage 
o Found on the ends of all bones in any joint—in the knee joint it covers the 
ends of the femur and tibia and the back of the patella. The articular cartilage 
is kept slippery by synovial fluid (which looks like egg white) made by the 
31 
 
synovial membrane (joint lining). Since the cartilage is smooth and slippery, 
the bones move against each other easily and without pain. 
 In a healthy knee, the rubbery meniscus cartilage absorbs shock and the side forces 
placed on the knee. Together, the menisci sit on top of the tibia and help spread the 
weight bearing force over a larger area. Because the menisci are shaped like a shallow 
socket to accommodate the end of the femur, they help the ligaments in making the 
knee stable. Because the menisci help spread out the weight bearing across the joint, 
they keep the articular cartilage from wearing away at friction points. 
 The weight bearing bones in our body are usually protected with articular cartilage, 
which is a thin, tough, flexible, slippery surface which is lubricated by synovial fluid. 
The synovial fluid is both viscous and sticky lubricant. Synovial fluid and articular 
cartilage are a very slippery combination—3 times more slippery than skating on ice, 
4 to 10 times more slippery than a metal on plastic knee replacement. Synovial fluid is 
what allows us to flex our joints under great pressure without wear. 
 
 The muscles in the leg keep the knee stable, well aligned and moving—the quadriceps 
(thigh) and hamstrings. There are two main muscle groups—the quadriceps and hamstrings. 
The quadriceps are a collection of 4 muscles on the front of the thigh and are responsible for 
straightening the knee by bringing a bent knee to a straight position. The hamstrings is a 
group of 3 muscles on the back of the thigh and control the knee moving from a straight 
position to a bent position. 
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The Joint Capsule 
 The capsule is a thick, fibrous structure that wraps around the knee joint. Inside the 
capsule is the synovial membrane which is lined by the synovium, a soft tissue that secretes 
synovial fluid when it gets inflamed and provides lubrication for the knee. 
Bursae 
 There are up to 13 bursae of various sizes in and around the knee. These fluid filled 
sacs cushion the joint and reduce friction between muscles, bones, tendons and ligaments. 
There are bursa located underneath the tendons and ligaments on both the lateral and medial 
sides of the knee. The prepatellar bursa is one of the most significant bursa and is located on 
the front of the knee just under the skin. It protects the kneecap. In addition to bursae, there is 
a infra patellar fat pad that helps cushion the kneecap. 
Plicae 
 Plicae are folds in the synovium. Plicae rarely cause problems but sometimes they can 
get caught between the femur and kneecap and cause pain. 
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KNEE FUNCTION: 
 So now we have all the parts, let’s see how the knee moves (articulates) which is how 
we walk, stoop, jump, etc.  The knee has limited movement and is designed to move like a 
hinge. 
 The Quadriceps Mechanism is made up of the patella (kneecap), patellar tendon, and 
the quadriceps muscles (thigh) on the front of the upper leg. The patella fits into the 
patellofemoral groove on the front of the femur and acts like a fulcrum to give the leg its 
power. The patella slides up an down the groove as the knee bends. When the quadriceps 
muscles contract they cause the knee to straighten. When they relax, the knee bends. 
  In addition the hamstring and calf muscles help flex and support the knee. 
 While age is a major risk factor for osteoarthritis of the knee, young people can get it, 
too. For some individuals, it may be hereditary. For others, osteoarthritis of the knee can 
result from injury or infection or even from being overweight. Here are answers to your 
questions about knee osteoarthritis, including how it's treated and what you can do at home to 
ease the pain. 
 Osteoarthritis, commonly known as wear-and-tear arthritis, is a condition in which the 
natural cushioning between joints cartilage wears away. When this happens, the bones of the 
joints rub more closely against one another with less of the shock-absorbing benefits of 
cartilage. The rubbing results in pain, swelling, stiffness, decreased ability to move and, 
sometimes, the formation of bone spurs. 
 Osteoarthritis is the most common type of arthritis. While it can occur even in young 
people, the chance of developing osteoarthritis rises after age 45. According to the Arthritis 
Foundation, more than 27 million people in the U.S. have osteoarthritis, with the knee being 
one of the most commonly affected areas. Women are more likely to have osteoarthritis than 
men. 
 The most common cause of osteoarthritis of the knee is age. Almost everyone will 
eventually develop some degree of osteoarthritis. However, several factors increase the risk 
of developing significant arthritis at an earlier age.  
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CAUSES: 
 Age. The ability of cartilage to heal decreases as a person gets older. 
 Weight. Weight increases pressure on all the joints, especially the knees. Every 
pound of weight you gain adds 3 to 4 pounds of extra weight on your knees. 
 Heredity. This includes genetic mutations that might make a person more likely 
to develop osteoarthritis of the knee. It may also be due to inherited abnormalities 
in the shape of the bones that surround the knee joint. 
 Gender. Women ages 55 and older are more likely than men to develop 
osteoarthritis of the knee. 
 Repetitive stress injuries. These are usually a result of the type of job a person 
has. People with certain occupations that include a lot of activity that can stress 
the joint, such as kneeling, squatting, or lifting heavy weights (55 pounds or 
more), are more likely to develop osteoarthritis of the knee because of the constant 
pressure on the joint. 
 Athletics. Athletes involved in soccer, tennis, or long-distance running may be at 
higher risk for developing osteoarthritis of the knee. That means athletes should 
take precautions to avoid injury. However, it's important to note that regular 
moderate exercise strengthens joints and can decrease the risk of osteoarthritis. In 
fact, weak muscles around the knee can lead to osteoarthritis. 
 Other illnesses. People with rheumatoid arthritis, the second most common type 
of arthritis, are also more likely to develop osteoarthritis. People with certain 
metabolic disorders, such as iron overload or excess growth hormone, also run a 
higher risk of osteoarthritis. 
SYMPTOMS OF OSTEOARTHRITIS OF THE KNEE MAY INCLUDE: 
• Pain that increases when you are active, but gets a little better with rest 
• Swelling 
• Feeling of warmth in the joint 
• Stiffness in the knee, especially in the morning or when you have been sitting for 
a while 
• Decrease in mobility of the knee, making it difficult to get in and out of chairs or 
cars, use the stairs, or walk 
• Creaking, crackly sound that is heard when the knee moves 
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PATHOPHYSIOLOGY: 
 The knee joint consists of both approximation of the proximal tibia and the distal end 
of the femur. The cartilage located on the ends of the femur and tibia contain an extra cellular 
matrix that contains type 2 protoglycans that function by drawing fluid into the joint causing 
increased shock absorption and proper joint nutrition.There is some evidence to support that 
as the aging process occurs the type 2 collagen fibers decrease in size and therefore less fluid 
an nutrition gets into the joint surfaces eventually leading to decreased protection along 
boney surfaces.  
 The knee (art. genus) is a synovial joint, which consists of 3 articulations. The 
primary joint, art. tibiofemoral, is located between the convex femoral condyles and the 
concave tibial condyles.There is also the art. patellofemoralis between the femur and the 
patella and the art. tibiofibularis located between the tibia and fibula. OA can only occur in 
the two primary articulations of the knee, namely the tibiofemoral and patellofemoral joint, 
because they have to sustain more motion than the art. tibiofibularis. 
 “The pathogenesis of knee OA have been linked to biomechanical and biochemical 
changes in the cartilage of the knee joint.” The cartilage ensures that the bone surfaces can 
move painless and with low friction to each other. In OA, the cartilage decreases in thickness 
and quality, it becomes thinner and softer, cracks may occur and it will eventually crumble 
off. Cartilage that has been damaged, cannot recover. Finally the cartilage will disappear. The 
bone surfaces can also be affected, the bone will expand and spurs (osteophytes) will 
develop. 
 Not only the cartilage can be affected, there is also occur laxity of the ligaments and 
muscle atrophy.  
CHARACTERISTICS / CLINICAL PRESENTATION: 
 Signs of knee osteoarthritis are pain at beginning of the movement, later on pain 
during movement and eventually permanent pain. These patients will also experience a loss 
of function like stiffness, decreased range of motion (ROM) and impairment in everyday 
activities. Other possible characteristics of knee OA are bony enlargement, crepitus, joint-line 
tenderness and elevated sensitivity to cold and/or damp. 
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We can subdivide knee osteoarthritis in 5 stages: 
 Stage 0: This is the “normal” knee health, without any pain in the joint functions.  
 Stage 1: A person in this stage has very minor bone spur growth and is not 
experiencing any pain or discomfort.  
 Stage 2: This is the stage where people will experience symptoms for the first time. 
They will have pain after a long day of walking and will sense a greater stiffness in 
the joint. It is a mild stage of the condition, but X-rays will already reveal greater 
bone spur growth. The cartilage will likely remain at a healthy size.  
 Stage 3: Stage 3 is considered as a moderate osteoarthritis. People with this stage will 
experience a frequent pain during movement. The joint stiffness will also be more 
present, especially after sitting for long periods and in the morning. The cartilage 
between the bones shows obvious damage, and the space between the bones is getting 
smaller.  
 Stage 4: This is the most severe stage of osteoarthritis. The joint space between the 
bones will be dramatically reduced, the cartilage will almost be completely gone and 
the synovial fluid will be decreased. That is why people will experience lots of pain 
and discomfort during walking or moving the joint. 
DIFFERENTIAL DIAGNOSIS: 
 The diagnosis can be established by clinical examination, and it can be confirmed by 
X-rays. The main characteristics are changes in the subchondral bone, joint space narrowing, 
subchondral sclerosis, subchondral cyst formation and osteophytes. In early stage of 
osteoarthritis, the results of the radiography can show a minimal unequal joint space 
narrowing. If it deteriorates you still find the same problems, but the patient experiences a 
lateral subluxation of the tibia as well. If it deteriorates more, the joint line will disappear 
completely. It is shown in the picture that the medial joint space is more narrow than the 
lateral joint line. 
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Some differential diagnosis can be: bursitis, iliotibial band syndrome, ligamentous instability 
(medial and lateral collateral ligaments) and meniscal pathology, these are conditions in 
whereby the soft tissues of the knee are affected. But also other forms of arthritis can lead to 
differential diagnosis of the knee, think of gout and pseudogout, rheumatoid arthritis and 
septic arthritis. 
DIAGNOSTIC PROCEDURES: 
SYMPTOMS: 
PRIMARY: 
 Pain  
 Stiffness, particularly in the morning  
 Sensitivity when kneeling or bending 
 Decrease in the abilities of daily functioning  
 More commonly diagnosed 
SECONDARY: 
 Loss of mobility in the affected joint  
 Decrease in muscle power  
 Instability of the joint  
 Crepitations  
 This type of OA can be caused by obesity, trauma, inflammatory or genetically 
X-ray: The basic X-ray is used to research breakdown of cartilage, narrowing of joint space, 
forming of bone spurs and to exclude other causes of pain in the affected joint.  
Arthrocentesis: This is a procedure which can be performed at the doctor’s office. A sterile 
needle is used to take samples of joint fluid which can then be examined for cartilage 
fragments, infection or gout.  
Arthroscopy: is a surgical technique where a camera is inserted in the affected joint to obtain 
visual information about the damage caused to the joint by the osteoarthritis.  
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The European League against Rheumatism developed diagnostic criteria for diagnosing knee 
osteoarthritis. The most important factors are shown in the following figure. 
 
EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis 
EXAMINATION: 
 If a patient is referred to you by a doctor, it is most likely he performed a medical 
examination. It is imperative to look at his/her findings when examination the patient.  
 Inspection: Mind the position of the joints when in rest and how the patient moves. 
This can be accomplished by making the patient perform simulations of daily 
activities such as getting up from and down on a chair, stair climbing, etc. 
 Palpation: Mind: swelling, temperature differences, muscle tonus. Also be wary of 
possible bone spurs (osteocytes) that have formed on the edge of the joint. These 
osteocytes are a serious indication towards osteoarthritis.  
 Examination of basic functions: Testing of muscle power, coordination, mobility, 
balance and also stability of the joint. These factors can be tested by active test like 
standing on one leg and passive manual tests. When testing stability of the joint 
muscle strength and proprioception are of significant importance. 
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MATERIALS AND METHODS 
 The clinical study on Azhal Keel vayu (osteoarthritis of knee joint) was carried out in 
the post graduate department of sirappu Maruthuvam, Government Siddha Medical College, 
at Palayamkottai.  In this study 40 patients (who satisfy the inclusion criteria and exclusion 
criteria) were treated as OP and IP 
Selection of the patients  
Age : 30 – 60 yrs 
Sex : Both Male and Female 
Clinical findings 
Inclusion criteria 
The patients were selected on the basis of the following clinical findings.   
 Patients having symptoms of joint pain in one or both knee joints, swelling, 
tenderness, stiffness, crepitation, restricted movements of joints. 
 Patients who are willing to give blood samples for laboratory investigation. 
 Patients who are willing to take radiological imaging before and after 
treatment. 
 Patients who are willing to participate in this study with the knowledge of 
potential risks. 
 
The detailed history was taken from the patient about 
1. Occupation 
2. Socio economic status 
3. Diet and habits 
Pain assessment 
 Universal pain assessment scale 
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A. 0  -  No pain 
B. 1-3 - Mild pain 
C. 4-6 - Moderate pain 
D. 7-10 - Severe pain 
 
Reference: Clinical Manual for Nursing Practice. (National Institute of Heatlth Warren Grant 
Magnuson Clinical centre. 
 
GRADATION: 
Grade 1: Fit for all activities to do their work without support (Normal)  
Grade 2: Mild Pain and Mild restriction of Movements  
Grade 3: Moderate Pain and Moderate restriction of Movements  
Grade 4: Severe Pain and Severe restriction of Movement  
Diagnosis 
 The diagnosis was made by following siddha diagnostic methods kaalam, poriaridhal, 
pulanaridhal, udalthathukkal, Naadi and Envagai Thervugal and the diagnosis of Azhal Keel 
vayu obtained which correlated with modern diagnosis of osteoarthritis of knee joints by the 
x-ray findings. 
 
Exclusion criteria 
 
 Cardiac disease 
 Rheumatoid arthritis 
 Use of narcotic drugs 
 Pregnancy and lactating women 
 History of trauma 
 Carcinoma patient 
 Other Systemic Illness 
 Tuberculosis 
 Immuno compromised patient  
 Clinically significant abnormal laboratory values.  
 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor Patient compliance & defaulters 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness. 
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INVESTIGATION 
  The following investigations were done in all selected patients in the laboratory of 
Government Siddha Medical College, Palayamkottai. 
 
BLOOD 
 Total WBC count 
 Differential WBC count 
 Erythrocyte sedimentation rate 
 Haemoglobin estimation 
 Estimation of Blood sugar 
 Estimation of Blood urea 
 Estimation of serum cholesterol 
URINE 
 Albumin 
 Sugar 
 Deposit 
RADIOLOGICAL INVESTIGATIONS 
 X-ray of both knee joint- AP view and lateral view 
TREATMENT 
 Vellai ennai 15ml at early morning, in empty stomach with hot water.  All the patients 
were treated with the following medicine. 
 Kandathri leghiyam(Internal) 
6 grms (BD) 
 NAKKA PUSA MUKKUTTENNAI 
      60ml, as external application 
 Varmam and yoga asanam are applied as the complimentary therapy 
 All patients were advised to follow the dietary regimens (or) pathiyam. 
 The Bio-Chemical analysis was done in the Biochemistry Department and 
Pharmacological analysis was done in the Pharmacological laboratory of KMCH college of 
Pharmacy. 
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RESULTS AND OBSERVATION 
  For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, Government Siddha Medical College and Hospital, 
Palayamkottai.  Results were observed with respect to the following criteria. 
1. Gender distribution 
2. Age distribution 
3. Kaalam 
4. Occupation 
5. Seasonal variations 
6. Thinai 
7. Socio-economic status 
8. Dietary habits 
9. Precipitating factors 
10. Mode of onset 
11. Duration of conditions 
12. Clinical features 
13. Conflict in Kanmethiriam 
14. Disturbance in Vatham 
15. Disturbance in Pitham 
16. Disturbance in Kabam 
17. Disturbance in Udal kattugal 
18. Envagai Thervugal 
19. Naadi 
20. Neikuri 
21. Selection of patients 
22. Assessment of results 
 Assessment of curative effect in knee osteoarthritis patients treated 
with trial drugs alone. 
 Trial drugs along with complementary therapy (Yoga asanam) 
 Trial drugs along with complementary therapy (Varmam) 
 Effect of Trial drug along with complements therapies. 
 Comparison between effective of trial drug and trial drug with 
complementary therapies 
 Overall Results after treatment. 
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RESULTS AND OBSERVATION 
 
1. GENDER DISTRIBUTION 
 
S.No Gender No of Cases Percentage (%) 
1 Male 11 27.5 
2. Female 29 72.5 
 Total 40 100 
 
 
 
Inference 
 Among the 40 patients selected for this study 27.5% are male and 72.5% are female. 
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2. AGE DISTRIBUTION 
 
S.No Age (years) No of Cases Percentage (%) 
1 30-40 3 7.5 
2. 41-50 11 27.5 
3. 51-60 26 65 
 Total 40 100 
 
 
 
Inference 
 The prevalence of the diseases is found to be higher in the age group of 51-60 years. 
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3. KAALAM 
 
S.No Kaalam No of Cases Percentage (%) 
1 Vathakaalam (Upto 33 years) 1 2.5 
2. Pithakaalam (33 years to 66 years) 39 97.5 
3. Kabhakaalam (Above 66 years) 0 0 
 Total 40 100 
 
 
 
 
Inference 
 Out of 40 cases, 97.5% of cases were found to be in pithakaalam. 
           2.5%  of cases were found to be in vadhakaalam. 
  
2.5
97.5
0
0
20
40
60
80
100
120
vaathakaalam(1-33 yrs) pithakaalam(34-66yrs) kabakaalam(67-100)
p
e
rc
e
n
ta
g
e
%
kaalam
46 
 
5.OCCUPATION 
 
S.No Occupation No of Cases Percentage (%) 
1 Farmer & Labour 10 25 
2. Carpenter/ Mason 1 2.5 
3. Teacher 4 10 
4. Housewife 25 62.5 
5. House keeper 0 0 
 Total 40 100 
 
 
 
Inference 
 Out of 40 cases, in this study the rates of incidence is higher in occupational group 
which includes housewives 62.5% and farmer & labour 25% and teacher 10% and 
carpenter/mason  2.5%. 
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6. SEASONAL VARIATIONS 
S.No Seasons No of Cases Percentage (%) 
1 Kaarkaalam (Aug 16- Oct 15) 0 0 
2. Koothirkaalam (Oct 16- Dec 15) 2 5 
3. Mupanikaalam (Dec 16- Feb 15) 38 95 
4. Pinpani kaalam (Feb 16 – Apr 15) 0 0 
5. Ilavenirkaalam (Apr 16-June15) 0 0 
6. Muthuvenilkaalam (June 16 – Aug 0 0 
 Total 40 100 
 
 
 
 
Inference 
 Out of 40 cases, 2 patients (5%) were admitted in koothirkaalam, 38 patients (95%) 
were admitted in Munpanikaalam . 
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7. THINAI 
 
S.No Seasons No of Cases Percentage (%) 
1 Kurinji (Hill area) 3 7.5 
2. Mullai (Forest area) 0 0 
3. Marutham (Fertile area) 34 85 
4. Neithal (Coastal area) 3 7.5 
5. Paalai (Desert land) 0 0 
 Total 40 100 
 
 
 
 
Inference 
 Among 40 cases, majority were from marutha nilam. 
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8. SOCIO-ECONOMIC STATUS 
S.No Class No of Cases Percentage (%) 
1 Rich 3 7.5 
2. Middle - class 15 37.5 
3. Poor 22 55 
 Total 40 100 
 
 
 
 
Inference 
 Out of 40 cases 55% of the cases were from poor socio-economic status, 37.5% cases 
were from middle class families and only 7.5% from Rich background. 
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9. DIETARY HABITS 
S.No Dietary No of Cases Percentage (%) 
1 Vegetarian 8 20 
2. Non-vegetarian 32 80 
 Total 40 100 
 
 
 
 
Inference 
 Most of the cases have non-vegetarian diet habit. 
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10. PRECIPITATING FACTORS 
 
S.No Precipitating factors No of Cases Percentage (%) 
1 Trauma 0 0 
2. Obesity 9 22.5 
3. Occupation related overuse of the 
joint 
10 25 
4. Menopause 20 50 
5. Hereditary 1 2.5 
 Total 40 100 
 
 
 
 
Inference 
 Among the 40 patients, 20 patients of them (50%) were in the post menopause stage, 
10 of them (25%) had history of over use of the joints, 9 of them (22.5%) were obese, and 1 
of them (2.5%) were hereditary. 
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11. MODE OF ONSET 
 
S.No Mode of onset No of Cases Percentage (%) 
1 Acute 10 25 
2. Gradual 30 75 
 Total 40 100 
 
 
 
 
Inference 
 According to this study 75% of cases were reported gradual onset of disease. 
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12. DURATION OF CONDITIONS 
S.No Duration (Months) No of Cases Percentage (%) 
1 0-3 0 0 
2. 4-6 7 17.5 
3. 7-12 6 15 
4. 13-24 10 25 
5. Above 24 17 42.5 
 Total 40 100 
 
 
 
 
Inference 
 Among the 40 cases, 7 cases (17.5%) were come under 4-6 months, 6 cases (15%) 
were come under 7-12 months, 10 cases (25%) were come under 13-24 months and 17 cases 
(42.5%) were came beyond 24 months.  
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13. CLINICAL FEATURES 
S.No Clinical features No of Cases Percentage (%) 
1 Pain 40 100 
2. Swelling 28 70 
3. Tenderness 30 75 
4. Morning stiffness 8 20 
5. Crepitation 40 100 
6. Deformity 7 17.5 
7. Restricted movements 35 87.5 
8. Sleeplessness 22 55 
 
 
 
 
 Inference 
 Pain, crepitation were found in all 40 cases (100%) 
 Swelling was found in 28 cases (70%) 
 Tenderness was found in 30 cases (75%) 
 Restricted movements was found in 35 cases (87.5%) 
 Morning stiffness was found in 8 cases (20%) 
 Sleeplessness was found in 22 cases (55%). 
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14. CONFLICT IN KANMENTHIRIAM 
S.No Kanmenthiriam No of Cases Percentage (%) 
1 Vaai 0 0 
2. Kai 0 0 
3. Kaal 40 100 
4. Eruvai 16 40 
5. Karuvaai 0 0 
 
 
Inference 
 Among all the kanmenthiriam (Kai, kaal, vai, eruvai, karuvai) kaal was affect in all 
the 40 cases (100%) and Eruvai was affected in 16 cases (40%). 
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15. TABLE SHOWING THE DISTURBANCES IN VATHAM 
S.No Vatham No of Cases Percentage (%) 
1 Pranan 0 0 
2. Abanan 16 40 
3. Udhanan 0 0 
4. Viyanan 40 100 
5. Samanan 40 100 
6. Nagan 0 0 
7. Koorman 0 0 
8. Kirukaran 11 27.5 
9. Devathathan 11 27.5 
10. Dhananjeyan 0 0 
 
 
Inference 
 Viyanan and Samanan were affected in all the 40 cases (100%) Abanan were affected 
in 16 cases (40%) and Kirukaran and Devathathan affected in 11cases (27.5%). 
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16. DISTURBANCES IN PITHAM 
S.No Pitham No of Cases Percentage (%) 
1 Anar pitham 14 35 
2. Ranjaga pitham 15 37.5 
3. Sathaga pitham 40 100 
4. Prasaga pitham 0 0 
5. Alosaga pitham 0 0 
 
 
 
Inference 
 Sathaga Pitham was affected in all 40 cases (100%), Ranjagapitham was affected in 
15 cases (37.5%) Anarpitham was affected in 14 cases (35%). 
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17. TABLE SHOWING THE DISTURBANCE OF KABAM 
S.No Kabam No of Cases Percentage (%) 
1 Avalambagam 40 100 
2. Kilethagam 0 0 
3. Bothagam 0 0 
4. Tharpagam 0 0 
5. Santhigam 40 100 
 
 
 
Inference 
 Among all Santhigam and avalambagam was affected in all 40 cases (100%) 
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18. DISTURBANCE IN UDAL KATTUGAL 
S.No Udal kattugal No of Cases Percentage (%) 
1 Saaram 40 100 
2. Seneer 9 22.5 
3. Oon 0 0 
4. Kozhuppu 40 100 
5. Enbu 40 100 
6. Moolai 0 0 
7. Sukilam/suronidham 0 0 
 
 
 
 
Inference 
 It was diagnosed, during the study that among the seven udalkattukal saaram, 
kozhuppu, Enbu were affected in 40 cases (100%) and seneer is affected in 9 cases (22.5%). 
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19. ENVAGAI THERVUGAL 
S.No Envagai thervugal No of Cases Percentage (%) 
1 Naa 0 0 
2. Niram 0 0 
3. Mozhi 0 0 
4. Vizhi 0 0 
5. Malam 15 40 
6. Moothiram 0 0 
7. Sparisam 0 0 
8. Naadi 40 100 
 
 
 
 
Inference 
  It was learnt during the study that Naadi was noted in all 40 cases (100%) 
Malam was affected in 15 cases (40%) 
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20. NAADI 
Pulse reading (Naadi) 
S.No Parameters No of Cases Percentage (%) 
1 Vathapitham 27 67.5 
2. Pitha vatham 10 25 
3. Kabavatham 3 7.5 
 
 
 
 
Inference 
 As mentioned above naadi was noted in all cases and among them 27 cases (67.5%) 
were vathapitha naadi, 10 cases (25) were pithavatha naadi and remaining 3 cases (7.5%) 
were kabavatha naadi. 
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21. NEIKURI 
S.No Inference No of Cases Percentage (%) 
1 Spreading like snake 21 52.5 
2. Spreading like a ring 9 22.5 
3. Stands like a pearl 10 25 
4. Combination of ring and snake 0 0 
 
 
 
Inference 
  In Neikuri analysis, 52.5% of the cases presented with vatha neer, 22.5% with 
pithaneer, 25% with kaba neer . 
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TABLE 22. ASSESSMENT OF CURATIVE EFFECTS IN PATIENTS TREATED 
ONLY WITH TRAIL DRUG   
(INTERNAL AND EXTERNAL MEDICINES) 
symptoms Initial readings Final readings 
No of patients percentage No of patients Percentage 
No pain 0 0 10 50 
Mild 5 25 4 20 
Moderate 7 35 2 10 
severe 8 40 4 20 
 
 
 
Inference  
    From the above study, it was inferred that severe pain that was noted in patients 
before treatment had a remarkable decline after treatment similarly moderate and mild pain 
were also observed to have decreased after treatment. 
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TABLE 23. ASSESSMENT OF CURATIVE EFFECTS IN OSTEOARTHRITIS 
PATIENTS TREATED WITH TRAIL DRUGS ALONG WITH COMPLIMENTARY 
THERAPY (YOGA) 
symptoms Initial readings Final readings 
No of patients percentage No of patients Percentage 
No pain 0 0 5 50 
Mild 4 40 2 20 
Moderate 3 30 2 20 
severe 3 30 1 10 
 
 
Inference 
  Administration of trial drug along with complementary therapy reduced severe pain 
almost all the cases also in mild and moderate cases were notably reduced. 
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TABLE 24. ASSESSMENT OF CURATIVE EFFECTS IN OSTEOARTHRITIS 
PATIENTS TREATED WITH TRAIL DRUGS. ALONG WITH COMPLEMENTARY 
THERAPY (VARMAM) 
symptoms Initial readings Final readings 
No of patients Percentage No of patients Percentage 
No pain 0 0 6 60 
Mild 3 30 3 30 
Moderate 2 20 1 10 
severe 5 50 0 0 
 
 
 
Inference 
 Administration of trial drug along with complementary therapy reduced severe pain in 
almost all the cases, mild and moderate cases were notably reduced. 
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TABLE 25.  EFFECT OF TRAIL DRUG ALONG WITH COMPLEMENTARY 
THERAPIES 
S.no Effect of therapy No. Of patients Percentage(%) 
1 Marked effect 11 55 
2 Moderate effect 3 15 
3 Mild effect 5 25 
4 No effect 1 5 
 
 
 
Inference 
 Administration of trial drug along with complementary therapies had 55% good 
effect, 15% moderate effect and  25% mild effect and 5 % no effect. 
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TABLE 26. COMPARISON BETWEEN EFFECTIVE OF TRAIL DRUG AND TRAIL 
DRUG WITH COMPLEMENTARY THERAPIES 
 
S.no 
 
 
Effect of therapy 
Trail drug alone Trail drug with 
external therapy 
No.Of 
cases 
percentage No.Of 
cases 
percentage 
1 Good 10 50 11 55 
2 Moderate 4 20 3 15 
3 Mild 2 10 5 25 
4 No 4 20 1 5 
 
 
 
Inference: 
    In comparative study , the  trial drug with  external therapy is more effective than trial drug 
alone. 
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TABLE 27. EFFECT OF THERAPY 
S.no Effect of therapy No. Of patients Percentage(%) 
1 Marked effect 24 60 
2 Moderate effect 7 17.5 
3 Mild effect 8 20 
4 No effect 1 2.5 
 
 
 
 
Inference 
 Thus from the analysis of the data collected during the course of treatment and at 
the end of treatment it is inferred that the overall effect of the therapy (internal, external and 
complementary) had marked effect of 60%, moderate effect of 17.5% and mild effect of 20% 
,no effect of 2.5%. 
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MEASUREMENT OF THE KNEE JOINTS 
 
S.NO 
 
PATIENT NAME 
 
AGE/SEX 
 
OP/IP NO 
 
BEFORE TREATMENT 
 
AFTER TREATMENT 
Right (cm) Left (cm) Right(cm) Left(cm) 
1  Palaniyammal 60/f 3358 35 33 31 30 
2  Jeyanthi 43/f 113318 38 36 34 33 
3  Raja lakshmi 60/f 1194 39 38 33 32 
4  Kala 56/f 5669 34 33 30 30 
5  Poovaiya 55/m 2942 35 32 33 29 
6  Sherina 57/f 9038 36 35 32 31 
7 Chendhura paundiyan 58/m 2154 33 32 29 30 
8 Valliyammal 48/f 114833 40 39 35 34 
9 Iyyam perumal 60/m 114059 32 35 28 27 
10  Meera 46/f 12319 31 33 26 28 
11 Anaikarai muthu 56/m 548 41 39 38 37 
12 Kaliyappan 52/m 46 38 31 36 33 
13 Anuthai 52/f 233 39 37 36 33 
14 Mariyammal 41/f 380 30 37 28 35 
15 Sagunthala 43/f 5986 24 28 22 26 
16 Nadarajan 60/m 430 33 30 31.5 28 
17 mariyammal 45/f 10363 34 31 33 27 
18 Ramalingam 54/m 11323 35 32 31 30 
19 Kuruvammal 60/f 1115 37 36 33 30 
20 Shanmugasuntharam 55/m 12388 40 38 38 35.5 
 
INFERENCE:   Knee joint swelling is reduced approximately 2-3 cms after treatment. 
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CASE PRESENTATION – SUMMARY OF OUT PATIENTS 
1. KANDATHIRI  LEGHIYAM – INTERNAL    2.NAKKA PUSA MUKKUTTENNAI – EXTERNAL 
 
 
S.no Op.no Name Age/sex Occupation Date of 
registration 
Date of completion 
of treatment 
No. Of days 
treated 
Result 
1 110149 Navamani 59/m Farmer 14-12-17 02-02-18 49 MODERATE 
2 113318 Jeyanthi 43/f House wife 23-12-17 02-02-18 42 MILD 
3 114833 Valliyammal 48/f House wife 28-12-17 16-02-18 48 MARKED 
4 114059 Iyyam perumal 60/m Farmer 29-12-17 02-02-18 35 MARKED 
5 1759 Rasammal 50/f House wife 04-01-18 20-02-18 48 MODERATE 
6 5669 Kala 56/f House wife 17-01-18 27-02-18 42 MARKED 
7 5810 Jeyarani 52/f Teacher 17-01-18 25-02-18 42 MILD 
8 5986 Sagunthala 43/f Teacher 17-01-18 21-01-18 35 MARKED 
9 7792 Krishnaveni 59/f House wife 23-01-18 06-03-18 42 MODERATE 
10 7905 Subbuthai 50/f House wife 23-01-18 12-03-18 48 MARKED 
11 8584 Fathima 40/f House wife 25-01-18 08-03-18 42 MARKED 
12 9038 Sherina 57/f House wife 26-01-18 08-03-18 42 MILD 
13 10280 Umayammal 60/f House wife 30-01-18 12-03-18 42 MARKED 
14 10363 mariyammal 45/f House wife 30-01-18 12-03-18 42 MARKED 
15 11323 Ramalingam 54/m Formar 02-02-18 22-03-18 48 MODERATE 
16 12071 Inthira 56/f House wife 05-02-18 19-03-18 42 MARKED 
17 12319 Meera 46/f Teacher 05-02-18 12-03-18 36 MILD 
18 12388 Shanmugasuntharam 55/m Farmer 05-02-18 19-03-18 42 MARKED 
19 13389 Sownthararajan 58/m Farmer 08-02-18 28-03-18 48 MARKED 
20 13480 Sutha 42/f Teacher 08-02-18 28-03-18 48 MILD 
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LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.KANDATHIRI  LEGHIYAM – INTERNAL    2.NAKKA PUSA MUKKUTTENNAI – EXTERNAL 
 
S.NO IP.NO NAME AGE/SEX OCCUPATION DATE OF ADMISSION 
DATE OF 
DISCHARGE 
TOTAL NO. OF 
DAYS TREATED TOTAL NO. 
OF DAYS RESULT IP OP 
1 2004 Ashwathi 52/f House wife 11-07-17 16-08-17 37 11 48 MARKED 
2 2115 Maharasi 55/f House wife 25-07-17 29-08-17 36 12 48 MARKED 
3 2154 Chendhura 
paundiyan 
58/m Farmer 30-07-17 16-08-17 17 31 48 MODERATE 
4 2942 Poovaiya 55/m Farmer 21-10-17 21-11-17 32 16 48 MARKED 
5 3094 Velammal 51/f House wife 20-11-17 18-12-17 29 19 48 MILD 
6 3285 Sornam 59/f House wife 15-12-17 09-01-18 26 22 48 MARKED 
7 3358 Palaniyammal 60/f House wife 27-12-17 10-02-18 46 2 48 MODERATE 
8 46 Kaliyappan 52/m Farmer 08-01-18 26-02-18 49 0 48 MARKED 
9 233 Anuthai 52/f House wife 30-01-18 14-03-18 46 2 48 MILD 
10 380 Mariyammal 41/f House wife 13-02-18 01-03-18 17 31 48 MARKED 
11 383 Lakshmi 60/f House wife 14-02-18 16-03-18 28 20 48 MODERATE 
12 389 Pon selvi 48/f House wife 14-02-18 16-03-18 28 20 48 MARKED 
13 430 Nadarajan 60/m Farmer 23-02-18 18-03-18 29 19 48 MILD 
14 533 Ponnuthai 60/f House wife 27-02-18 15-03-18 17 31 48 NO EFFECT 
15 548 Anaikarai muthu 56/m Farmer 28-02-18 29-03-18 30 18 48 MARKED 
16 838 Vasugi 40/f House wife 27-03-18 17-04-18 22 26 48 MARKED 
17 1045 Annamalai 60/f House wife 17-04-18 05-06-18 50 0 48 MARKED 
18 1073 Pandiyaraj 33/m Masson 19-04-18 22-05-18 34 14 48 MARKED 
19 1115 Kuruvammal 60/f House wife 24-04-18 29-07-18 35 13 48 MARKED 
20 1194 Raja lakshmi 60/f House wife 03-05-18 11-06-18 37 11 48 MARKED 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – OP PATIENT 
S.N
O OP.NO 
TC DC HB ESR BLOOD SUGAR BLOOD SERUM N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT 
A
T BT AT 
1 110149 7500 8100 64 67 29 29 7 4 0 0 0 0 12.1 12.4 15 10 97 92 149 135 28 27 185 176 
2 113318 7400 7600 72 69 25 28 3 3 0 0 0 0 13.1 13 22 19 124 118 168 155 40 31 208 201 
3 114833 7200 7500 64 63 32 34 4 3 0 0 0 0 9.5 9.9 28 19 99 90 149 132 29 22 159 149 
4 114059 7800 7400 65 64 31 32 4 4 0 0 0 0 9.6 10.1 34 25 108 102 189 172 36 22 221 201 
5 1759 7500 7600 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 20 96 92 176 140 34 29 179 177 
6 5669 7700 7300 62 64 32 34 6 2 0 0 0 0 13.5 13.6 31 23 122 108 154 146 37 31 167 157 
7 5810 6900 6700 59 61 37 36 4 3 0 0 0 0 12.2 12.4 19 11 136 127 179 161 22 19 196 187 
8 5986 8200 7900 69 69 28 29 3 2 0 0 0 0 12.8 12.9 32 21 142 128 165 148 35 32 139 165 
9 7792 8000 8100 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 11 127 167 156 29 34 29 179 149 
10 7905 7300 7100 66 67 33 31 1 2 0 0 0 0 13.5 13.7 28 19 99 90 149 132 29 22 159 149 
11 8584 7800 7700 59 61 37 36 4 3 0 0 0 0 12.2 12.4 27 20 106 97 167 165 37 34 186 172 
12 9038 7100 6900 64 62 33 36 3 2 0 0 0 0 11.8 13.6 15 10 97 92 149 135 28 27 185 176 
13 10280 8800 8400 63 65 35 34 2 1 0 0 0 0 12.2 12.4 19 11 129 117 179 161 22 19 186 174 
14 10363 8400 7900 64 63 32 34 4 3 0 0 0 0 9.5 9.9 34 28 89 85 149 140 34 29 179 165 
15 11323 7300 7100 71 69 24 28 3 3 0 0 0 0 13.5 13.7 28 19 99 90 149 132 29 22 159 149 
16 12071 7200 7500 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 19 136 127 167 156 29 25 196 185 
17 12319 6900 6700 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 20 96 92 176 168 29 22 199 187 
18 12388 7800 7500 69 67 28 31 3 2 0 0 0 0 12.2 12.4 19 11 99 90 149 132 29 22 159 149 
19 13389 9200 9000 70 70 26 25 4 5 0 0 0 0 10.9 11.1 30 19 136 128 159 139 42 37 165 157 
20 13480 6700 6900 61 62 34 34 5 4 0 0 0 0 11.8 12.2 26 18 121 118 172 159 19 15 194 188 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – IP PATIENT 
S.N
O IP.NO 
TC DC HB ESR BLOOD SUGAR BLOOD SERUM N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT 
A
T BT AT 
1 2004 7100 7500 66 67 33 31 1 2 0 0 0 0 13.5 13.7 28 19 99 98 130 133 29 22 159 149 
2 2115 7300 7600 59 61 37 36 4 3 0 0 0 0 12.2 12.4 27 20 86 90 132 135 37 34 186 172 
3 2154 7600 7400 64 62 33 36 3 2 0 0 0 0 11.8 13.6 15 10 87 90 126 125 28 27 185 176 
4 2942 7700 7800 65 64 31 32 4 4 0 0 0 0 9.6 10.1 34 25 80 82 130 132 36 22 221 201 
5 3094 7400 7600 71 69 24 28 3 3 0 0 0 0 12.2 12.4 11 99 88 85 132 136 29 25 196 185 
6 3285 7900 7700 59 61 36 34 5 5 0 0 0 0 12.2 12.4 19 136 89 87 139 140 29 22 199 187 
7 3358 6700 6900 64 62 33 36 3 2 0 0 0 0 9.5 9.9 11 136 79 85 127 128 34 29 179 177 
8 46 8100 8500 69 69 28 29 3 2 0 0 0 0 12.8 12.9 32 21 89 88 130 138 35 32 139 165 
9 233 8300 8400 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 11 90 88 136 138 34 29 179 149 
10 380 7100 7300 69 67 28 31 3 2 0 0 0 0 12.2 12.4 19 11 87 90 120 130 29 22 159 149 
11 383 7700 7800 70 70 26 25 4 5 0 0 0 0 10.9 11.1 30 19 86 88 127 139 42 37 165 157 
12 389 7000 7200 59 61 37 36 4 3 0 0 0 0 12.2 12.4 19 11 83 87 130 136 22 19 196 187 
13 430 7800 8000 63 65 35 34 2 1 0 0 0 0 12.2 12.4 19 11 79 77 125 126 22 19 186 174 
14 533 7400 7500 64 63 32 34 4 3 0 0 0 0 9.5 9.9 34 28 89 85 123 138 34 29 179 165 
15 548 6300 6500 71 69 24 28 3 3 0 0 0 0 13.5 13.7 28 19 79 88 130 134 29 22 159 149 
16 838 7100 7300 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 19 89 87 132 137 29 25 196 185 
17 1045 6700 6900 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 20 95 92 129 134 29 22 199 187 
18 1073 7500 7700 59 61 36 34 5 5 0 0 0 0 12.5 12.7 24 23 98 96 130 133 34 29 179 177 
19 1115 7200 7500 62 64 32 34 6 2 0 0 0 0 13.5 13.6 31 23 82 90 135 140 37 31 167 157 
20 1194 6800 7000 61 62 34 34 5 4 0 0 0 0 11.8 12.2 26 18 81 88 126 130 19 15 194 188 
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URINE EXAMINATION BEFORE & AFTER TREATMENT – OUT  PATIENTS 
S.no 
 
Op.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 110149 NIL NIL NAD NIL NIL NAD 
2 113318 NIL NIL NAD NIL NIL NAD 
3 114833 NIL NIL NAD NIL NIL NAD 
4 114059 TRACE            NIL 1-2 PUS CELLS NIL NIL NAD 
5 1759 NIL NIL NAD NIL NIL NAD 
6 5669 NIL NIL NAD NIL NIL NAD 
7 5810 NIL NIL NAD NIL NIL NAD 
8 5986 NIL NIL NAD NIL NIL NAD 
9 7792 NIL NIL NAD NIL NIL NAD 
10 7905 NIL NIL NAD NIL NIL NAD 
11 8584 NIL NIL NAD NIL NIL NAD 
12 9038 NIL NIL NAD NIL NIL NAD 
13 10280 NIL NIL NAD NIL NIL NAD 
14 10363 NIL NIL NAD NIL NIL NAD 
15 11323 NIL NIL NAD NIL NIL NAD 
16 12071 TRACE NIL 1-3 PUS CELLS NIL NIL NAD 
17 12319 NIL NIL NAD NIL NIL NAD 
18 12388 NIL NIL NAD NIL NIL NAD 
19 13389 NIL NIL NAD NIL NIL NAD 
20 13480 NIL NIL NAD NIL NIL NAD 
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RINE EXAMINATION BEFORE & AFTER TREATMENT – IN PATIENTS 
S.no 
 
Ip.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 2004 NIL NIL NAD NIL NIL NAD 
2 2115 Trace NIL 2-3 pus cells Trace NIL NAD 
3 2154 NIL NIL NAD NIL NIL NAD 
4 2942 NIL NIL NAD NIL NIL NAD 
5 3094 NIL NIL NAD NIL NIL NAD 
6 3285 NIL NIL NAD NIL NIL NAD 
7 3358 NIL NIL NAD NIL NIL NAD 
8 46 NIL NIL NAD NIL NIL NAD 
9 233 NIL NIL NAD NIL NIL NAD 
10 380 NIL NIL NAD NIL NIL NAD 
11 383 NIL NIL NAD NIL NIL NAD 
12 389 NIL NIL NAD NIL NIL NAD 
13 430 NIL NIL NAD NIL NIL NAD 
14 533 NIL NIL NAD NIL NIL NAD 
15 548 NIL NIL NAD NIL NIL NAD 
16 838 Trace NIL 1-2 pus cells NIL NIL NAD 
17 1045 NIL NIL NAD NIL NIL NAD 
18 1073 NIL NIL NAD NIL NIL NAD 
19 1115 NIL NIL NAD NIL NIL NAD 
20 1194 NIL NIL NAD NIL NIL NAD 
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DISCUSSION 
Osteoarthritis is a chronic disorder of synovial joints in which there is progressive 
softening and disintegration of articular cartilage and bone at the joint margins (osteophytes), 
cyst formation and subchondral sclerosis, mild synovitis and capsular fibrosis. 
Classified as 
Primary  (localized or generalized)  
Secondary ( Traumatic, congenital, metabolic) 
- Characterized by focal and progressive loss of hyaline cartilage of joints, underlying 
bony changes. 
Symptoms 
 Pain 
 Swelling 
 Stiffness 
The trial drug given below was used in treating the disease azhal Keel vayu the trial 
drugs are 
 KANDATHIRI LEGHIYAM   - Internal 
 NAKKA PUSA MUKKUTENNAI-External 
The clinical approval was done as per the protocol and the data were collected by 
using approved forms.  The disease Azhal Keel vayu (Osteoarthritis of knee joint) was 
considered under various criteria to gather the secondary objectives of the study and the 
results were observed and tabulated.  A variety of criteria and the results were discussed here 
under. 
Gender distribution 
 From the above mentioned tabulation, Among the 40 patients selected, 72.5% were 
female and 27.5% were male. 
Age distribution 
 Among the 40 patients selected this study shows high incidence of Azhal Keel vayu 
(Osteoarthritis of knee joint) was in above 51-60 yrs (65%) of age, Azhal Keel vayu which is 
compared with osteoarthritis of knee joint which is degenerative disease, so the above 
interference explained it’s significant as the age plays an important role upon the 
degenerative disease. 
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Kaalam distribution 
 From the above mentioned tabulation, Among the 40 patients selected in this study.  
Its shows the higher incidence was initiated to be pitha kaalam (97.5%). 
Occupational status 
 In this study the rate of incidence is higher in occupational group which includes 
Housewives (62.5%), Farmer and Labour (25%) and carpenter, Mason (2.5%),Teacher (10%) 
This study shows heavy work housewives are mostly affected. 
Seasonal variations 
 From the above mentioned tabulation 38 patients 95% were admitted in Munpani 
kaalam, 2 patients 5% were admitted in Koothirkaalam.  Mostly the patients were admitted in 
Munpani kaalam. 
Thinai 
 From the above mentioned tabulation.  34 cases (85%) were from Marutham and 3 
cases (7.5%) were from Kurinji and 3 cases (7.5%) were from Neithal thinai. 
 Even though siddha literatures mention Marutham as a disease free zone, most of the 
patients came from Marutham Nilam.  This may be due to the altered lifestyle, environment 
and food habits.  Since this is a single centered study, located in Marutham thinai, it may also 
have influenced the study. 
Socio-economic status 
 From the above mentioned tabulation, Out of 40 patients 55% were from low socio-
economic status (poor), 37.5% were middle class, and 7.5% were rich.  This higher incidence 
in the low socio-economic status may be due to over usage by farmer and manual worker 
among the poor.  The incidence in the further population group may be due to improper 
nutrition and also the people living in poor sanitation. 
Dietary habits 
 From the above mentioned tabulation patients 80% were reported to have mixed diet 
8 patients 20% were reported vegetarian.  So this has no statistically significant results. 
Precipitating factors 
 From the mentioned above tabulation result that the Menopause 50%, the occupation 
relation 25% ,obesity 22.5% and Hereditary 2.5% were the most important precipitating 
factors. 
Mode of onset 
 From the above mentioned tabulation it shows that 75% of the cases were reported to 
be having gradual onset. 
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 Since osteoarthritis is a degenerative disorder it usually has a gradual onset of 
symptoms. 
Clinical features 
 According to this study, 100% of them had pain, crepitation, 75% of them had 
tenderness, swelling 70%, Restricted movement 87.5% patient had sleeplessness 55%,   
Disturbances in kanmenthiriam 
 From the above mentioned tabulation, among 40 patients kaal have been affected in 
100% of cases and in 16 patients eruvai have been affected (40%). 
Distribution of Three Dhosham 
Derangement in Vatham 
 Viyanan and Samanan were affected in all 40 cases (100%).  Abanan were affected in 
16 cases (40%) and kirukaran and Devathathan affected in 11 cases (27.5%) 
Derangement in Pitham 
 Sathaga pitham was affected in all 40 cases (100%) Ranjagapitham was affected in 15 
cases (37.5%), Anarpitham was affected in 14 cases (35%). 
Derangement in kabam 
 Avalambagam,Santhigam was affected in all 40 cases (100%). 
Udal kattukal 
 In all 40 cases, among the seven udal kattukal saaram, Kozhuppu, Enbu were found 
affected 100% (Restricted movements, swelling, crepitations present) and and senneer  is 
affected in 9 cases (22.5%). 
Envagai Thervugal 
 The analysis showed the efficacy of this method and the prime importance of Naadi. 
 Among the 40 cases Naadi have been affected in all cases while malam have affected 
in 15 cases (40%)  
Naadi 
 In Naadi, among all 27 cases (67.5%) were vathapitha naadi, 10 cases (25%) were 
pithavatha naadi and remaining 3 cases (7.5%) were having kabavatha naadi. 
Neikuri 
 In Neikuri analysis, 52.5% of the cases presented with vatha neer, 22.5% with 
pithaneer, and 25% with kabaneer. 
 Laboratory investigations were done in all the cases before and after treatment.  The 
significant variations occur in parameters like Hb, while other parameters have insignificant 
variation. 
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Pre-clinical studies 
 The Biochemical study of KANDATHIRI LEGHIYAM   had revealed the presence of 
Calcium,  chloride, starch,  Iron (ferrous), Unsaturated compound, Reducing sugar, Amino 
acid. 
Pharmacological studies 
 The pharmalogical studies done in KANDATHIRI LEGHIYAM   revealed the 
presence of actions such as 
1. Anti inflammatory action 
2. Analgesic activity. 
Toxicity studies 
 Acute toxicity and sub acute studies have done for KANDATHIRI LEGHIYAM   in 
rats and it is analyzed that they have no toxicity. 
Treatment 
 The treatment was aimed to retain the deranged dhosham and providing relief from 
symptoms.  Before treatment the patients were advised to take Vellai ennai – 15ml with hot 
water during early morning in empty stomach for first day of treatment.  The patients was 
asked to take rest from internal medicine and other activities on that day.  From the next day, 
onward the internal medicine to be given. 
 The author treated the patients with trial drugs KANDATHIRI LEGHIYAM   
(Internal Medicine) 6gms BD and NAKKA PUSA MUKKUTTENNAI(External Medicine).  
During treatment, the patients were advised to follow pathiyam (avoid tamarind, tubers, meat 
etc).  But all aspects of pathiyam could not be imposed due to practical difficulties. 
 
 
 
 
 
 
 
 
 
80 
 
 
SUMMARY 
 Osteoarthritis is the most common form of arthritis.  It causes pain, swelling and 
reduced motion in joints. 
 I have taken this as my dissertation and treated with KANDATHIRI LEGHIYAM   as 
internal medicine and NAKKA PUSA MUKKUTTENNAI as external medicine in azhal keel 
vayu (Osteo arthritis of knee joint).  
40 cases with azhal keel vayu were diagnosed clinically and admitted in the Inpatient 
ward and Outpatient ward of Post graduate department of Sirappu Maruthuvam, Government 
Siddha Medical College hostpital, Palayamkottai and treated by the trial medicines. 
 Laboratory diagnosis of azhal keel vayu was done by siddha diagnostic principles and 
endorsed by modern methods of investigations. 
 The various siddha aspects of examination of the disease were carried out and were 
recorded in the proforma. 
 The trial medicine chosen for both internal and external treatment were 
KANDATHIRI LEGHIYAM   in 6 grm twice a day for forty eight days as per the 
severity of the diseases, NAKKA PUSA mukuttuennai(External). 
 Before starting the treatment careful detailed history was carried out and recorded for 
the forty selected cases. 
 During the period of treatment all the patients were put under pathiyam (A specific 
dietary regimen). 
 A periodical laboratory investigation was made for all the cases along with the 
radiological investigations. 
 The observations made during the clinical study shows that the main internal drug 
KANDATHIRI LEGHIYAM   is clinically effective. 
 Though there was appreciable clinical improvement, there were not much remarkable 
radiographic changes. 
  The action of external application of NAKKA PUSA MUKKUTTENNAI with 
varmam and asanam were given best results in patients than the patients were treated with 
internal medicine alone. 
Treatment 
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 The treatment was aimed to retain the deranged dhoshas and providing relief from 
symptoms.  Before treatment the patients were advised to take Vellai ennai-15ml with hot 
water in early morning for first day of treatment. 
 From the second day onwards internal medcine KANDATHIRI LEGHIYAM   6 gms 
two times day after food and NAKKA PUSA mukuttuennai is given as external. 
 At the time of treatment the patients were advised to follow Pathiyam and specially 
advised to avoid foods which increase vadha. 
 Along with the course of treatment the complementary therapies like varmam and 
Asanam  were given additionally to some of the patients. 
 The outcome of this study is mainly assessed by reduction in pain, swelling, stiffness 
in knee joint.  Increased range of reduction of restricted movements and improvement in 
quality of life universal pain assessment scale was also used to detect proper outcome.  No 
adverse effect was noted for both Internal and External medicine along with the course of 
treatment. 
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CONCLUSION 
 All 40 patients (20 OPD and 20 IP – 10 patients with trial medicines and Varmam, 10 
with Asanam along with trial medicines) were treated for this dissertation work with 
KANDATHIRI LEGHIYAM   6gms two times a day and NAKKA PUSA 
MUKKUTTENNAI(externally) 
 In the pre clinical study pharmacological evaluation of the trial drug shows. 
- Significant analgesic effect 
- Significant Anti inflammatory effect (Internal medicine) 
In the preclinical study toxicity study of “KANDATHIRI LEGHIYAM  ” shows that the 
trial drug had no acute toxicity. 
The overall effect of the clinical trial drug are  
 Marked effect  - 60% 
 Moderate effect - 17.5% 
 Mild effect  - 20% 
 No effect  - 2.5% 
 This result of the clinical trial illustrates the marked effect of the drugs and 
complementary therapy. 
 The trial drug KANDATHIRI LEGHIYAM   and external NAKKA PUSA 
MUKKUTTENNAI is effective.  No adverse effects were noticed during the treatment 
period.  So the trial medicine is safe and easily preparable medicine.  
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INGREDIENTS OF KANDATHIRI LEGHIYAM   (Internal)  
CHUKKU THIPPILI 
ELAM KIRAMBU 
SEERAGAM MULLANGI 
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PASUNEI INJI CHARU 
ELUMICHAI PASUMPAL 
NERUNJIL MILAGU 
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PANAIVELLAM KANDANGATHIRI 
THALISAPATHIRI VAIVIDANGAM 
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INGREDIENTS OF MUKKUTTENNAI (External) 
MANJAL AMANAKKU ENNAI 
THENGAI ENNAI KUNTHIRIGAM 
NALLAENNAI KAADI NEER 
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ERUKKU PULIELAI 
NOCHI 
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KANDATHIRI LEGHIYAM   (Internal) 
 
 NAKKA PUSA MUKKUTTENNAI (External) 
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ANNEXURE – I 
PREPARATION AND PROPERTIES OF THE TRIAL DRUG 
 
INTERNAL MEDICINE: 
“KANDATHIRI LEGHIYAM  ” 
(Ref: Agathiyar Vaithiya soothiram-650 Pg 161) 
g{<mik<kqiq!Ozgqbl<< < << < << < <!
&p<gOu!g{<mik<kqiq!Ozgqbl<!osiz<Oue<!
Lg<gqblil<!-R<sqvsl<!hckioeie<X!
fQp<gOu!g{<mr<gk<kqiqbqe<!%m!uqm<M!
kip<gOu!ofVR<sq!fQi<h<!hckie<!ye<X!
kh<hilz<!Lt<tr<gqh<!hcfQi<!uqm<M!
uQp<gOu!hps<siX!hckie<!uqm<M!
uqbeie!Nuqe<!hiz<!hc-v{<Om/!
!
-v{<mie!hjeouz<zl<!hzf<kie<!wm<M!
f[gqbjk!nMh<Ohx<xqh<!hiGOkxqz<!
Ge<xie!kqiqgMG!sQvgl<!Wzl<!
G{lie!uib<uqtr<gl<!gqvil<H!kitqsl<!
fe<xigh<!hzolie<X!$v{qk<K!
fzLmOe!fix<hckie<!uzEl<!OsOv/!
!
uii<k<kh<hi!gq{<cbjk!olPG!Ohiz!
utlie!Ozgqbk<jkh<!hkel<!h{<[!
hii<k<kh<hi!hig<gtU!uQkligh<!
hkxilz<!-V!Ofvl<!ogit<Tl<!gizl<!
gii<k<kh<hi!l{<mzf<kie<!ogi{<mibieiz<!
Ohik<Kxi!fx<hqk<koliM!uif<kq!$jz!
HgPfz<!upquqzGl<!hxf<K!OhiGOl/!
!
Ohil<h<hi!nOvisqgr<gt<!ne<e!Oki]l<!
ohiXg<gik!Ge<ll<!wm<Ml<!ohiVlz<!uqg<gz<!
silh<hi!hqk<kk<kqe<!wiqU!-okz<zil<!
sicuqMl<!gMh<H!uzq!sif<kliGl<!
filh<hi!hqk<kk<kqe<!gihzg<!Gk<kz<!
fimiK!lbg<golz<zil<!fMr<gqObiMl<!
Oklh<hi!Gliqbqm!jkz!&p<gqz<!
kqxlie!kf<k!Ofib<!kQVl<!hiOv/!
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INGREDIENTS: 
Sl.No  DRUGS  BOTANICAL NAME QUANTITY 
1 Ingi  (Juice) Zingiber officinale  1 Padi (1440 ml) 
2 Kandangathri 
(Juice)  
Solanum surattense 1 Padi (1440 ml) 
3 Mullangi (Juice) Raphanus sativus  1 Padi (1440 ml) 
4 Neringil  (Juice) Tribulus terrestris 1 Padi (1440 ml) 
5 Elumichai  (Juice)\ Citrus limon  1 Padi (1440 ml) 
6 Chukku  
 
Zingiber officinale 
1Palam (35 gm) 
7 Milagu 
 
Piper Nigrum  1Palam (35 gm) 
8 Vaivilangan  
 
Embelia ribes  1Palam (35 gm) 
9 Seeragam  
 
Cuminum cyminum  1Palam (35 gm) 
10 Elam Elettaria cardamomum 1Palam (35 gm) 
11 Thippili 
 
Piper Longum 1Palam (35 gm) 
12 Kirambu  
 
Syzygium aromaticum 1Palam (35 gm) 
13 Thalisapaththiri Abies spectabilis  1Palam (35 gm) 
14 Cows milk  2 Padi (2880 ml) 
15 Cows ghee  4 Padi (5760 ml)  
16 Pannaivellam (Palm 
jaggery)  
 
8 Palam (280 gm) 
PURIFICATION:  
  All above drugs are purified under the formulation of “Anupoga Vaithiya Bramma 
Ragasiyam and Sarakku Suthi Muraigal”  
Dose   : Pakkalavu (6.022 grm)  
Adjuvant  : Milk 
Duration  : 48 days. 
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SOURCE OF RAW DRUGS: 
 The required raw drugs are purchased from authorized centers and standardized 
before preparing medicines. The raw drugs will be authenticated and then they are purified 
and the medicines are prepared in Gunapadam laboratory of Government Siddha Medical 
College, Palayamkottai. 
 
PREPARATION:  
 Inji juice, Kandathiri juice, Mullangi juice, Neruchi juice and  Lemon juice are taken 
in same ratio (1 Padi), and or mixed together along with this mixture cow’s milk 2 padi also 
mixed.  
 After that 8 Palam palmjaggery is added to this mixture and placed in the stove and 
heat it. When paagu patham arrive add purified raw drugs pounded to powdered form. After 
that add 4 padi cow’s ghee and mix well until mezhugu patham appear. Store in clean and air 
tight container.       
 
DRUG STORAGE: 
Leghiyam is stored in a clean and dry container and it is dispensed to the patient in 
packets.  
 
1.-R<sq)<<< Ingi) 
OuX!ohbv<gt<;nz<zl<!Ni<k<kvgl<!-zig<ogim<jm!fXlXh<H!lkqz<!
Botanical Name: Zingiber Officinale 
Family: Zingiberaceae  
Part used: Rhizome  
Sju:!gii<h<H 
ke<jl;!ouh<hl< 
hqiqU;!gii<h<H 
osb<jg;!ouh<hL{<mig<gq?!hsqk<kQk<K~{<c?!ngm<Muib<ugx<xq 
Chemical Constituents: Phellandrene, Gingerol, Gingerine, Terpene, Tanin. 
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ohiK!G{l<;!
! -R<sqg<!gqpr<Gg<!gqVlz<Jbl<!yg<gitl<!
! uR<sqg<GR<!se<eqSvl<!ue<Ohkq.!uqR<Sgqe<x!
! $jzbXl<!uikl<Ohif<!Ki{<mik!kQhelil<!
! OujzBXr<!g{<{ib<.uqtl<H!!!!!!!!!!!!!!!!!!n/G!
! !npz<Gx<xl<,Lg<Gx<xl<!fQr<Gl</!
 
2/g{<mr<gk<kqiq<< < < << < < << < < <( Kantankathiri) 
Botanical Name: Solanum Surattense 
Family: Solanaceae 
Part used: Whole plant 
Sju:!gii<h<H 
ke<jl;!ouh<hl< 
hqiqU;!gii<h<H 
osb<jg;!Ogijpbgx<xq?sqXfQi<ohVg<gq?!ngm<Muib<ugx<xq 
Chemical Constituents: Solonocarpine, Carpesterol, Solasomine, Solacarpidin. 
ohiK!G{l<;!
 “gis!Suisr<!gkqk<k]b!lf<klez<!
! !uQSSvR<!se<eq!uqjtOkiml<!.!NSXr<giz<!
! -k<kjvB!{qx<gi!wiqgivR<!Osi<g<g{<mr<!
! gk<kiqB{<!miligqx<!gi{<”/<!!
! ! ! .!ngk<kqbi<!G{uigml<< < << < << < <!
! gisl<?Suisl<?!]bl<?!ng<eqlf<kl<?!kQs<Svl<?! se<equikl<?! WPujgk<! Okimr<gt<?!
uikOfib<!ngqbju!Ohil</!
! !
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4/Lt<tr<gq!)< << << < Mullangi*!
OuX!ohbv<gt<;&zhl<!
Botanical Name: Raphanus sativus 
Family: Brassicaceae 
Part used: Rhizome 
Sju:!gii<h<H 
ke<jl;!km<hl< 
hqiqU;!gii<h<H 
osb<jg;!ouh<hL{<mig<gq?!hsqk<kQk<K~{<c?!N{<jlohVg<gq,lzlqtg<gq/!
Chemical Constituents: Polysaccharides,Proteoglycan,Sulphur. 
ohiK!G{l<;!
uikr<!gvh<hie<!ubqx<oxiqU!$jzGmz<!
uikr<gi!sjlbl<!ue<kjzOfib<!.!OliKfQi<g<!
Ogijuhe<Oeib<!hz<sqzf<kq!Ge<llqjvh<!Hg<gMh<HR<!
siULt<tr<!gqg<gf<kk<!kiz</!!!!)n/G*!
G{l<;!
!!!!gvh<hie<, kjzuzq, hz<sqzf<kq,!ubqx<oxiqU!kQVl</!
!
5/ofVR<sqz<)< << << < Nerunjil* 
kqvqg{<ml<!Ogig{ml< ,!gqm<cvl</!
Botanical Name: Tribulus terrestris 
Family: Zygophyllaceae 
Part used: Whole plant  
Sju:!Kui<h<H,-eqh<H!
ke<jl;sQkl<!
hqiqU;!-eqh<H 
osb<jg;!N{<jlohVg<gq,!Kui<h<hq,!dvlig<gq, sqXfQv<ohVg<gq,!dt<tpix<xq! 
94 
 
Chemical Constituents: Dioscin, Protodioscin, Diosgenin 
ohiK!G{l<;!
Olgoum<jm!fQv<s<SXg<G!uQXkqvq!Okiml<H{<!
OugiSv!kigouh<hl<!uqm<omipqBl<.Ohigf<!
kVR<sqe!lkjzolipqk<!jkbOz!fz<z!
ofVR<sq!zkje!fqje/!
fQv<s<SXg<G,!gz<zjmh<H,!Lg<Gx<xl,<!fQv<Oum<jg,!LmuiB!kQVl</!
!
6/wZlqs<js)<<< Elumichai*!
Botanical Name: Citrus limon 
Family: Rutaceae 
Part used: Fruit 
Sju:!Htqh<H!
ke<jl;!ouh<hl<!
hqiqU;!giv<h<H!!
osb<jg;!Gtqv<s<sqB{<mig<gq 
Chemical Constituents: b-pinene,myrcene,a-terpene,limonene 
ohiK!G{l<;!
kQokZ!lqs<sr<gib<!Omv<Lk<Oki!mk<jkBLe<!
uikgh!$jzjbBl<!liogicb.sikqobER<!
sv<k<kqGe<!lk<jkBLe<!kr<glVf<!kqm<mjkBl<!
hqk<kouh<jh!Bf<k{qg<Gl<!OhS!
Lg<Gx<xl<!$jz!uif<kq!Ge<ll<!-MlVf<K!kQVl</!!
! !
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7/lqtG:(Milagu) 
OuX!ohbv<gt<;!gxq, gibl<, Ogitgl<, sVlhf<kl<,!lisl<,!ljzbitq,!kqvr<gl<. 
Botanical Name: Piper nigrum 
Family Name: Piperaceae 
Part Used: Dried unripe fruit 
Sju;!jgh<H,!giv<h<H/!!
ke<jl;!ouh<hl</!
hqvqU;!giv<h<H/!
Chemical constituents:Alkaloids-Piperine,piperidine,chavicin (Present in Masocarp), 
Dipiperamides D&E 
osb<jg;!uiklmg<gq,!uQg<gr<gjvs<sq/! 
!!!Ogi[gqe<x!hg<guzq!Gb<bUOvi!gl<uik!
!!!Osi{qkr<g!Pk<kqx<Gt<!Okie<XOfib<.gi{vqb!
!!!giKOfib<!likv<Ge<ll<!gilijz!lf<kole<xQv<!!
!!!WKOfib<!gibqVg<gqz<!=r<G/!
!! .Okjvbv<!G{uigml<!
8/!sQvgl<)Q <Q <Q < Seeragam*!
OuX! ohbv<gt<;!njs,! sQvq,!dhGl<hQsl<,! fx<sQvq,!Kk<ksil<hzl,<! hqk<k! fisqeq,! Ohise!
GOmivq,!Olk<kqbl</!
Botanical Name: Cuminum cyminum 
Family Name: Apiaceae 
Part Used: Seeds 
Sju;!giv<h<H!
ke<jl;!km<hl<!
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hqvqU;!-eqh<H!
osb<jg;!ngm<Muib<ugx<xq,ouh<hL{<mig<gq,hsqk<kQk<K~{<c/!
Chemical Constituents: Essential oil-thymene, cuminol, cumic aldehyde. 
ohiKg<G{l<!;!
!!!!!!!!!!!uiBouiM!fisqOfib<!ue<hqk<kR<!OsviK!
!!!!!!!!!!!gibl<!ofgqpiK!g{<GtqVf<!.!K~blzv<g<!
!!!!!!!!!!!givtgh<!oh{<lbqOz"!jgg{<m!kqk<kjeBR<!
!!!!!!!!!!!sQvgk<jk!fQkqeLf<!kqe<!
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.ngk<kqbv<!G{uigml<!
9/!Wzl<)<<< Elam*!
OuX!ohbv<gt<;!NR<sq,!Ogivr<gl,<!Kc/!!
Botanical Name: Elettaria cardamomum. 
Family Name: Zingiberaceae 
Part used: Unriped Fruit 
Sju;!giv<h<H!
ke<jl;!ouh<hl<!
hqvqU;!giv<h<H!
osb<jg;!ouh<hL{<mig<gq,!ngm<Muib<ugx<xq,!sqXfQv<h<ohVg<gq/!
Chemical constituents: Fixed oil, Essential oil, Volatile oil, Terpinyl acetate, 
Terpineol,Limonene. 
ohiKg<G{l<;<!!
!!!!!!!!!!oki{<jm!uib<gUt<!kiZG!kr<gtqz<!
!!!!!!!!!!Okie<Xl<!Ofibkq!sivl<!Olgk<kiz<!
!!!!!!!!!!d{<jm!Ohiz<wPr<!gm<c!gvqs<svl<!
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!!!!!!!!!!dpjz!uif<kq!sqzf<kq!uq]R<Svl<!
!!!!!!!!!!h{<jm!oug<jg!uqkigOfib<!gisLl<!
!!!!!!!!!!hiPR<!Osilh<!hq{quqf<K!fm<mLl<!
!!!!!!!!!!n{<jm!bQjtue<!hqk<kl<!-jug<ogz<zil<!
!!!!!!!!!!Nz!lir<glp<!Wz!lVf<Ok/!
!
9.!gqvil<H!)<<< Kirambu*!
OuXohbv<gt<;!nR<Sgl,<!dx<gml< ,!gVuib<g<gqvil<H,!Osisl,<!kqvtq,!uvir<gl</!
Botanical name: Syzygium aromaticum 
Family name: Myrtaceae 
Part used: Flower 
Sju;!giv<h<H!
ke<jl;!ouh<hl<!
hqvqU;!giv<h<H!
osb<jg;!-squgx<xq,!ngm<Muib<ugx<xq,!hsqk<kQk<K~{<c/!
Chemical Constituents: Essential oil,B-caryophyllene,Eugenyl acetate, 
ohiKg<G{l<; 
!!!!!!!!!!hqk<k!lbg<gl<!OhkqobiM!uif<kqBl<Ohil<!
!!!!!!!!!!Sk<kuqvk!<kg<gMh<Hf<!Okie<XOli.olk<k!
!!!!!!!!!!-zur<gr<!ogi{<muVg<!Ogx<!SgliGl<!
!!!!!!!!!!lzlr<Og!gm<Mole!uip<k<K/!
!
!
!
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21/ uib<uqmr<gl<)< < << < << < < Vaividangam*!
OuXohbv<gt<;!Ogvtl< ,!uv<eje/!
Botanical name: Emblica ribes 
Family name: Primulaceae 
Part used: Seeds 
Sju;!jgh<H!
ke<jl;!ouh<hl<!
hqvqU;!giv<h<H!
osb<jg;!HPg<ogiz<zq,!ngm<Muib<ugx<xq,!ouh<hL{<mig<gq/!
Chemical constituents: Emblic acid, Tanin, Alkaloids-Cristembine,Vidangin,Emblin.!
ohiKg<G{l; 
!!!!!!!!!!hi{<MGm<ml<!Ge<ll<!hVf<K~z!Ofib<uikf<!
!!!!!!!!!!kQ{<M!kqvquqmf<!sqvf<K{<ml<.H,{<mlc!
!!!!!!!!!!Ofib<uqtr<gg<!gim<mik!F{<gqVlq!biseh<H{<!
!!!!!!!!!!uib<uqtr<gr<gim<muqVliv</!
!
22/kitqshk<kqvq)<<< Thalisapathiri*!
Botanical name:Abies spectabilis 
 Family name:Pinaceae 
Part used:!Leaf 
Sju;!giv<h<H!
ke<jl;!ouh<hl!
hqvqU;!giv<h<H!
osb<jg;!hsqk<kQk<K~{<c, ngm<Muib<ugx<xq, Ogijpbgx<xq, dvlig<gq/!
!
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ohiKg<G{l<;!fisq!gth<hq{qgt<!fim<hm<m!-gisR<S!
!!!!!!!!!!!uisl<!nVsq!uelr<giz<!.uQsquV!
!!!!!!!!!!!Olglf<kl<!nk<kqSvl<!uqm<OmGf<!kitqs<sk<kiz<!
!!!!!!!!!!!NGR<!Sgh<hqvs!ul</!
kQVl<!Ofib<gt<;!gpqs<sz< ,!Svl< ,!fim<hm<m!-Vlz< ,!-jvh<H,!uif<kq,!uib<U,!nsQi{l< ,!
nk<kqSvl<!kQVl</!-keiz<!Sgh<hqvsul<!d{<miGl</!
23/Sg<G<<< (Chukku) 
nVg<ge<?! dhGz<zl<?! dzi<f<k-R<sq?! S{<c?! fuSX?! figvl<?! uqm&cb! nlqi<kl<?!
Oui<ogil<H/ 
Botanical Name: Zingiber Officinale 
Family: Zingiberaceae  
Part used: Dried rhizome  
Sju:!gii<h<H 
ke<jl;!ouh<hl< 
hqiqU;!gii<h<H 
osb<jg;!ouh<hL{<mig<gq?!hsqk<kQk<K~{<c?!ngm<Muib<ugx<xq 
Chemical Constituents: Phellandrene, Gingerol, Gingerine, Terpene, Tanin. 
ohiK!G{l<;<<< !
! !osiqbijl?!lii<ohiqs<sz<?!HtqObh<hl<?!ouh<hl<?!gQp<uib<!Ofib<?!-jvh<H?!-Vlz<?!
gpqs<sz<?!fQOvx<xl<?!Ge<ll<?!ubqx<Xh<hqsl<?!giKGk<kz<?LgOfib<?!kjzOfib<?!
Gjzuzq?!hi{<M?!ubqx<Xg<!Gk<kz<?!JbSvl<!Ohil</!
!
!
!
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! ! “$jzlf<kl<!ofR<osiqh<H!OkimOlh<!hl<lpjz!
! ! ! &zl<!-jvh<hqVlz<!&g<GfQi<!.!uizgh!
! ! Okimlkq!sivf<!okimi<uik!Ge<lfQI!
! ! ! Okiml<N!ll<Ohig<GR<!Sg<G”/!!
! ! ! ! .!ngk<kqbi<!G{uigml<!
  ‘uikh<!hq{qubq!Xkp<!osuquib< 
! ! ! uzqkjz!uzqGjz!uzqbqV!uqpqfQi<!
! ! sQkk<!okiVuiq!Ohkqh<!hzOvi!
! ! ! sqglzq!Lglg!Lglqc!ghlii<!
! ! sQk!Svl<uqiq!Ohks<!SvOfib<!
! ! ! okxqhMoleolipq!Gui<Huq!keqOz!
! ! =Kg<!GkUlq!kQKg!Gkui!
! ! ! okEl<uqkq!bqjzfu!SXG{!LeOu”!
! ! ! ! .!Okjvbi<!G{uigml<!
13. kqh<hqzq)<<< Thippli) 
OuXohbi<!<<< !
! Ni<gkq?! d{<svl<?! dzjufisq?! gile<?! GOmiiq?! OgijpbXg<gq?! hqh<hqzq?!
NkqlVf<K!
Botanical name - piper longum 
Family  - Piperaceae 
Part used - fruit  
Sju!!;!-eqh<H!
ke<jl!;!km<hl<!
hqiqU!!;!-eqh<H!
Constituents 
  Piperine, rutin  beto - carpophylleneliperline,  piperamine, lialool 
osb<jg<<< !
 ouh<hL{<mig<gq!
 ngm<Muib<ugx<xq!
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ohiKG{l<!;!<<<  
‘gm<cobkqi<fqe<XgMOfiobz<zil<!h{qBl<!
kqm<cuqjebgZl<!Okgolk<k!.!Hm<cbil<!
! lilEg<Glilolelx<xui<g<Glx<xueir<!
gilolEf<!kqh<hqzqg<Gl<!jg”!!!!!!!!!!.Okve<ou{<hi!
15.!ofb<;<<<  
English Name:Ghee 
ohiKg<G{l<;/!
!!!!!!!!!!!kigLp!jzgm<gl<!uif<kq!hqk<kl<!uiBhqv!
!!!!!!!!!!!Olgl<!ubqx<oxvqU!uqg<gzpz<.ligisr<!
!!!!!!!!!!!Ge<ll<!uxm<sq!Gmx<Hvm<m!z^<kqgm<gR<!
!!!!!!!!!!!osie<&zl<!Ohig<gfqjxk<!Kh<H/  
27/hje!ouz<zl<< << << <!
ohiK!G{l<;<<< !
//////////////////kr<Ghje!
ouz<zk<kiz<!uikhqk<kR<!uQXghR<!se<eqOfib<!
uz<zVsq!Ge<llX!liz</!
kQVl<!Ofib<gt<;!Q < < <Q < < <Q < < < !
Lg<Gx<xl<!Lh<hq{q!Ge<ll<!Sjubqe<jl!fQr<Gl<!
 
17. hSl<hiz<< << << <!
OuXohbI!;!!hbS?!Sjk?!Kk<kl<?!gQvl<?!hbl<?!nLK< < Q < << < Q < << < Q < < !
ohiKG{l<;!<<< !
hizI!gqpuI!hpR<Svk<OkiI!H{<{itq!
S,jzbI!KIh<hzk<OkiI!OlgOfibitq!WZlquI!
wz<ziIg<G!liGl<!-jtk<kuIg<GR<!sikglib<!
fz<zib<!hSuqe<hiz<!fim<M!
ohiVt<!;<<< !hizI!Lkz<!gqpuI!ujv!NGl<!S,jz?!Olg!Ofib<!fQr<Gl</!
!
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EXTERNAL MEDICINE: 
“NAKKA PUSA MUKKUTTENNAI” 
 (Ref: Yugimuni vaithiya kaviyam Pg 37) 
fg<g!h,s!Lg<%m<om{<o{b<!
NOlbqkx<Gfz<oz{<o{b<!bil{g<og{<o{b<Okr<gib<!ofb<!
OhiOlofis<sqobVg<gqjzBl<!Htqbqe<siovie<oxiVfipq!
fiOlosie<Oeil<Gf<kiqg<gl<!fz<zlR<stqjuobig<g!
h,OlObiovie<jxr<gpR<S!hqtqk<kgicfipqbqOm!
!
-m<Ombjvk<Kbqjugzf<K!Obgg<Gjph<hqobiqk<kqxg<g!
okim<Omh{uqjmkieg<gq!KuijzbqmUl<!uz<zQvib<!
&m<MuikLmr<gz<uzq!Lkqi<f<khzhzuikolzir<!
ofm<Ome<ogm<Omeoeoeh<OhiGr<Ogm<GLzOgivg<gqKlVf<Ok/ 
Ingredients  
Sl. 
No  
DRUGS  BOTANICAL NAME  QUANTITY 
1 Notchi elai  Vitex negundo 1 Nazhi ( 1.34 lr ) 
2 Erruku elai Calotropis Gigantea 1 Nazhi ( 1.34 lr ) 
3 Puli Elai Tamaringus indica 1 Nazhi ( 1.34 lr ) 
4 Kunthirikkam  Boswellia serrata 5 Kazhanju (25.5grm) 
5 Manjal  Curcuma longa  5 Kazhanju (25.5grm)  
6 Gingely oil Sesamum indicum 1 Nazhi ( 1.34 lr ) 
7 Coconut oil Cocos nucifera 1 Nazhi ( 1.34 lr ) 
8 Gaster oil Ricinus communis 1 Nazhi ( 1.34 lr ) 
9 Pulitha kaadi (Vinigar)   
PURIFICATION:  
  All above drugs are purified under the formulation of “Anupogu Vaithiya Bramma 
Ragasiyam and Sarakku Suthi Muraigal” 
METHOD OF PREPARATION :  
Gingely oil, castor oil, coconut oil, Nochi juice, erukku elai Juice, Pulielai juice, all 
same radio 1 Nazhi. Kunthirikam, Manjal 5 Kazhanju, Pulitha kaadi 1 Nazhi, Mix all above 
juices and kaadi and heat and drain it.   
INDICATIONS: 
 It is indicated externally for Joint Pain. 
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2/!wVg<G<<< !
Botanical Name : Calotropis Gigantea 
Family : Asclepiadaceae 
Part Used : Leaf 
Sju! ;! giIh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Anti inflammatory, Analgesic 
Chemical Constituents  :   Caoutchouc, Asclepin, Gigastin, Mudarine. 
ohiKG{l<;<<< !
wzquqmr<!Gm<mjlb!OlX!gqVlq!!
uzqS,jz!uiBuqm!lf<kl<.lzhf<kl<!!
wz<zi!lgZ!olVg<gqjz!jbg<g{<miz<!
uqz<ziI!FkOz"!uqtl<H/!
! ! ! .!ngk<kqbI!G{uigml<!
ohiVt<;<<< !wVg<gqjzbqeiz<!gQz<!uQg<gl<?!utq!-ju!Ohil</!
!
3/!ofis<sq<<< !
Botanical Name : Vitex Negundo 
Family : Verbenaceae 
OuX!ohbI! ;! -f<kqvS,iqbl<?!fqIg<G{<c?!sqf<Kl!sqf<Kuivl<!
Part Used : Leaf 
Sju! ;! jgh<H?!giIh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Alterative, Vermituge, Antivatha activity 
ohiKG{l<;<<< !
…gvofis<sqx<!hm<jmbK!
kt<T!se<eq!uiklgx<Xl<…!
! ! ! .!ngk<kqbI!G{uigml<!
ohiVt<;<<< !ofis<sqbqeiz<!Lh<hq{qBl<?!utq!OfiBl<!fQr<Gl</!
! !
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!
4/!Htq!-jz!
Botanical Name : Tamarindus Indica 
Family : Caesalpiniaceae 
OuX!ohbI! ;! sqf<K~vl<?!sqf<kgl<?!Nl<hqvl<!
Part Used : Leaf 
Sju! ;! Htqh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Refrigerant, Antibilios, Stimulant, Laxative, Antivatha activity 
Chemical Constituents  :   Tartaric acid 
ohiKG{l<;<<< !
nPH{<j{!fQg<Gl<!nmz<Osijh!lix<Xl<!
wPhi{<M!juh<Ohig<Gl<!-h<hiz<!.!LPKl<!
ntqbs<!squf<kg{<O{i!bix<Xr<!gezil<!
Htqbqjzjb!fe<xib<h<!Hgz</!
! ! ! .!ngk<kqbI!G{uigml<!
!
5/!Gf<kiqg<gl<< < << < << < <!
Botanical Name : Boswellia Serrata 
Family : Burseraceae 
OuX!ohbI! ;! GjlR<sie<?!fXl<hqsqe<?!hxr<g<s<sil<hqvi{q!
Part Used : Gum Resin 
Sju! ;! jgh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Stomachic, Diaphoretic, Astrigent, Refrigerant, Diuretic,  
        Emmenagogue, Expectorant 
ohiKG{l<;!<<< Gf<kqiqg<gl<!“fvl<H!sl<hf<klig!Ofib<gTg<Gl<?!uik!Ofib<gTg<Gl<” sqxf<k!
lVf<kiGl</!
!
! !
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6/!lR<st<< << << <!
Botanical Name : Curcuma Longa 
Family : Zingiberaceae 
OuX!ohbI! ;! niqsel<?!hQkl<?!fqsq!
Part Used : Rhizome 
Sju! ;! jgh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Carminative, Stimulant, Hepatic tonic 
Chemical Constituents :   Curcumin, Curcuminoid, Demethoxycurcumin, Zingiberene 
!
ohiKG{l<;!<<< !
ohie<eqxlil<!Oleq!Hzieix<x!Ll<OhiGl<!
le<E!HVm!usqblil<.hqe<eqobPl<!
uif<kqhqk<k!Okimjlbl<!uikl<Ohif<!kQhelir<!
%If<klR<s!tqe<!gqpr<Gg<G!
.!ngk<kqbI!G{uigml<!
ohiVt<!;<<< !utq?!kQ?!Jbg<Gx<xl<!-ju!fQr<Gl</!
!
!!!!
7/!Okr<gib<!w{<o{b<< < < << < < << < < <!
!dbIf<k! nPk<kk<kqe<! &zl<! ‘ogih<hjv’! weh<hMl<! Okr<gibqzqVf<K! “Okr<gib<!
w{<o{b<”!wMg<gh<hMgqxK/!
Botanical Name : Cocos Nucifera 
Family : Arecaceae 
OuX!ohbI! ;! H,Ozig!gx<hguqVm<sl<?!fitqOgvl<?!-zir<gzq?!kijp!
Part Used : Seed 
Sju! ;! -eqh<H!
uQiqbl<! ;! km<hl<!
hqiqU! ;! -eqh<H!
Therapeutic Actions  :   Nutrient Antiulcer, Antiinflammatory, than used for hair  
        growth,  
Chemical Constituents :   Lawric acid, Myristic acid 
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8/!fz<oz{<o{b<!)wt<*< < < << < < << < < < !
!!)wt<tqz<!-Vf<K!fz<oz{<o{b<!kbiiqg<gh<hMgqxK*< < < < < < < << < < < < < < << < < < < < < < !
Botanical Name : Sesamum Indicum 
Family : Pedaliaceae 
Part Used : Seed 
Sju! ;! -eqh<H!
ke<jl! ;! ouh<hl<!
hqiqU! ;! -eqh<H!
Therapeutic Actions  :   Emmlnagogie, Stimulant, Tonic, Diuretic, Galactogogce. 
Chemical Constituents  :   Vitamin E, Sesamin, Segamolin, Phytosterol. 
ohiKG{l<;<<< !
g{<[g<G!ytqjbBl<!dmZg<G!ue<jlBl<!kVl<!
GVkq!ohVg<jg!d{<miGl<!
! ! ! .!ngk<kqbI!G{uigml<!
!
9/!Nl{g<G!w{<o{b<!)uqtg<og{<o{b<*< < < < < << < < < < << < < < < < !
Botanical Name : Ricinus Communis 
Family : Euphorbiaceae. 
OuX!ohbI! ;! Wv{<ml<?!sqk<kqvl<?!kz'hl<!
Part Used : Seed 
Sju! ;! gsh<H!
uQiqbl<! ;! ouh<hl<!
hqiqU! ;! giIh<H!
Therapeutic Actions  :   Laxative, Emollient 
Chemical Constituents :   Ricinine, Ricin, Resin 
ohiKG{l<;!<<< !
Nl{g<!og{<o{b<!ke<je!b{qfqz!lxqb!Og{<lqe<!
H,l{s<!sf<KOkiXl<!ohiVf<kqb!uikl<!Ohig<Gl<!
kQlf<kk<!kiEl<!Ohig<Gf<!kqgp<Ume<!uqjvU!L{<mil<!
kQleg<!Gmzqz<!uikR<!OsIGm!Ozx<xl<!OhiOl!
.!wM!
ohiVt<!;<<< !Nl{g<og{<o{bqeiz<!uikl<!fQr<Gl</!
 
9. Tamilname; gicfQv<Q <Q <Q < 
Common name : rice vinegar 
Uses :   
  As a antiseptic.  
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ANNEXURES -II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF KANDATHIRI LEGHIYAM   (IN 
POWDER FORM) 
Preparation of the extract:   
  5gms of the drug was weighed accurately and placed in a 250ml clean 
beaker.  Then 50ml of distilled water is added and dissolved well.  Then it is 
boiled well for about 10 minutes.  It is cooled and filtered in a 100ml volumetric 
flask and then it is made to 100ml with distilled water.  This fluid is taken for 
analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in a clean test 
tube. To this add 2ml of 4% 
Ammonium oxalate solution. 
A white 
precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 
5% Barium chloride solution. 
No white 
precipitate is 
formed. 
Absence of 
sulphate. 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver 
nitrate solution. 
A white 
precipitate is 
formed. 
Indicates the 
presence of 
chloride. 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated HCL. 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
5. 
 
TEST FOR STARCH 
The extract is added with weak 
iodine solution. 
Blue colour is 
formed. 
Indicates the 
presence of 
starch. 
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6.  
TEST FOR FERRIC IRON 
The extract is acidified with 
Glacial acetic acid and 
potassium ferro cyanide. 
No blue colour is 
formed. 
Absence of ferric 
iron. 
7. 
TEST OF FERROUS IRON  
The extract is treated with 
concentrated Nitric acid and 
Ammonium thio cyanide 
solution. 
Blood red colour 
is formed. 
Indicates the 
presence of 
ferrous iron. 
8.  
TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid. 
No yellow 
precipitate is 
formed. 
Absence of 
phosphate. 
9.  
TEST FOR ALBUMIN 
The extract is treated with 
Esbach’s reagent. 
No Yellow 
precipitate is 
formed. 
Absence of 
Albumin. 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric 
chloride. 
No Blue black 
precipitate is 
formed. 
Absence of tannic 
acid. 
11.  
TEST FOR 
UNSATURATION 
Potassium permanganate 
solution is added to the extract. 
It gets 
decolourised. 
 
Indicates the 
presence of 
unsaturated 
compound. 
12.  
TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative 
solution is taken in a test tube 
and allowed to boil for 2 mts 
and add 8-10 drops of the 
extract and again boil it for 2 
Colour change 
occurs. 
Indicates the 
presence of 
Reducing sugar. 
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minutes. 
13.  
TEST FOR AMINO ACID 
One or two drops of the extract 
is placed on a filter paper and 
dried well. After drying, 1% 
Ninhydrin is sprayed over the 
same and dried it well. 
 Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. 
TEST FOR ZINC 
The extract is treated with 
Potassium Ferrocyanide. 
No white 
precipitate is 
formed 
Absence of Zinc. 
 
Inference: 
  The given sample of “KANDATHIRI LEGHIYAM  ” contains Calcium, 
Chloride, Starch. Ferrous iron,  Unsaturated compound, Reducing sugar and 
Amino acid. 
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ANNEXURE – III 
PHARMACOLOGICAL ANALYSIS 
 
EFFECT OF KANDATHIRI LEGHIYAM  ON CARRAGEENAN-INDUCED 
LOCALISED INFLAMMATORY PAIN IN RATS 
 The study plan was developed based on the guidelines of Vogel1 and also it has 
reference to Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, Risley EA, Nuss 
GW. Carrageenin induced edema in hind paw of the rat as an assay for anti-inflammatory 
drugs. Proc Soc Exp Biol Med. 1962; 111:544–7 
 The animals were housed in polypropylene cages with stainless steel top grills having 
facilities for holding pellet food and drinking water in bottle with stainless steel sipper tube. 
Each cage contained 6 rats. All rats had free access to potable water and standard pelleted 
laboratory animal diet ad libitum. Paddy husk was used as bedding material. The animals 
were divided into 5 groups (6 rats/group). Localized inflammatory pain was induced in all 
groups of animals by intraplantar injection of carrageenan (50 µl of 3% suspension). Group 1 
received vehicle orally, Group 2 received a standard anti-analgesic drug, Diclofenac sodium 
(10 mg/kg i.p), whereas groups 3, 4 and 5 received  KANDATHIRI LEGHIYAM  3.024mg, 
15.12mg and 75.6mg b.w. The doses of  KANDATHIRI LEGHIYAM  were prepared in 
Honey, where as Diclofenac sodium was dissolved in normal saline. 
 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group I received (0.1ml of 1%  carragennan) , Group II animals received 
Diclofenac sodium (20 mg/kg po). Group-III, IV and V animals received the 
KANDATHIRI LEGHIYAM  3.024mg, 15.12mg and 75.6mg b.w. After 30 min, the rats 
were challenged with subcutaneous injection of 0.1 ml of 1% w/v solution of carrageenan 
into the sub plantar region of left paw. The paw was marked with ink at the level of lateral 
malleolus and immersed in mercury up to the mark. The paw volume was measured at 0, 1, 2, 
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3, 4, 5 and 6th hr after carrageenin injection using Digital Plethysmometer. The difference 
between initial and subsequent reading gave the actual edema volume.  
INTRODUCTION 
 Intraplantar injection of carrageenan into the hind paw produces localized 
inflammation in rats (Urban et al., 2000). An intraplantar injection of carrageenan is widely 
used to produce a model of localized inflammatory pain. 
OBJECTIVE 
 To study the anti-inflammatory effect of KANDATHIRI LEGHIYAM  in the rat 
model of Carrageenan-induced localized inflammation.  
1.1.1 Study Guidelines  
 This study plan has reference to Vogel (2002), Chao Ma and Jun-Ming Zhang (2011) 
and Walker et al. (2003).  
1.1.2 MATERIALS AND METHODS 
1.1.3 Test System 
Species : Rat   
Strain  : Wistar 
Age  : 6-8 weeks at the time of dosing 
Total no. of Rats: 30 
Sex  : Male 
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EXPERIMENTAL DESIGN: 
Group-I: Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (20mg/kg,.po) + 
                (0.1ml of 1% carrageenin) 
Group-III: Received  KANDATHIRI LEGHIYAM (3.024mg/kg) + 
                 (0.1ml of 1% carrageenin) 
Group IV: Received KANDATHIRI LEGHIYAM  (15.12mg/kg) +  
                (0.1ml of 1% carrageenin) 
Group IV: Received  KANDATHIRI LEGHIYAM (75.6mg/kg) +  
                 (0.1ml of 1% carrageenin) 
Administration Procedure 
 Inflammatory pain was induced in animals belonging to all the Groups by injection of 
Carrageenan (50 µl of 3% suspension) into the intrplantar region of the right hind paw using a 
27-gauge needle attached to a Hamilton syringe under mild ether anaesthesia. The test item 
KANDATHIRI LEGHIYAM  and reference drug in Diclofenac sodium were administered 
orally with carrageenan injection to the respective groups. Prior to the above administrations, 
food alone was withdrawn from all the groups overnight (water was provided ad libitum). 
Parameters Assessed 
Paw volume was measured post treatment at 0, 1, 2, 3, 4, 5 and 6th hr after carrageenin 
injection using Digital Plethysmometer. 
DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose 
calculation procedure from recommended clinical dose. 
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CONVERSION FORMULA: 
Human dose is 6g day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of mice 
1000 mg x 2(a) x 0.018 (b) = 18 (c) /140gms of mice 
108/1000x140 = 15.12 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Dose /30 gms. 
weight 
 
Volume of 
administrati
on 
1 Vehicle Control -- -- 1 ml 
2 Therapeutic Dose 
 15.12 mg  
 
3.024mg 1 ml 
3 Middle  Dose 75.6mg 
  15.12mg 
 
1 ml 
4 High Dose 378mg 75.6mg 1 ml 
 
1.1.4 TABLE: EFFECT OF KANDATHIRI LEGHIYAM  ON CARRAGEENIN-
INDUCED PAW EDEMA IN RATS (BODY WEIGHT) 
 
 
Group 
Only 
Carrageenin 
Carrageenin + 
Standard 
Carrageenin+ 
KL-LD 
Carrageenin + 
KL  MD 
 
Carrageenin 
+ 
KL- HD 
 
INITIAL 
BODY 
WEIGHT 
123.167±0.9
09823 
 
 
129.167±1.0461
6 
 
 
136.833±0.83333
3 
 
 
131.333±1.3333
3 
 
 
140±1.3904
4 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way 
ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing treated 
group with control group 
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1.1.5 TABLE: EFFECT OF KANDATHIRI LEGHIYAM  ON CARRAGEENIN-
INDUCED PAW EDEMA IN RATS 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way 
ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing treated 
group with control group. 
 
  
 
Group 
Mean paw 
volume 
before 
carrageenan 
injection 
Paw Volume after induction with carrageenin  
Increase in paw volume (Mm) after carrageenan injection (mean ± 
SEM)/Percent inhibition of edema 
0 min 1h 2h 3h 4h 5h 6h 
Only 
carrageenan 
3.83± 
0.189367 
7.19667± 
0.131901 
7.67667± 
0.148272 
7.67167± 
0.0617747 
7.485± 
0.067614 
7.15333± 
0.0832133 
7.00833± 
0.0838418 
 
carrageenan 
+ Standard 
 
3.60833± 
0.125391 
 
7.23± 
0.152818 
 
7.37± 
0.127828 
 
7.28833± 
0.0352531* 
 
6.85167± 
0.141243** 
 
6.665± 
0.142144* 
 
6.15167± 
0.162448*** 
carrageenan 
+ KL LD 
3.64± 
0.116304 
6.80333± 
0.0956963 
7.48167± 
0.100745 
7.26667± 
0.0644291* 
7.09167± 
0.050492ns 
6.93667± 
0.0614094ns 
6.71333± 
0.052578ns 
carrageenan 
+ KL MD 
3.89667± 
0.169188 
7.31667± 
0.10388 
7.62167± 
0.142978 
7.365± 
0.138124ns 
7.04333± 
0.124971* 
6.645± 
0.111228** 
6.285± 
0.126221** 
carrageenan 
+ KL HD 
4.17333± 
0.166907 
7.25167± 
0.104384 
7.51667± 
0.124944 
7.16833± 
0.104385** 
6.75167± 
0.163022*** 
6.54667± 
0.120766** 
6.05± 
0.180924*** 
116 
 
1.1.6 TABLE: EFFECT OF KANDATHIRI LEGHIYAM  ON CARRAGEENIN-
INDUCED PAW EDEMA IN RATS 
 
 
 
 
 
 
 
 
 
Group 
Paw Volume after induction with carrageenin  
 
Increase in paw volume (Mm) after carrageenan injection (mean ± SEM)/Percent  
inhibition of edema 
Initial Paw 
volume(mm) 
Final Paw 
volume(mm) 
 
Difference Percentage protection (%) 
 
Control 
 
 
3.88± 
0.19836 
 
 
3.88± 
0.19836 
 
-------- 
 
------ 
 
Only 
carrageenan 
 
 
3.83± 
0.189367 
 
7.00833± 
0.0838418 
 
3.17 
 
82.76 % 
 
carrageenan 
+ Standard 
 
 
3.60833± 
0.125391 
 
6.15167± 
0.162448*** 
 
2.55 
 
70.83 % 
 
carrageenan 
+ KL LD 
 
3.64± 
0.116304 
 
6.71333± 
0.052578ns 
 
3.07 
 
84.34 % 
 
carrageenan 
+ KL MD 
 
3.89667± 
0.169188 
 
6.285± 
0.126221** 
 
2.39 
 
61.43 % 
 
carrageenan 
+ KL HD 
 
 
4.17333± 
0.166907 
 
6.05± 
0.180924*** 
 
 
1.88 
 
45.08 % 
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1.1.8 EFFECT OF KANDATHIRI LEGHIYAM  ON CARRAGEENIN-INDUCED 
PAW EDEMA IN RATS 
                   
          GROUP – I-CONTROL                               GROUP – II ONLY CARRAGEENIN 
 
                 
GROUP – III- CARRAGEENIN+ STD                GROUP –IV- CARRAGEENIN+ L.D 
                        
   GROUP – V- CARRAGEENIN+ M.D                GROUP – VI- CARRAGEENIN+ H.D 
 
1.1.9 CONCLUSION 
To conclude, the KANDATHIRI LEGHIYAM  were evidenced as a siddha drug for the 
treatment of pain and inflammation and it is found that it useful for inflammatory disorders.  
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EFFECT OF KANDATHIRI LEGHIYAM  WITH HONEY/GHEE ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and analgesic 
activity of a herbal formulation. Indian J.Experimental Biol. 2007; 45: 279. 
 
       Acetic acid induced writhing method was adopted for evaluation of analgesic activity. 
Writhing is defined as a stretch, tension to one side, extension of hind legs, contraction of the 
abdomen so that the abdomen of mice touches the floor, turning of trunk (twist). Any 
writhing is considered as a positive response. 
 
MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. 
The animals were housed comfortably in a group of six in a single clean plastic cage with a 
metal frame lid on its top. They were housed under standard environmental conditions of 
temperature (24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was 
followed. All animals had free access to water and standard pelletized laboratory animal diet 
ad libitum. All the experimental procedures and protocols used in this study were reviewed 
and approved via the Approval No. ----------------------------- by the Institutional Animal 
Ethical Committee (IAEC) of KMCH College of Pharmacy, Coimbatore 
(685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 constituted in accordance with the 
guidelines of the CPCSEA, Government of India. 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) and Indomethacin  were purchased 
from (Ranbaxy, India). All drugs were dissolved in saline. The different doses of 
KANDATHIRI LEGHIYAM  were prepared WITH HONEY/GHEE.The control group received 
vehicle as control. All drugs were prepared just before use. 
 PREPARATION OF ACETIC ACID: 
         A solution of acetic acid (1% v/v) in distilled water was prepared. 
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DOSAGE SCHEDULE: 
The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of mice 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /30 gm of mice 
108/1000x30 = 3.24 mg  
Experimental Doses Calculated as per the standard procedures are 
 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 0.5 ml 
 
2 Therapeutic Dose 3.24 mg /kg 
 
0.5 ml 
3 Middle  Dose   16.2mg/kg 0.5 ml 
4 High Dose 81mg/kg 0.5 ml 
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EXPERIMENTAL PROCEUDRE: 
        GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
       GROUP 2 -- IP injection of 0.1 ml 1% acetic acid + Indomethacin (5mg/kg, i.p) 
       GROUP 3 -- 0.1 ml 1% acetic acid (ip) + KANDATHIRI LEGHIYAM  WITH HONEY/GHEE  
                                   3.24MG /KG(PO)                        
                                      
       GROUP 4 -- 0.1 ml 1% acetic acid (ip) + KANDATHIRI LEGHIYAM  WITH HONEY/GHEE     
                                      16.2mg/Kg(Po) 
 
      GROUP 5 -- 0.1 ml 1% acetic acid (ip) + KANDATHIRI LEGHIYAM  WITH HONEY/GHEE  
                                             81mg/kg(po) 
 PROCEDURE: 
            Wister albino mice of either sex were divided into five different groups each 
containing  Six animals, the animals were marked individually. Food was withdrawn 12 hours 
prior to drug administration till completion of experiment. The animals were weighed and 
numbered appropriately. The test and standard drugs were given orally. After 60 minutes 
writhing was induced by intra-peritoneal injection of 1% acetic acid in volume of 0.1 ml/10g 
body weight. The writhing episodes were recorded for 30 minutes; stretching movements 
consisting of arching of the back, elongation of body and extension of hind limbs were 
counted. Anti-nociceptive  activity was expressed as the percentage inhibition of abdominal 
constrictions using the ratio:  
             (Control mean – Treated mean) × 100/Control mean 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
--- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764*** 
 
49.98 % 
 
KANDATHIRI  LEGHIYAM  
0.028mg/kg(po) 
 
 
33.33±1.764* 
 
26.47 % 
 
KANDATHIRI  LEGHIYAM  
0.014mg/kg(po) 
 
 
26.33±1.453** 
 
41.91 % 
 
KANDATHIRI  LEGHIYAM  
0.28mg/kg(po) 
 
 
22±2.309** 
 
51.46 % 
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EFFECT OF KANDATHIRI LEGHIYAM  WITH HONEY/GHEE ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
--- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764*** 
 
49.98 % 
 
KANDATHIRI  LEGHIYAM  
0.028mg/kg(po) 
 
 
33.33±1.764* 
 
26.47 % 
 
KANDATHIRI  LEGHIYAM  
0.014mg/kg(po) 
 
 
26.33±1.453** 
 
41.91 % 
 
KANDATHIRI  LEGHIYAM  
0.28mg/kg(po) 
 
 
22±2.309** 
 
51.46 % 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one 
way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 
calculate by comparing treated group with CONTROL group.         
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EFFECT OF KANDATHIRI LEGHIYAM  WITH HONEY/GHEE ON HOT PLATE 
METHOD IN MICE1 
 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. (eds.). 
Academic press, New York. 1965; 100.  
 
            The paws of mice and rats are very sensitive to heat at temperatures which are not                 
damaging the skin. The responses are jumping, withdrawal of the paws and licking of the 
paws. 
 MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. 
The animals were housed comfortably in a group of six in a single clean plastic cage with a 
metal frame lid on its top. They were housed under standard environmental conditions of 
temperature (24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was 
followed. All animals had free access to water and standard pelletized laboratory animal diet 
ad libitum. All the experimental procedures and protocols used in this study were reviewed 
and approved via the Approval No. ----------------------------- by the Institutional Animal 
Ethical Committee (IAEC) of KMCH College of Pharmacy, Coimbatore 
(685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 constituted in accordance with the 
guidelines of the CPCSEA, Government of India. 
      The hot plate, which is commercially available, consists of a electrically heated surface. 
The temperature is controlled for 55° to 56 °C. This can be a copper plate or a heated glass 
surface. The animals are placed on the hot plate and the time until either licking or jumping 
occurs is recorded by a stop-watch. 
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EXPERIMENTAL PROCEUDRE: 
 
        GROUP 1 – CONTROL  
       GROUP 2 – Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- KANDATHIRI LEGHIYAM  WITH HONEY/GHEE  
                                      3.24 mg /kg(po)           
              
       GROUP 4 – KANDATHIRI LEGHIYAM  WITH HONEY/GHEE     
                                      16.2mg/kg(po) 
 
      GROUP 5 -- KANDATHIRI LEGHIYAM  WITH HONEY/GHEE     
                                      81mg/kg(po) 
 
PROCEUDRE: 
  Mice were screened by placing them on a hot plate maintained at 55±1ºC and 
recording the reaction time in seconds for forepaw licking or jumping. Only mice which 
reacted within 15sec and which did not show large variation when tested on four separate 
occasions, each 15min apart, were taken for the test. The time for forepaw licking or jumping 
on the heated plate of the analgesiometer maintains at 55ºC was taken as the reaction time. 
Prior to treatment, the reaction time of each mouse (licking of the forepaws or jumping 
response) was done at 0- and 10-min interval. The average of the two readings was obtained 
as the initial reaction time (Tb). The reaction time (Ta) following the administration of the ---
------------, Pentazocine and distilled water was measured at 0.5, 1, 2, and 3h after latency 
period of 30min. 
 
The following calculation was:  
 
          Percentage analgesic activity = Ta-Tb/Tb × 100 
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EFFECT OF KANDATHIRI LEGHIYAM  WITH HONEY/GHEE ON HOT PLATE 
METHOD IN MICE1 
 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.288±0.112 
 
4.26±0.022 
 
3.99±0.3266 
 
4.26±0.23 
 
4.01±0.08841 
 
 
STANDARD 
 
3.185±0.119 
 
5.57±0.297** 
 
 
6.613±0.053*** 
 
7.16±0.24*** 
 
6.473±0.2101** 
 
 
KL + LOW 
DOSE 
 
3.79±0.214 
 
7.36±0.190*** 
 
7.767±0.22*** 
 
7.89±0.25*** 
 
8.02±0.08196*** 
 
 
KL + 
MIDDLE 
DOSE   
 
3.66±0.116 
 
 
6.85±0.200** 
 
7.105±0.089** 
 
7.02±0.25*** 
 
6.913±0.204** 
 
 
KL + HIGH 
DOSE 
 
3.29±0.0426 
 
6.063±0.100** 
 
6.663±0.125*** 
 
6.21±0.12*** 
 
6.22±0.3477** 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 calculated by 
comparing treated group with CONTROL group. 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY  
Table 1. Test substance details 
Name of the test substance KANDATHIRI LEGHIYAM  
With Honey/Ghee 
Colour of the test substance - brown 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex                       female 
Administration of dose and volume 6000 mg/kg in 200g body weight, single 
dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
1000,2000,3000,5000and 6000mg/kg 
Route of administration Oral Cavage (po) 
Vechicle 
 
GHEE AND PALM JAGGERY  
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Up to 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, diarrhea, 
lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous membrane, 
respiratory, circulatory, autonomic and 
central nervous systems, somato motor 
activity and behavior pattern etc. 
  
The time of death, if any, is recorded. (Complete observations: annexure I). After 
administration of the drug, food is withheld for a further 1-2 hours. 
Study procedure 
Acute oral toxicity was performed as per organization for economic co-operation for 
development (OECD) guideline 423 method. The KANDATHIRI LEGIYAM WITH GHEE AND 
PALM JAGGERY was administered in a single dose by tuberculin syringe. Animals are fasted 
3 h prior to dosing (food was withheld for 3 h but not water). Following the period of fasting 
animals was weighed and test substance was administered orally at a dose of 
1000,2000,3000,5000 and 6000mg/kg. After the KANDATHIRI LEGIYAM WITH GHEE AND 
PALM JAGGERY administration food was withheld 2 h in mice. Animals are observed 
individually after at least once during the first 30 minutes, periodically during the first 24 hrs, 
with special attention given during the first 4 hrs, and daily thereafter, for a total of 14 days.  
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REPORT 
Toxicological evaluation of KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY  
Table:5 Effect of KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY 
on acute toxicity test in female rats 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY  to Female Wister rats 
did not induce drug-related toxicity and mortality in the animals up to 
6000mg/kg in 200g female Wister rats. So No-Observed-Adverse-Effect- Level 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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(NOAEL) of  KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY is 6000 
mg/kg equal to human dose 
DISCUSSION 
KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY  was 
administered single time at the doses of 1000,2000,3000,5000 and 6000mg/kg to 
female Wister rats and observed for consecutive 14 days after administration. 
Doses were selected based on the pilot study and literature review. All animals 
were observed daily once for any abnormal clinical signs. Weekly body weight 
and food consumption were recorded. No mortality was observed during the 
entire period of the study. Data obtained in this study indicated no significance 
physical and behavioral signs of any toxicity due to administration of 
KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY  at the doses of 
1000,2000,3000,5000 and 6000mg/kg to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, 
hand held activity were observed. Home cage activities like Body position, 
Respiration, Clonic involuntary movement, Tonic involuntary movement, 
Palpebral closure, Approach response, Touch response, Pinna reflex, Sound 
responses, Tail pinch response were observed. Handheld activities like 
Reactivity, Handling, Palpebral closure, Lacrimation, Salivation, Piloercetion, 
Papillary reflex, abdominal tone, Limb tone were observed. Functional and 
behavioral examination was normal in all treated groups. Food consumption of 
all treated animals was found normal as compared to normal group. 
 
SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of 
KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY on female Wister rats. 
The study was conducted using 15 female Wister rats. The female animals were 
selected for study of 8- 12 weeks old with weight range of within ± 20 % of 
mean body weight at the time of randomization. The groups were numbered as 
group I, II, III, IV and V and dose with 1000,2000,3000,5000 and 6000mg/kg of 
LACTIC ACID BACTERIA. The drug was administered by oral route single time and 
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observed for 14 days. Daily the animals were observed for clinical signs and 
mortality.  
There were no physical and behavioral changes observed in Female 
Wister rats during 14 days. Mortality was not observed in any treatment groups. 
 
Conclusion: 
The study shows that KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY did not produce any toxic effect at dose of 1000,2000,3000,5000 and 
6000mg/kg to rats. So No-Observed-Adverse-Effect-Level (NOAEL) of 
KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY is 6000 mg/kg. 
 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of 
Experiments on Animals 
 
8.0 REFERENCES: 
 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute toxic 
class method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE TOXICITY 
PROFILE OF KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY 
Objective 
  The objective of this study is to evaluate the toxic effects, if any, as a result of the 
repeated once daily oral administration of KANDATHIRI LEGIYAM WITH GHEE AND 
PALM JAGGERYto Wister Albino rats for a minimum period of 28 consecutive days. This 
study will provide information on any major toxic effects, target organs and a rationale for 
concluding the No-Observed-Adverse-Effect-Level (NOAEL) and/or No Observed Effect 
Level (NOEL) / LOEL (Low Observed Effect Level) and risk assessment in humans. 
1. TEST GUIDELINES  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 
October, 2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 160.0to 180.0 g 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for five 
days prior to the commencement of dosing. During the acclimatization period, the 
animals will be observed daily for any apparent adverse clinical signs. Prior to 
assignment to the study and commencement of treatment, a detailed physical health 
examination will be performed on all animals by a veterinarian and animals with any 
evidence of ill health or poor physical condition will not selected for the study. 
1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination 
will be performed by veterinarian. Animals will be randomly allocated to different 
groups according to their body weight by using MS-Excel sheet as described in the 
randomization SOP. Animals will be divided into four groups (vehicle control, low, 
intermediate, and high dose). At the initiation of the treatment, the body weight 
variation between the groups did not exceed ±20% of the mean weight of each sex. 
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1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of the 
ear. The cages will be identified with an attached colored cage label showing study 
number, study code, group number, sex, dose, strain, species, cage number, route of 
administration and animal number. 
2. ANIMAL HUSBANDRY 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA registration number: 
Abc14).Their recommendations regarding animal care and handling will be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and the 
relative humidity between 30-70 %. The photoperiod will be 12 hours light and 12 
hours dark cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L x 
W x H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage will be 
fitted with a top grill having provision for keeping rodent pellet feed and an 
autoclaved polypropylene water bottle with stainless steel drinking nozzle. Cages will 
be placed on 3-tier racks and cage rotation will be performed every week. Cages will 
be changed at least twice a week. The cages and water bottles will be cleaned and 
autoclave sterilized. 
2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and bedding 
material will be changed once in three days and water bottles will be changed daily. 
All the experimental procedures will be done in a clean environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad 
libitum supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four hours 
prior to blood collection and necropsy. 
2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through 
water filter system (Aquaguard™) in autoclaved polypropylene bottles. Water bottles 
will be changed daily. Microbial analysis of water will be carried out once monthly 
and the report is maintained in the study file. 
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3. PERSONNEL SAFETY 
All personnel handling animals undergo regular medical examination. Protective clothing 
like apron, face mask, head cap, and gloves will be used to maintain hygienic conditions. 
4. MATERIALS AND METHODS  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and 
sacrifice time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan 
and Standard Operating Procedures (SOPs) of SLS. 
     4.6 DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose 
calculation procedure from recommended clinical dose. 
     CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 16.2 mg /kg 
 
1 ml 
3 Middle  Dose 81mg/kg 1 ml 
 
4 High Dose 405mg/kg 1 ml 
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1.1.10 Experimental Design 
 
 
5. OBSERVATIONS 
Animals will be observed daily throughout the treatment period at regular intervals. 
During the treatment period, animals will be observed twice daily for any clinical signs of 
toxicity, morbidity and mortality. All the surviving animals will be sacrificed at the end of 
scheduled period and subjected to gross necropsy and histopathological evaluations. 
5.1.Clinical Signs 
All the animals will be subjected to cage-side (home-cage) observations twice a day 
for any clinical signs of toxicity, preferably at the same time each day and considering 
the peak period of anticipated effect. In addition to home cage observations, a detailed 
clinical examination will be performed once prior to dosing and weekly thereafter 
during treatment period.  
5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before 
randomization, there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study period. 
5.5. Hematology and Clinical Biochemistry  
Hematology and clinical biochemistry tests will be performed with terminally 
collected blood samples on day-29 from all animals. Animals will be deprived of feed 
overnight and blood samples will be collected by tapping the ear for visibility of the 
vein site and inserted the needle into the marginal ear vein and collected the blood 
Group 
No. Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control HONEY/GHEE 5 5 
G2 
Low dose of   KANDATHIRI 
LEGIYAM WITH GHEE AND 
PALM JAGGERY 
               
16.2m g /kg 
 
5 5 
G3 
Intermediate dose KANDATHIRI 
LEGIYAM WITH GHEE AND 
PALM JAGGERY  
81mg/kg 5 5 
G4 
High dose  KANDATHIRI 
LEGIYAM WITH GHEE AND 
PALM JAGGERY  
405mg/kg 5 5 
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into micro centrifuge tube. Approximately 0.5 ml of blood will be collected in vials 
containing 1% EDTA (20µl) as an anticoagulant for hematological analysis. 
Approximately 2 ml blood will be collected from each animal in micro centrifuge 
tubes containing 15µl of heparin (19 units) and the plasma will be separated by 
centrifugation at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 oC 
± 2 and used for all clinical chemistry analysis. 
5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), 
Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular 
Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) and 
Platelet (PLTC). 
5.7. Clinical Biochemistry  
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), 
Alkaline phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, Cholesterol, 
Triglycerides, Sodium, Potassium, Calcium, and  Chloride. 
1.1.11 5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy under 
the supervision of the veterinary pathologist. Different tissues/organs of thoracic, 
abdominal and cranial cavities will be examined for any gross pathological changes. 
Tissues from vehicle control and high dose groups will be subjected to detailed 
histopathological analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs will be 
fixed using Bouin’s (reproductive organs) and 10% neutral buffered formalin 
(kidneys, liver, spleen, lungs).Processing of tissue will be done by spin tissue 
processer, embedding of the tissue by tissue embedder. The tissues will be initially 
trimmed to 10-20µ thickness and later 3-6µ to obtain thinner tissue sections by using 
rotary microtome. Haematoxylin and Eosin staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, heart, 
kidneys, liver, spleen and lungs will be recorded for all the animals after trimming 
adherent tissue immediately after dissection from the animal. Paired organs will be 
weighed together. Relative weights of these organs against fasting animal body 
weights will be calculated and reported. 
6. DATA COMPILATION  
Data will be summarised in a tabular form showing the number of animals, experimental 
design, dose groups, dose volume and concentrations, test item and vehicle control 
details. All findings like clinical signs, mortality and morbidity data, time of death, body 
weights, feed consumption, clinical signs, and necropsy and pathology observations will 
be recorded and given in the final report. One original copy of the final report is issued to 
the sponsor.  
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7. STATISTICAL ANALYSIS 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, 
organ weights (absolute and relative), biochemical parameters, and hematology 
parameters will be analyzed using SPSS software, version 16.0 by using one-way 
ANOVA test with multiple comparison (vehicle controls treated groups) in the study 
report, and p value < 0.05 is considered as statistically significant.  
8. REFERENCES 
1. Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) guidelines for Laboratory Animal Facility, The Gazette of India, 1998. 
2. Hayes AW, 2000. Principles and Methods of Toxicology, 4
th
 ed., Taylor and Francis, London. 
3. Karl-Heinz Diehl, R. H. (2001). A Good Practice Guide to the Administration of 
Substances and Removal of Blood, Including Routes and Volumes. journal of applied 
toxicology , 15-23. 
4. OECD – 407 - Repeated dose 28-day oral Toxicity Study in Rodents, Adopted    
October 3, 2008. 
5. Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
 
MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
  After the treatment period the animals were anaesthetized by ketamine hydrochloride 
and the blood was collected from Retro-orbital sinus by using capillary into a centrifugation 
tube which contains EDTA for haematological parameters The haematological parameters 
like RBC, WBC and Hb percentage, Differential cell count, MCV, MCHC, Hematocrit, 
MCH, platelet count were estimated by the following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
  Reagents : RBC diluting fluid 
Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn up to 
0.5 mark and RBC diluting fluid was taken up to mark II. The fluid blood mixture was 
shaken and transferred onto the counting chamber. The cells were allowed to settle to the 
bottom of the chamber for 2 min. See the fluid does not get dried. Using 45X or high power 
objective the RBC’s were counted uniformly in the larger corner squares.   
The cells were expressed as number of cells x1012/l 
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2. ENUMERATION OF WBC: 2    JOHN 1972) 
      REAGENTS: 
  TURK’S FLUID: TURK’S FLUID WAS PREPARED BY MIXING 2ML OF ACETIC 
ACID WITH 100 ML OF DISTILLED WATER. TO THIS 10 DROP OF AQUEOUS 
METHYLENE BLUE 3 %    W/V) WAS ADDED. THIS SOLUTION HAEMOLYSIS THE 
RED CELLS DUE TO ACIDITY SO THAT COUNTING OF WHITE CELLS BECOMES 
EASY. 
Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was drawn up 
to 0.5 mark and WBC diluting fluid was taken up to mark II. The fluid blood mixture was 
shaken and transferred onto the counting chamber. The cells were allowed to settle to the 
bottom of the chamber for 2 min. See the fluid does not get dried. 
 Using 10X or low power objective the WBC’s were counted uniformly in the larger 
corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      JOHN 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 133ml of 
acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil immersion and 
the different types of WBCs were identified. The percentage distribution of these cells was 
then determined. Smears were made from anticoagulant blood specimens and stained with 
leishmann’s stain. The slides were preserved for counting the number of lymphocytes and 
neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and 
neutrophil count were calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
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DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the 
animals by puncturing the retro-orbital plexus and centrifuged. The serum collected after 
centrifugation was analyzed for various biochemical parameters like SGOT, SGPT, 
ALP,TC.TG,HDL All of the above biochemical parameters were estimated using semi 
autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits procured from Piramal 
Healthcare limited, Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. The 
colorimetric indicator is quinoneimine, which is generated from 4-aminoantipyrine and 
phenol by hydrogen peroxide under the catalytic action of peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
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NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of total 
cholesterol in serum, Clin. Chem., 1983, 29:1798-802. 
 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein lipase. 
Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4- chlorophenol by 
hydrogen peroxidase under the catalytic action of peroxidase. 
Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
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Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
 Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, In 
Rifai N, Warnick G.R, Dominiczak M.H, Handbook of lipoprotein testing, 
Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid and 
magnesium ions to the sample. Centrifugation leaves only the HDL in the supernatant. The 
cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent (from HDL 
kit) in 1.5 ml centrifuge tube and mixed well. Centrifuged the above solution at 4000 rpm for 
10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL 
cholesterol, Clin. Chem., 1972, 18:499-502. 
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4. ESTIMATION OF SERUM GLUTAMATE PYRUVATE TRANSAMINASES 
(SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate Transaminase 
(GOT) catalyses the transamination of L-aspartate and α keto glutarate to form oxaloacetate 
and L- glutamate. Oxaloacetate formed is coupled with 2,4- Dinitrophenyl hydrazine to form 
hydrazone, a brown coloured complex in alkaline medium which can be measured 
colorimetrically. 
Reagents  
  Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  working 
pyruvate standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified 
water). 
Procedure  
  Rietman and Frankle method was adopted for the estimation of SGOT. 
(Reitmann S, Frankel S, 1957. A colorimetric method for the determination of serum 
oxaloacetic and glutamic pyruvate transminases. American Journal of Clinical Pathology.28: 
56-63.The reaction systems used for this study included blank, standard, test (for each serum 
sample) and control (for each serum sample). 0.25 ml of buffered aspartate was added into all 
the test tubes. Then 0.05 ml of serum was added to the test group tubes and 0.05 ml of 
working pyruvate standard into the standard tubes. After proper mixing, all the tubes were 
kept for incubation at 37oC for 60 min, after which 0.25 ml each of 2,4- DNPH reagent was 
added into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml of each serum sample 
was added to the blank and the serum control tubes respectively. The mixture was allowed to 
stand at room temperature for 20 min. After incubation, 2.5 ml of solution I was added to all 
test tubes. Mixed properly and optical density was measured in a spectrophotometer at 505 
nm within 15 min. 
The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ (Absorbance 
of standard - Absorbance of blank)] x concentration of the standard         
2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) catalyses the 
transamination of L-alanine and α keto glutarate to form pyruvate and L- Glutamate. 
Pyruvate so formed is coupled with 2,4 – Dinitrophenyl hydrazine to form a corresponding 
hydrazone, a brown coloured complex in alkaline medium which can be measured 
colorimetrically. 
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Reagents 
  Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate 
standard, solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The reaction 
systems used for this study included blank, standard, test (for each serum sample) and control 
(for each serum sample). 0.25 ml of buffered alanine was added into all the test tubes. This 
was followed by the addition of 0.05 ml of serum into the test group tubes and 0.05 ml of 
working pyruvate standard into the standard tubes. After proper mixing, all the tubes were 
kept for incubation at 37oC for 60 minutes, after which 0.25 ml each of 2,4- DNPH reagent 
was added into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml of each serum 
sample was added to the blank and the serum control tubes respectively. The mixture was 
allowed to stand at room temperature for 20 min. After incubation, 2.5 ml of solution I was 
added to all test tubes. Mixed properly and optical density was read against purified water in 
a spectrophotometer at 505 nm within 15 min. 
  The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = [(Absorbance 
of test - Absorbance of control)/ (Absorbance of standard - Absorbance of blank)] x 
concentration of the standard.        
            
3. Determination of alkaline phosphatase (ALP) 
  Alkaline phoshatase from serum converts phenyl phosphate to inorganic phosphate 
and phenol at pH 10.0. Phenol so formed reacts in alkaline medium with 4-aminoantipyrine 
in presence of the oxidising agent potassium ferricyanide and forms an orange-red coloured 
complex, which can be measured spectrometrically. The color intensity is proportional to the 
enzyme activity. 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. In-vitro 
determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 321-22\). The 
working solution was prepared by reconstituting one vial of buffered substrate with 2.2 ml of 
water. 0.5 ml of working buffered substrate and 1.5 ml of purified water was dispensed to 
blank, standard, control and test. Mixed well and incubated at 370C for 3 min. 0.05 ml each of 
serum and phenol standard were added to test and standard test tubes respectively. Mixed 
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well and incubated for 15 min at 370C. Thereafter, 1 ml of chromogen reagent was added to 
all the test tubes. Then, added 0.05 ml of serum to control. Mixed well after addition of each 
reagent and the O.D of blank, standard, control and test were read against purified water at 
510 nm. 
Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from 
impaired hepatic uptake of unconjugated bilirubin, such a situation can occur in generalized 
liver cell injury, certain drugs (e.g Rifampin and probenecid) interfere with the rat uptake of 
bilirubin by the liver cell and may produce a mild unconjugated hyperbilirubinemia. Bilirubin 
level rises in diseases of hepatocytes, obstruction to bilirubin excretion into duodenum, in 
haemolysis and defects of hepatic uptake and conjugation of Bilirubin pigment such as 
Gilbert’s disease.  
  Elevation of total serum bilirubin may occur due to:  
1.Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic disease of 
the new born. 
2.Liver diseases.Eg.Hepatitis and cirrhosis. 
3.Obstruction of the biliary tract.Eg.Gall stones. 
  The method is based on the reaction of Sulfonilic acid with sodium nitrite to form 
azobilirubin which has maximum absorbance at 546nm in the aqueous solution. The intensity 
of the color Produced is directly proportional to the amount of direct or total bilurubin 
concentration present in the sample. 
 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
  Kind & King’s method was followed for the estimation of Bilirubin. Five hundred µl 
of working reagent was added to 50 µl of rat serum & incubated for 5 min at 37°C. 
Absorbance was measured AT 546 NM in semi auto analyzer against the standard. 
  The Bilirubin content was calculated using the following equation: 
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Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States associated 
with elevated levels of urea in blood are referred to as hyper uremia or azotemia.  
Method 
  Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                        
Table 14. Reagents 
 
 
 
 
 
 
 
 
Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 nm 
optical path 1 cm against reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
  
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the most 
common complication of  hyperuricemia, ie. Increased serum levels of uric acid lead to 
formation of  monosodium urate crystal around the joints. 
Method  
  Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-m- 
toluidin) 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
7. ESTIMATION OF CREATININE:  
Principle: 
Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
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Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this add 100 
µl of serum. Mix well and immediately read the test sample at Hg 492 nm 1cm light path and 
note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
 
TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KANDATHIRI LEGIYAM WITH 
GHEE AND PALM JAGGERY ON BODY WEIGHT IN Gram (PHYSICAL PARAMETER) 
Effect Of Sub Acute Doses (28 Day) 0f Kandathiri Legiyam With Ghee And Palm Jaggery On Body Weight In 
Gram (Physical Parameter). 
GPs Control Low Dose Middle Dose High Dose 
 Male Female Male Female Male Female Male Female 
1stwk 131.7± 
2.028 
137.3± 
1.764 
140± 
1.155 
135.7± 
2.028 
137.3± 
2.906 
141± 
4.509 
136± 
4.619 
136.7± 
2.404 
2ndwk 138.3± 
2.028 
145.3± 
1.667 147±1 
141.3± 
1.856 
144.3± 
2.728 
146.7± 
4.485 
141± 
2.517 
144± 
2.082 
3rdwk 145± 
2.082 
153.7± 
2.603 
155.3± 
1.453 
148.3± 
2.404 
152± 
3.055 
154.7± 
3.844 
149.3± 
2.603 
153± 
2.887 
 
4thwk 
157.7± 
0.8819 
163± 
2.517 
162.3± 
1.764 
157.7± 
2.603 
160.7± 
1.856 
163.7± 
3.93 
157.3± 
2.404 
159.7± 
2.333 
Values are expressed as the mean ± S.D 
148 
 
1st wk body weight
M F M F M F M F
0
50
100
150
200
w
ei
gh
t (
g)
      
            2nd WK BODY WEIGHT
M F M F M F M F
0
50
100
150
200
w
e
ig
ht
 
(g
)
 
 
3rd WK BODY WEIGHT
M F M F M F M F
0
50
100
150
200
w
ei
gh
t (
g)
 
 
149 
 
 
4th WK BODY WEIGHT
M F M F M F M F
0
50
100
150
200
w
ei
gh
t (
g)
 
 
  EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KANDATHIRI LEGIYAM WITH GHEE AND 
PALM JAGGERY ON FOOD INTAKE In Gram  
Effect Of Sub Acute Doses (28 Days) 0f KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY ON FOOD 
INTAKE IN Gram 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 54 18 54 48 68 70 56 64 
DAY2 48 80 64 56 42 64 70 56 
DAY3 62 50 60 65 60 70 60 62 
Day 4 56 62 54 56 58 68 62 18 
DAY5 32 78 40 56 37 70 58 54 
Day 6 48 34 58 64 72 64 88 48 
DAY7 62 56 78 58 64 68 44 68 
DAY8 66 50 34 27 56 68 56 34 
Day 9 74 24 68 56 82 68 82 62 
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DAY10 62 64 58 72 64 85 78 42 
Day 11 56 72 68 69 58 78 62 68 
DAY12 61 56 37 44 56 62 56 60 
DAY13 58 50 28 56 62 68 64 28 
Day 14 27 38 82 62 78 72 48 70 
DAY15 64 54 68 54 62 68 56 56 
Day 16 72 56 48 61 74 76 44 42 
DAY17 68 66 59 38 79 27 58 64 
DAY18 81 72 68 46 54 90 95 58 
Day 19 74 64 72 68 54 44 56 47 
DAY20 72 44 68 56 44 62 48 56 
DAY21 64 42 68 56 74 56 48 72 
Day 22 71 56 34 68 72 38 78 88 
DAY23 62 64 78 66 58 68 34 58 
DAY24 56 56 48 34 60 81 54 72 
Day 25 48 68 56 64 78 56 62 61 
DAY26 39 38 14 87 81 46 52 79 
DAY27 54 18 54 48 68 70 56 64 
DAY28 48 80 64 56 42 64 70 56 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KANDATHIRI LEGIYAM WITH GHEE AND 
PALM JAGGERY ON WATER INTAKE IN ml 
Effect Of Sub Acute Doses (28 Day) 0f KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERYon Water 
Intake in ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 60 105 61 68 56 48 50 130 
DAY2 50 80 85 40 55 75 110 90 
DAY3 65 40 50 65 60 75 110 50 
Day 4 50 65 130 110 85 60 70 60 
DAY5 10 65 50 60 65 60 70 50 
Day 6 70 95 70 85 60 40 40 120 
DAY7 95 110 50 60 65 105 60 70 
DAY8 100 105 130 85 60 80 85 50 
Day 9 95 90 90 50 70 75 90 50 
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DAY10 90 75 40 80 90 115 80 95 
Day 11 65 85 60 85 110 95 10 80 
DAY12 34 60 140 70 110 60 130 56 
DAY13 140 85 70 90 115 80 80 30 
Day 14 120 95 80 85 65 130 60 85 
DAY15 40 60 70 125 80 56 40 65 
Day 16 90 95 55 85 100 70 110 70 
DAY17 85 65 30 90 95 70 130 60 
DAY18 85 60 120 65 90 110 130 80 
Day 19 125 90 60 110 55 60 90 60 
DAY20 85 120 85 40 120 85 30 80 
DAY21 75 60 60 40 90 140 40 60 
Day 22 85 60 80 60 40 40 130 60 
DAY23 60 70 30 115 110 90 105 80 
DAY24 70 75 90 95 60 60 75 110 
Day 25 140 60 90 78 90 120 160 100 
DAY26 60 105 61 68 56 48 50 130 
DAY27 50 80 85 40 55 75 110 90 
DAY28 65 40 50 65 60 75 110 50 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KANDATHIRI LEGIYAM WITH GHEE 
AND PALM JAGGERY ON ORGAN WEIGHT in gm 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
0
100
200
300
400
500
600
700
800
900
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
in
 m
l
Water Intake 
F
M
F
M
F
M
F
M
GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  WEIGHT 7.078±0.65 4.811±0.613 6.043±0.012 5.944±0.122 
KIDNEY 
WEIGHT 
L 0.987±0.095 0.7055±0.0175 0.7505±0.0325 0.872±0.076 
R 1.306±0.372 0.737±0.045 0.6995±0.0145 0.894±0.032 
HEART WEIGHT 0.8855±0.0065 0.9295±0.0635 0.7745±0.0535 1.076±0.1535 
LUNGS  WEIGHT 2.09±0.298 0.7575±0.0685 1.14±0.284 2.008±0.3205 
TESTIS WEIGH 2.713±0.625 2.375±0.649 1.978±0.55 2.627±0.5995 
UTERUS 0.442±0.08 0.5005±0.0455 0.3905±0.0385 0.739±0.037 
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY ON HAEMATOLOGICAL PARAMETERS  
Effect Of  Sub Acute Doses (28 Day) 0f KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY On 
Haematological Parameters 
 
GROUP 
 
Normal 
 
L.D 
 
M.D 
 
H.D 
 
RBC (X10^6/µL) 5.107±0.5573 5.127±0.2404 6.02±0.3635 5.417±0.2087 
 
WBC(X10^3/µL) 13.37±1.027 15.27±1.362 11.17±0.636 13.73±0.786 
 
HB (g/dl) 13.37±1.12 12.43±0.7446 15.07±1.091 13.27±0.6227 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
 
GROUP 
 
Normal 
 
L.D 
 
M.D 
 
H.D 
TOTAL BILURBIN (g/ml) 
 
0.32±0.1311 
 
 
0.9733±0.08511 
 
 
0.4833±0.07446 
 
 
0.3833±0.04485 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
 
GROUP 
 
Normal 
 
L.D 
 
M.D 
 
H.D 
 
SGOT (U/L) 
 
203.8±47.31 
 
419.1±63.96** 
 
324±23.75 
 
297.2±5.067 
 
 
SGPT (U/L) 
 
38.33±3.139 
 
63.67±6.822* 
 
66.57±8.175* 
 
73.7±5.133** 
 
 
ALP (U/L) 
 
83.47±1.438 
 
151.9±35.35 
 
240.9±72.47* 
 
211.6±24.75 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY ON BIOCHEMICAL PARAMETER (KIDNEY PROFILE) 
 
GROUP 
 
Normal 
 
L.D 
 
M.D 
 
H.D 
 
UREA (mg/dl) 
 
76.9±2.787 
 
77.5±3.404 
 
65.67±2.146 
 
69.03±2.149 
 
 
CREATININE  
(mg/dl) 
 
0.34±0.02887 
 
 
0.1733±0.04667 
 
 
0.2533±0.0318 
 
 
0.1733±0.04667 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KANDATHIRI LEGIYAM WITH GHEE AND PALM 
JAGGERY ON BIOCHEMICAL PARAMETER (LIPID PROFILE) 
 
GROUP 
 
Normal 
 
L.D 
 
M.D 
 
H.D 
Total 
cholesterol 
(mg/dl) 
108.5±11.43 
 
113.5±8.083 
 
93.2±8.67 
 
73.17±9.332 
 
 
TG (mg/dl) 
 
45.73±4.638 
 
73.13±12.68 
 
128.2±24.51 
 
73.97±2.385 
 
 
HDL (mg/dl) 
 
18.57±2.881 
 
17.9±0.9849 
 
16.67±2.934 
 
 
 
18.73±0.9615 
 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, 
calculated by comparing treated groups with control group.  
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the dosing   
period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout the 
dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed by 
animals from different dose groups was found to be comparable with that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table No.4 
Comparison of organ weights of treated animals with respective control animals on day 29 
was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; however, the increase or decrease in the values 
obtained was within normal biological and laboratory limits or the effect was not dose 
dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in Table 2 
revealed the following significant changes in the values of hepatic serum enzymes studied. 
When compared with those of respective control. However, the increase or decrease in the 
values obtained was within normal biological and laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison with 
control and treated animal. 
 DISCUSSION: 
164 
 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg survived 
throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during the 
dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain with that 
of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable throughout 
the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, revealed no 
abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no abnormalities 
attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found to be 
comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with control 
and treated animal. 
 SUMMARY AND CONCLUSION:  
In conclusion KANDATHIRI LEGIYAM WITH GHEE AND PALM JAGGERY can 
be considered safe, as it did not cause either any lethality or adverse changes with general 
behavior of rats and also there were no observable detrimental effects (100 to 300 mg/kg 
body weight) over a period of 28 days. Our results have demonstrated that the KANDATHIRI 
LEGIYAM WITH GHEE AND PALM JAGGERY is relatively safe when administered orally 
in rats. 
9.0 ABBRVIATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
R&D   Research and Development 
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EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on 
Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    : KANDATHIRI LEGHIYAM  . 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes shows 
reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids show 
dilatation. 
  
10x shows mild altered lobular architecture 40x shows bile duct hyperplasia 
40x shows central vein congestion 40x shows kupffer cell hyperplasia 
40x shows kupffer cell 40x shows normal hepatocytes 
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SPECIMEN    :  B) spleen. 
Group – :  KANDATHIRI LEGHIYAM   
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
        Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming 
germinal centre. The pencillar artery shows normal morphology. Megakaryocytes 
10x shows normal red pulp and white pulp 10x shows normal spleen 
40x shows lymphocytic infiltration (2) 40x shows lymphocytic infiltration 
40x shows lymphocytic infiltrtion 40x shows red pulp and white pulp with                   
pencillar artery 
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    SPECIMEN  :  C)  Kidney. 
Group – :  KANDATHIRI LEGHIYAM   
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
 Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is no 
evidence of toxic changes. 
  
10x shows normal kidney 10x shows normal interstitium 
10x shows segmental glomerulo nephritis 40x shows focal segmental nephritis 
40x shows glomeruli 40x shows mild lymphocytic infiltration 
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SPECIMEN  :  D) Testis 
Group – :  KANDATHIRI LEGHIYAM   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
           Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
  
 
10x shows normal seminiferous tubules 40x shows normal maturation 
40x shows normal spermatogenesis 40x shows spermatogenesis 
40x shows tubules with normal maturation 40x shows tubules 
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Name   : 
Ref. No. : [H0 329A/18] 
 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
              TOXICITY STUDY            
 
 
SPECIMEN                   :  A) Liver 
    
Group –                   : Vigneshwari- K.L. 
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.4x2.3x1.2cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows mild altered lobular architecture with kupffer cell hyperplasia. 
Individual Hepatocytes shows no pathology. Portal triad shows bile duct hyperplasia. Central vein 
shows congestion. Sinusoids show dilatation. 
 
 
        
                                                                                                                             
Dr.C.R.Ajeethkumar.M.D. (Path). 
             
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   : 
Ref. No. : [H0 329B/17] 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) Spleen. 
    
Group –                   : Vigneshwari- K.L. 
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.0x0.8x0.4cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen shows normal white pulp and red pulp. Red pulp shows 
pigment laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming 
germinal centre. The pencillar artery shows normal morphology. There is no evidence of toxic 
changes. 
 
 
    
 
                                                                                      
                                                                                Dr.C.R.Ajeeth kumar. M.D. (Path), 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 329C/18]                      
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : C)Kidney. 
 
Group –                       : Vigneshwari- K.L . 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.3x0.6x0.5cms and 1.2x0.5x0.5cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli shows focal segmental 
glomerulonephritis(less than 50%) (mesangeal matrix expansion and hypercellularity). Tubules shows 
no significant pathology. Interstitium shows scattered lymphocytic infiltrates. Blood vessels show 
congestion. 
 
 
                                                                       
Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 329D/18]                      
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : D)Testis. 
 
Group –                      : Vigneshwari- K.L. 
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.2x0.6x0.5cms and 1.1x0.5x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with seminiferous tubules showing normal spermatogenesis. Sertoli 
cells and interstitium shows normal morphology. No evidence of toxic changes. 
 
 
 
                                                                       
Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
 
FORM I – SCREENING & SELECTION PROFORMA 
1. OP / IP NO    : ___________ 
2. NAME   : ___________ 
3. RELIGION    : H / C / M / O 
4. AGE / GENDER  : ___________ 
5. OCCUPATION  : ___________ 
6. INCOME   : ___________ 
7. CONTACT NO  : ___________ 
8. INCLUSION CRITERIA :  
Inclusion criteria 
• Age : 30 – 60 yrs 
• Sex : Both Male and Female 
• Patients having symptoms of joint pain in one or both knee joints, 
swelling, tenderness, stiffness, crepitation, restricted movements  
of  joints. 
• Patients who are willing to give blood samples for laboratory 
investigation. 
• Patients who are willing to take radiological imaging before and 
after treatment. 
• Patients who are willing to participate in this study with the 
knowledge of potential risks. 
 
175 
 
Exclusion criteria 
• Cardiac disease 
• Rheumatoid arthritis 
• Use of narcotic drugs 
• Pregnancy and lactation 
• History of trauma 
• Carcinoma patient 
• Other Systemic Illness 
• Tuberculosis 
• Immuno compromised patient  
• Clinically significant abnormal laboratory values.  
 
ADMITTED TO TRIAL: 
    YES  NO 
If Yes Serial Number: 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
 
FORM I A – HISTORY PROFORMA 
1. SL.NO     : ___________ 
2. OP / IP NO     : ___________ 
3. NAME    : ___________ 
4. RELIGION     : H / C / M / O 
5. AGE / GENDER   : ___________ 
6. OCCUPATION   : ___________ 
7. INCOME    : ___________ 
8. CONTACT NUMBER  : ___________ 
9. MARITAL STATUS   : Married / Unmarried 
10. COMPLAINTS & DURATION : 
 
11. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES SPECIFY DURATION 
Smoking    
Tobacco Chewing    
Alcohol    
Narcotic Drug Addiction    
12. DRUG HISTORY: 
 Whether the Patient has underwent any allopathic Treatment  
1. Yes    2. No. 
 If yes specify the nature of the drug and treatment duration _____ 
13. FAMILY HISTORY: 
 Whether this problem runs in family? 
1. Yes  2. No 
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If yes, mention the relationship of affected person(s) 
1. ___________ 
2. ___________ 
14. DIETARY HABITS : 
 
   1. Pure vegetarian 
   2. Non-Vegetarian 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
 
FORM II AND II-A  CLINICAL ASSESSMENT ON ENROLLMENT AND ON 
VISITS 
 
1. OP / IP No     :  
2. BED No    :  
3. SL. NO    : 
4. NAME    : 
5. AGE     : 
6. GENDER    : 
7. OCCUPATION   : 
8. SOCIAL STATUS   : 
9. DATE OF ADMISSION  : 
10. DATE OF DISCHARGE  : 
11. POSTAL ADDRESS   : 
12. COMPLAINTS & DURATION : 
13. HISTORY OF PRESENT ILLNESS : 
14. PAST HISTORY   : 
15. FAMILY HISTORY   : 
 
16. MENSTRUAL HISTORY (If Applicable): 
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17. HABITS: 
1. Smoker    : 
2. Alcoholic    : 
3. Tobbaco chewer   :  
4. Betel nut chewer   : 
5. Non-Vegetarian   : 
6. Drug addiction   : 
18. GENERAL EXAMINATION: 
1. Body weight (Kg)   : 
2. Height (Cm)   :  
3. Body Temperature (F)  :  
4. Blood Pressure (mmHg)  : 
5. Pulse Rate (/min)   : 
6. Heart Rate (/min)   : 
7. Respiratory Rate (/min)  :  
8. Pallor    :  
9. Jaundice    : 
10. Clubbing    : 
11. Cyanosis    : 
12. Pedal Oedema   :  
13. Lymphadenopathy  :  
14. Jugular venous pulsation  : 
19. CLINICAL EXAMINATION: 
I. INSPECTION: 
1. Attitude    : 
2. Muscular spasm   : 
3. Muscle wasting – Proximal :  
4. Muscle wasting – Distal  : 
5. Minor Joint Swelling  : 
6. Major Joint Swelling  : 
7. Nodules    : 
8. Deformity    : 
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II. PALPATION: 
1. Swelling    : 
2. Tenderness   :  
3. Joint Stiffness   : 
4. Muscle wasting   : 
5. Local heat    : 
6. Local Lymphadenopathy  : 
7. Pitting Oedema   : 
8. Nodules    : 
III. MOVEMENTS: 
Restriction of joint movements 
1. Neck              :            Full            Partial    
2. Shoulder  : 
3. Elbow joint  : 
4. Knee joint  : 
5. Ankle joint  : 
6. Hip joint  : 
7. Minor joints  : 
IV. PAIN: 
1. Onset :   Sudden : Gradual : 
2. Early morning stiffness :  Present  : absent  : 
3. Nature of pain:  Mild  : Moderate :     Severe: 
4. Aggravating factor –Movements  : 
5. Relieving factor – rest   : 
6. Stiffness     : 
7. Tenderness    :  
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V. CLINICAL ASSESSMENT :  
1. Arthritis of three or more Joints  : 
2. Arthritis of hand joints   : 
3. Morning Stiffness    : 
4. Fever     : 
5. Anorexia     : 
6. Anaemia     : 
7. Spindle appearance of fingers  : 
8. Restricted movements   : 
9. Rheumatoid Nodules   : 
10. Numbness     : 
20. EXAMINATION OF OTHER SYSTEMS:  
1. CVS    : 
2. RS     : 
3. CNS    : 
4. ABDOMEN   : 
5. GENITO – URINARY  : 
 
EXAMINATION – SIDDHA ASPECTS 
1. NILAM: 
 1. Kurinji 2. Mullai 3. Marutham 4. Neithal 5. Paalai 
2. KAALAM: 
 1. Kaar Kaalam 2. Koothir Kaalam 3. Munpani Kaalam 
 4. Pinpani Kaalam 5. Elavenir Kaalam 6. Mudhuvenir Kaalam 
3. YAAKKAI:  
 1. Vatham   2. Pitham   3. Kabam 
 4. Vathapitham  5. Pithavatham  6. Kabavatham 
 7. Vathakabam  8. Pithakabam   9. Kabapitham 
4. GUNAM:  
 1. Sathuvam   2. Rasatham   3. Thamasam 
 
5. KANMENDHIRIUM / KANMAVIDAYAM 
 1. Kai   : 
 2. Kaal   : 
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 3. Vaai   : 
 4. Eruvaai  : 
5. Karuvaai  : 
6. UYIR THATHUKKAL: 
I. VATHAM: 
1. Piraanan  : 
2. Abaanan  : 
3. Viyaanan  : 
4. Uthaanan  : 
5. Samaanan  : 
6. Naagan  : 
7. Koorman  : 
8. Kirukaran  : 
9. Devathathan : 
10. Dhananjeyan : 
II. PITHAM : 
1. Analagam  : 
2. Ranjagam  : 
3. Saathagam  : 
4. Aalosagam : 
5. Praasagam  : 
III. KABAM: 
1. Avalambagam : 
2. Kilethagam : 
3. Pothagam  : 
4. Tharpagam : 
5. Santhigam  : 
 
7. UDAL THAATHUKKAL: 
1. Saaram  : 
2. Senneer  : 
3. Oon  : 
4. Kozhuppu  : 
5. Enbu  : 
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6. Moolai  : 
7. Sukkilam / Suronitham: 
8. ENVAGAI THERVUGAL: 
1. Naadi  : 
2. Sparisam  : 
3. Naa  :  
4. Niram  : 
5. Mozhi  : 
6. Vizhi  : 
7. Malam :  
i. Niram:  ii. Thanmai: iii. Irugal: iv.Ilagal: 
8. Moothiram : 
 
I. NEERKURI: 
 a. Niram : 
 b. Manam : 
 c. Edai  : 
 d. Nurai : 
 e. Enjal : 
II. NEIKURI: 
 Vatha Neer  :  Pittha Neer   :    Kaba Neer : 
   
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
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FORM III – LABORATORY INVESTIGATION 
1. BLOOD: 
1. TC   : (Cells / Cumm) 
2. DC (%)  : N : L : M : E : 
3. ESR (mm)  : ½ hr : 1 hr : 
4. Hb   : 
5. Blood Sugar : a) Fasting : b) Post Prandial : 
6. Renal function tests: 
Blood Urea:  Serum creatinine: 
7. Lipid profile : 
HDL:   LDL:  VLDL: 
Total Cholesterol : TGL : 
8. Liver Function tests: 
Serum Bilirubin :  Total  Direct  Indirect 
 
SPECIFIC INVESTIGATIONS 
 RA factor   : 
 ASO titre   : 
 C-Reactive Protein  : 
 SGOT    : 
SGPT    : 
 Serum albumin & globulin : 
 Total protein   : 
II. URINE: 
1. Albumin   : 
2. Sugar   : 
3. Epithelial cells  : 
4. Pus cells   : 
5. Red blood cells  : 
6. Casts / Crystals  : 
III. MOTION: 
1. Ova   : 
2. Cyst   : 
3. Occult blood  : 
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4. Pus cells   : 
IV. X-RAY FINDINGS 
 
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
    
FORM IV A – CONSENT FORM 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature ______________ 
Date      ______________ 
Name    ______________ 
CONSENT BY PATIENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 I exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of “SARVANGA VATHA CHOORANAM” (Internal drug) and 
“KETHAKI THYLAM” (External drug) for the treatment of “AZHAL KEEL VAYU” 
(OSTEOARTHRITIS)”. 
 
Place :        Signature  :  
Date :         Name  : 
        Witness Signature: 
        Name  : 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
FORM IV B WITHDRAWL FORM 
1. SL.NO    : ___________ 
2. OP / IP NO    : ___________ 
3. NAME   : ___________ 
4. RELIGION    : H / C / M / O 
5. AGE / GENDER  : ___________ 
6. OCCUPATION  : ___________ 
7. SOCIAL STATUS  : ___________ 
8. CONTACT NO  : ___________ 
9. DATE OF TRIAL COMMENCEMENT  : ___________ 
10. DATE OF WITHDRAWAL FROM TRIAL : ___________ 
11. REASONS FOR WITHDRAWAL   : ___________ 
 Long absence at reporting   :  Yes / No 
 Irregular treatment    :  Yes / No 
 Shift of locality    :  Yes / No 
 Increase in severity of symptoms  :  Yes / No 
 Development of severe adverse drug reactions:  Yes / No 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
189 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III (SIRAPPU MARUTHUVAM) 
 
AN OPEN CLINICAL TRIAL OF KANDATHRI LEGIYAM(INTERNAL) 
& NAKKA PUSA MUKUTTENNAI (EXTERNAL) FOR AZHAL KELL 
VAYU  (OSTEOARTHRITIS) 
FORM IV – C   DRUG COMPLIANCE FORM 
Name of the Drug : KANDATHRI LEGIYAM 
Drugs issued  : (Mg / Gram) 
Drugs returned : (Mg / Gram) 
 
S. NO DATE DRUG TAKEN TIME 
MORNING / TIME EVENING / TIME 
Day 1    
Day 2    
Day 3    
Day 4     
Day 5    
Day 6    
Day 7    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 25    
Day 26    
Day 27    
Day 28    
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Day 29    
Day 30    
Day 31    
Day 37    
Day 38    
Day 39    
Day 40    
Day 41    
Day 42    
Day 43    
Day 44    
Day 45    
Day 46    
Day 47    
Day 48     
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD  
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 URINE EXAMINATION BEFORE & AFTER TREATMENT – IN PATIENTS 
S.no 
 
Ip.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 2004 NIL NIL NAD NIL NIL NAD 
2 2115 Trace NIL 2-3 pus cells Trace NIL NAD 
3 2154 NIL NIL NAD NIL NIL NAD 
4 2942 NIL NIL NAD NIL NIL NAD 
5 3094 NIL NIL NAD NIL NIL NAD 
6 3285 NIL NIL NAD NIL NIL NAD 
7 3358 NIL NIL NAD NIL NIL NAD 
8 46 NIL NIL NAD NIL NIL NAD 
9 233 NIL NIL NAD NIL NIL NAD 
10 380 NIL NIL NAD NIL NIL NAD 
11 383 NIL NIL NAD NIL NIL NAD 
12 389 NIL NIL NAD NIL NIL NAD 
13 430 NIL NIL NAD NIL NIL NAD 
14 533 NIL NIL NAD NIL NIL NAD 
15 548 NIL NIL NAD NIL NIL NAD 
16 838 Trace NIL 1-2 pus cells NIL NIL NAD 
17 1045 NIL NIL NAD NIL NIL NAD 
18 1073 NIL NIL NAD NIL NIL NAD 
19 1115 NIL NIL NAD NIL NIL NAD 
20 1194 NIL NIL NAD NIL NIL NAD 
 
  
LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.KANDATHIRI  LEGHIYAM – INTERNAL    2.NAKKA PUSA MUKOOTTENNAI – EXTERNAL 
 
S.NO IP.NO NAME AGE/SEX OCCUPATION DATE OF 
ADMISSION 
DATE OF 
DISCHARGE 
TOTAL NO. 
OF DAYS 
TREATED 
TOTAL NO. 
OF DAYS 
RESULT 
IP OP 
1 2004 Ashwathi 52/f House wife 11-07-17 16-08-17 37 11 48 MARKED 
2 2115 Maharasi 55/f House wife 25-07-17 29-08-17 36 12 48 MARKED 
3 2154 Chendhura paundiyan 58/m Farmer 30-07-17 16-08-17 17 31 48 MODERATE 
4 2942 Poovaiya 55/m Farmer 21-10-17 21-11-17 32 16 48 MARKED 
5 3094 Velammal 51/f House wife 20-11-17 18-12-17 29 19 48 MILD 
6 3285 Sornam 59/f House wife 15-12-17 09-01-18 26 22 48 MARKED 
7 3358 Palaniyammal 60/f House wife 27-12-17 10-02-18 46 2 48 MODERATE 
8 46 Kaliyappan 52/m Farmer 08-01-18 26-02-18 49 0 48 MARKED 
9 233 Anuthai 52/f House wife 30-01-18 14-03-18 46 2 48 MILD 
10 380 Mariyammal 41/f House wife 13-02-18 01-03-18 17 31 48 MARKED 
11 383 Lakshmi 60/f House wife 14-02-18 16-03-18 28 20 48 MODERATE 
12 389 Pon selvi 48/f House wife 14-02-18 16-03-18 28 20 48 MARKED 
13 430 Nadarajan 60/m Farmer 23-02-18 18-03-18 29 19 48 MILD 
14 533 Ponnuthai 60/f House wife 27-02-18 15-03-18 17 31 48 NO EFFECT 
15 548 Anaikarai muthu 56/m Farmer 28-02-18 29-03-18 30 18 48 MARKED 
16 838 Vasugi 40/f House wife 27-03-18 17-04-18 22 26 48 MARKED 
17 1045 Annamalai 60/f House wife 17-04-18 05-06-18 50 0 48 MARKED 
18 1073 Pandiyaraj 33/m Masson 19-04-18 22-05-18 34 14 48 MARKED 
19 1115 Kuruvammal 60/f House wife 24-04-18 29-07-18 35 13 48 MARKED 
20 1194 Raja lakshmi 60/f House wife 03-05-18 11-06-18 37 11 48 MARKED 
 
 
                                      
CASE PRESENTATION – SUMMARY OF OUT PATIENTS 
1. KANDATHIRI  LEGHIYAM – INTERNAL    2.NAKKA PUSA MUKOOTTENNAI – EXTERNAL 
 
 
 
S.no Op.no Name Age/sex Occupation Date of 
registration 
Date of completion 
of treatment 
No. Of days 
treated 
Result 
1 110149 Navamani 59/m Farmer 14-12-17 02-02-18 49 MODERATE 
2 113318 Jeyanthi 43/f House wife 23-12-17 02-02-18 42 MILD 
3 114833 Valliyammal 48/f House wife 28-12-17 16-02-18 48 MARKED 
4 114059 Iyyam perumal 60/m Farmer 29-12-17 02-02-18 35 MARKED 
5 1759 Rasammal 50/f House wife 04-01-18 20-02-18 48 MODERATE 
6 5669 Kala 56/f House wife 17-01-18 27-02-18 42 MARKED 
7 5810 Jeyarani 52/f Teacher 17-01-18 25-02-18 42 MILD 
8 5986 Sagunthala 43/f Teacher 17-01-18 21-01-18 35 MARKED 
9 7792 Krishnaveni 59/f House wife 23-01-18 06-03-18 42 MODERATE 
10 7905 Subbuthai 50/f House wife 23-01-18 12-03-18 48 MARKED 
11 8584 Fathima 40/f House wife 25-01-18 08-03-18 42 MARKED 
12 9038 Sherina 57/f House wife 26-01-18 08-03-18 42 MILD 
13 10280 Umayammal 60/f House wife 30-01-18 12-03-18 42 MARKED 
14 10363 mariyammal 45/f House wife 30-01-18 12-03-18 42 MARKED 
15 11323 Ramalingam 54/m Formar 02-02-18 22-03-18 48 MODERATE 
16 12071 Inthira 56/f House wife 05-02-18 19-03-18 42 MARKED 
17 12319 Meera 46/f Teacher 05-02-18 12-03-18 36 MILD 
18 12388 Shanmugasuntharam 55/m Farmer 05-02-18 19-03-18 42 MARKED 
19 13389 Sownthararajan 58/m Farmer 08-02-18 28-03-18 48 MARKED 
20 13480 Sutha 42/f Teacher 08-02-18 28-03-18 48 MILD 
  
S.NO 
 
PATIENT NAME 
 
AGE/SEX 
 
OP/IP NO 
 
BEFORE 
TREATMENT 
 
 
AFTER 
TREATMENT 
Right 
(cm) 
Left (cm) Right(cm) Left(cm) 
1       Palaniyammal 60/f 3358 35 33 31 30 
2         Jeyanthi       43/f       113318 38 36 34 33 
3       Raja lakshmi      60/f         1194 39 38 33 32 
4            Kala      56/f         5669 34 33 30 30 
5          Poovaiya     55/m         2942 35 32 33 29 
6          Sherina     57/f        9038 36 35 32 31 
7 Chendhura paundiyan     58/m         2154 33 32 29 30 
8 Valliyammal 48/f 114833 40 39 35 34 
9 Iyyam perumal 60/m 114059 32 35 28 27 
10          Meera       46/f      12319 31 33 26 28 
11       Anaikarai muthu      56/m        548 41 39 38 37 
12 Kaliyappan 52/m         46 38 31 36 33 
13 Anuthai 52/f         233 39 37 36 33 
14 Mariyammal 41/f         380 30 37 28 35 
15       Sagunthala      43/f       5986 24 28 22 26 
16         Nadarajan    60/m         430 33 30 31.5 28 
17 mariyammal 45/f 10363 34 31 33 27 
18 Ramalingam 54/m 11323 35 32 31 30 
19         Kuruvammal    60/f        1115 37 36 33 30 
20 Shanmugasuntharam   55/m       12388 40 38 38 35.5 
 
INFERENCE: 
  Knee joint swelling is reduced approximately 2-3 cms after treatment. 
 
 
 
  
 BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – IP PATIENT 
 
 
S.N
O 
IP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT B
T 
A
T 
BT AT 
1 2004 7100 7500 66 67 33 31 1 2 0 0 0 0 13.5 13.7 28 19 99 98 130 133 29 22 159 149 
2 2115 7300 7600 59 61 37 36 4 3 0 0 0 0 12.2 12.4 27 20 86 90 132 135 37 34 186 172 
3 2154 7600 7400 64 62 33 36 3 2 0 0 0 0 11.8 13.6 15 10 87 90 126 125 28 27 185 176 
4 2942 7700 7800 65 64 31 32 4 4 0 0 0 0 9.6 10.1 34 25 80 82 130 132 36 22 221 201 
5 3094 7400 7600 71 69 24 28 3 3 0 0 0 0 12.2 12.4 11 99 88 85 132 136 29 25 196 185 
6 3285 7900 7700 59 61 36 34 5 5 0 0 0 0 12.2 12.4 19 136 89 87 139 140 29 22 199 187 
7 3358 6700 6900 64 62 33 36 3 2 0 0 0 0 9.5 9.9 11 136 79 85 127 128 34 29 179 177 
8 46 8100 8500 69 69 28 29 3 2 0 0 0 0 12.8 12.9 32 21 89 88 130 138 35 32 139 165 
9 233 8300 8400 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 11 90 88 136 138 34 29 179 149 
10 380 7100 7300 69 67 28 31 3 2 0 0 0 0 12.2 12.4 19 11 87 90 120 130 29 22 159 149 
11 383 7700 7800 70 70 26 25 4 5 0 0 0 0 10.9 11.1 30 19 86 88 127 139 42 37 165 157 
12 389 7000 7200 59 61 37 36 4 3 0 0 0 0 12.2 12.4 19 11 83 87 130 136 22 19 196 187 
13 430 7800 8000 63 65 35 34 2 1 0 0 0 0 12.2 12.4 19 11 79 77 125 126 22 19 186 174 
14 533 7400 7500 64 63 32 34 4 3 0 0 0 0 9.5 9.9 34 28 89 85 123 138 34 29 179 165 
15 548 6300 6500 71 69 24 28 3 3 0 0 0 0 13.5 13.7 28 19 79 88 130 134 29 22 159 149 
16 838 7100 7300 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 19 89 87 132 137 29 25 196 185 
17 1045 6700 6900 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 20 95 92 129 134 29 22 199 187 
18 1073 7500 7700 59 61 36 34 5 5 0 0 0 0 12.5 12.7 24 23 98 96 130 133 34 29 179 177 
19 1115 7200 7500 62 64 32 34 6 2 0 0 0 0 13.5 13.6 31 23 82 90 135 140 37 31 167 157 
20 1194 6800 7000 61 62 34 34 5 4 0 0 0 0 11.8 12.2 26 18 81 88 126 130 19 15 194 188 
 BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – OP PATIENT 
 
 
S.N
O 
OP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT B
T 
A
T 
BT AT 
1 110149 7500 8100 64 67 29 29 7 4 0 0 0 0 12.1 12.4 15 10 97 92 149 135 28 27 185 176 
2 113318 7400 7600 72 69 25 28 3 3 0 0 0 0 13.1 13 22 19 124 118 168 155 40 31 208 201 
3 114833 7200 7500 64 63 32 34 4 3 0 0 0 0 9.5 9.9 28 19 99 90 149 132 29 22 159 149 
4 114059 7800 7400 65 64 31 32 4 4 0 0 0 0 9.6 10.1 34 25 108 102 189 172 36 22 221 201 
5 1759 7500 7600 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 20 96 92 176 140 34 29 179 177 
6 5669 7700 7300 62 64 32 34 6 2 0 0 0 0 13.5 13.6 31 23 122 108 154 146 37 31 167 157 
7 5810 6900 6700 59 61 37 36 4 3 0 0 0 0 12.2 12.4 19 11 136 127 179 161 22 19 196 187 
8 5986 8200 7900 69 69 28 29 3 2 0 0 0 0 12.8 12.9 32 21 142 128 165 148 35 32 139 165 
9 7792 8000 8100 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 11 127 167 156 29 34 29 179 149 
10 7905 7300 7100 66 67 33 31 1 2 0 0 0 0 13.5 13.7 28 19 99 90 149 132 29 22 159 149 
11 8584 7800 7700 59 61 37 36 4 3 0 0 0 0 12.2 12.4 27 20 106 97 167 165 37 34 186 172 
12 9038 7100 6900 64 62 33 36 3 2 0 0 0 0 11.8 13.6 15 10 97 92 149 135 28 27 185 176 
13 10280 8800 8400 63 65 35 34 2 1 0 0 0 0 12.2 12.4 19 11 129 117 179 161 22 19 186 174 
14 10363 8400 7900 64 63 32 34 4 3 0 0 0 0 9.5 9.9 34 28 89 85 149 140 34 29 179 165 
15 11323 7300 7100 71 69 24 28 3 3 0 0 0 0 13.5 13.7 28 19 99 90 149 132 29 22 159 149 
16 12071 7200 7500 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 19 136 127 167 156 29 25 196 185 
17 12319 6900 6700 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 20 96 92 176 168 29 22 199 187 
18 12388 7800 7500 69 67 28 31 3 2 0 0 0 0 12.2 12.4 19 11 99 90 149 132 29 22 159 149 
19 13389 9200 9000 70 70 26 25 4 5 0 0 0 0 10.9 11.1 30 19 136 128 159 139 42 37 165 157 
20 13480 6700 6900 61 62 34 34 5 4 0 0 0 0 11.8 12.2 26 18 121 118 172 159 19 15 194 188 
URINE EXAMINATION BEFORE & AFTER TREATMENT – OUT  PATIENTS 
 
S.no 
 
Op.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 110149 NIL NIL NAD NIL NIL NAD 
2 113318 NIL NIL NAD NIL NIL NAD 
3 114833 NIL NIL NAD NIL NIL NAD 
4 114059 TRACE            NIL 1-2 PUS CELLS NIL NIL NAD 
5 1759 NIL NIL NAD NIL NIL NAD 
6 5669 NIL NIL NAD NIL NIL NAD 
7 5810 NIL NIL NAD NIL NIL NAD 
8 5986 NIL NIL NAD NIL NIL NAD 
9 7792 NIL NIL NAD NIL NIL NAD 
10 7905 NIL NIL NAD NIL NIL NAD 
11 8584 NIL NIL NAD NIL NIL NAD 
12 9038 NIL NIL NAD NIL NIL NAD 
13 10280 NIL NIL NAD NIL NIL NAD 
14 10363 NIL NIL NAD NIL NIL NAD 
15 11323 NIL NIL NAD NIL NIL NAD 
16 12071 TRACE NIL 1-3 PUS CELLS NIL NIL NAD 
17 12319 NIL NIL NAD NIL NIL NAD 
18 12388 NIL NIL NAD NIL NIL NAD 
19 13389 NIL NIL NAD NIL NIL NAD 
20 13480 NIL NIL NAD NIL NIL NAD 
 
